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Zusammenfassung 
In einem Organismus sind zahlreiche Regulierungssysteme aktiv, um den sich 
ständig wechselnden Umwelteinflüssen zu begegnen und so ein Überleben zu 
ermöglichen. Anpassungen an die jeweilige Situation erfordern dabei sowohl 
die Regulation auf der Stufe Organismus als auch auf Stufe Zelle. Im Zentrum 
des zellulären Regulierungssystems, welches die Anpassung an eine 
Sauerstoffmangel-Situation (Hypoxie) bewerkstelligt, steht der Hypoxie-
induzierbare Transkriptionsfaktor (HIF). HIF ist ein heterodimerer 
Transkriptionsfaktor bestehend aus einer nicht regulierten β-Untereinheit und 
einer regulierten, labilen α-Untereinheit. Als Zellantwort auf eine Hypoxie 
erfolgt eine verminderte Hydroxylierung der labilen α-Untereinheit. Dies führt 
zu einem Unterbruch des proteasomalen Abbaus der labilen α-Untereinheit 
und daher zur Akkumulation von HIFα, was mit einer erhöhten Expression 
von HIF-Zielgenen einhergeht. Die Hydroxlierung an HIFα vermittelt so auf 
elegante Weise einen direkten Zusammenhang zwischen 
Sauerstoffkonzentration und HIF abhängiger Transkription, wobei die für die 
Hydroxylierung verantwortlichen Enzyme, die Prolyl-4-Hydroxylasen (PHD), 
als eigentliche Sauerstoffsensoren fungieren. Wir betrachteten deshalb die 
Regulation und Aktivtät der PHDs genauer, um die bekannte Korrelation von 
erhöhtem HIFα mit Tumortherapie-Resistenz und Tumorprogression 
aufzuklären. Tatsächlich etablierten in vitro Versuche einen „feed-back loop“, 
wodurch basale Mengen von HIFα dem vorherrschenden 
Sauerstoffpartialdruck angeglichen werden. Eine Störung der basalen 
Mengen von HIFα in Tumoren könnte zu einem schlechteren 
Behandlungserfolg des Krebses führen. So haben wir, beim Vergleich von 
HIFα defizienten (Hif1a-/-) mit unveränderten (Hif1a+/+) Maus Fibroblasten 
(MEF) unter Normoxie (d.h. basale Mengen von HIF) für mutante MEF-Hif1a-/-
 eine erhebliche grössere Empfindlichkeit gegenüber DNA Doppelstrang 
brechenden Chemotherapeutika (z.B. Etoposid) festgestellt – 
korrespondierend zu einer erhöhten Zahl von DNA Doppelstrangbrüchen nach 
Etoposidebehandlung. Beim Vergleich der mRNA Mengen von MEF-Hif1a+/+ 
und MEF-Hif1a-/- Zellen für bekannte DNA Reparatur Proteine, stiessen wir 
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auf einen signifikanten Unterschied in der Menge von DNA-PK mRNA. DNA-
PK ist eine Kinase mit zentraler Funktion im Nicht-Homologen End-joining 
(NHEJ) einem Hauptmechanismus der zellulären DNA Doppelstrangbruch 
Reparatur. Zudem sind auch die Proteinmengen des trimeren DNA-PK 
Komplexes drastisch tiefer in den mutanten MEF-Hif1a-/-. Basale Mengen von 
HIF-1α scheinen daher die Konzentration der DNA-PK und damit auch die 
Reparaturkapazität einer Zelle zu beeinflussen, was in einer HIF-abhängigen 
Tumortherapie-Resistenz resultiert. 
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SUMMARY 
 
Summary 
Tissue homeostasis is strictly controlled by numerous regulatory systems that 
are occupied with balancing the ever changing environmental conditions to 
ensure viability of the cell associations. This involves changes on the 
organismic as well as on the cellular level. The regulatory system which 
modulates the oxygen demand of a cell under oxygen limiting conditions 
vastly depends on the transcriptional activity of the hypoxia-inducible factor 
(HIF).  
The transcriptional active form of HIF consists of a heterodimer with a non-
regulated β- and a labile α-subunit. Upon hypoxic exposure, hydroxylation of 
the constitutively synthesized α-subunit decreases, thereby proteasomal HIFα 
degradation ceases and HIFα accumulates, leading to enhanced HIF-target 
gene expression.  
The hydroxylation reaction of HIFα is governed by prolyl hydroxylases (PHDs) 
which depend on molecular oxygen (O2) for activity and thus represent the 
sensory system that translates the O2 partial pressure (pO2) into the 
respective HIF-dependent gene expression profile.  
In order to research the well-known correlation between HIFα levels, tumor 
progression and cancer therapy resistance, we examined the activity and 
regulation of the PHDs. In vitro PHD assays established a feed-back loop that 
might set basic levels of HIFα to the respective pO2.  
The deregulation of basic levels of HIFα in cancerous tissues could contribute 
to poor clinical therapy outcome. We found mouse embryonic fibroblasts 
(MEFs) deficient for HIF-1α (mutant MEF-Hif1a-/-) to be more sensitive to 
double-strand inducing chemo-therapeutics (e.g. etoposide) than wild-type 
MEF-Hif1a+/+ under normoxia (room air oxygen concentration) that is basic 
level function of HIF.  
We could show that this corresponds to higher accumulation of double-strand 
breaks (DSB) after etoposide treatment. Furthermore, we compared mRNA 
expression levels of enzymes involved in DSB-repair for wild-type MEF-
Hif1a+/+ and mutant MEF-Hif1a-/-. Hence, we discovered that the expression of 
DNA-PK, the primary kinase in non-homologous end-joining (a major DSB-
 XIV 
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repair pathway), is significantly lowered in mutant MEF-Hif1a-/- cells when 
compared to wild-type MEF-Hif1a+/+. In addition, also protein levels of the 
timeric DNA-PK complex are decreased in the mutant MEF-Hif1a-/- cell line. 
Thus, basic levels of HIF-1α may influence DNA-PK levels and dictate cellular 
DSB repair capacity that results in a HIF-dependent therapy resistance of 
cancerous tissues. 
 XV

INTRODUCTION 
1 Introduction  
1.1 The hypoxia-inducible factor (HIF) 
HIF is a heterodimeric transcription factor which becomes stabilized after 
exposal to low oxygen conditions and thereafter induces expression of a 
distinct set of genes. It consists of a constitutively expressed subunit called 
HIFβ (also partner to the dioxin receptor/aryl hydrocarbon receptor (AhR), 
therefore also called AhR nuclear translocator (ARNT)) and an oxygen-
regulated subunit called HIFα. The labile α-subunit is constitutively transcribed 
and translated but immediately degraded under normoxic conditions. In 
addition to HIF-1α two paralogues of the α-subunit (HIF-2α, HIF-3α) are 
known, each with a more restricted tissue distribution than the ubiquitously 
expressed HIF-1α (Wenger 2002). 
Sequence comparison reveals that the two subunits (α, β) belong to the same 
family of basic–Helix-Loop-Helix-Per-ARNT-SIM (bHLH-PAS) proteins. The 
HLH and PAS motifs are required for dimer formation while the basic region 
mediates specific binding to DNA via short stretches of nucleotides encoding 
for hypoxia response elements (HREs, 5`-RCGTG-3`) in the vicinity of HIF 
target genes (Wang et al. 1995; Yang et al. 2005). 
 
 
 
Figure 1. Outline of HIFα: regions/ domains are depicted as followed: b (=bHLH) [green], PAS [red], 
ODD [orange], N-TAD and C-TAD [blue] – P indicates a proline residue, N indicates an asparagine 
residue and OH reflects hydroxylation. 
 
Other important regions - next to the dimerization and DNA binding domains - 
are the oxygen-dependent degradation (ODD) domain necessary for oxygen-
regulated stability and two transactivation domains (TAD), named after their 
relative localization in the amino acid sequence of the protein: N-terminal or 
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C-terminal transactivation domain, N-TAD or C-TAD, respectively (Huang et 
al. 1998) (Fig.3). 
1.2 Regulation of HIF activity 
HIFα accumulation and activity is tightly coupled to the pO2. In normoxia HIFα 
is immediately hydroxylated on proline 402 and/or 564 which form the 
conserved consensus sequence LXXLAP located in the ODD domain (Dann 
and Bruick 2005). This leads to von Hippel-Lindau (pVHL) ubiquitin E3 ligase 
complex interaction. pVHL recognition in turn leads to poly-ubiquitination of 
HIFα and thereby marks it for degradation by the 26S proteasome (Maxwell et 
al. 1999; Kaelin 2005). Another post-translational modification used to restrict 
HIFα activity under high oxygen partial pressure includes hydroxylation of an 
asparagine residue in the C-TAD which prevents association of HIFα with the 
common transcriptional co-activators CBP and p300 (Hirota and Semenza 
2005) (Fig.4). 
 
 
 
 
Figure 2. Regulation of HIFα under normoxic as well as hypoxic conditions. pVHL binding leads to 
ubiquitination and subsequent degradation of the protein. The prolyl hydroxylases are responsible for 
hydroxylation on specified proline residues. The hydroxylation is necessary for pVHL to interact. FIH 
hydroxylation prevents co-factor binding and thus suppresses transactivation of HIF-target genes (figure 
taken from Hirota and Semenza 2005). 
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Both hydroxylation events are performed by enzymes belonging to the family 
of 2-oxoglutarat-dependent dioxygenases (Aravind and Koonin 2001; 
Hausinger 2004). Whereas the enzyme controlling asparagine hydroxylation 
and co-activator recruitment is called factor inhibiting HIF (FIH) (Mahon et al. 
2001), the oxygenases involved in HIF degradation by targeting the proline 
residues in the ODD domain are named prolyl-4-hydroxylase domain (PHD) 
proteins (Bruick and McKnight 2001; Schofield and Ratcliffe 2004). 
The reaction performed by the 2-oxoglutarat-dependent dioxygenases adds 
one atom of molecular oxygen to a specific amino acid residue while oxidizing 
by the second oxygen atom 2-oxoglutarat, which in turn decarboxylates, 
forming carbon dioxide (CO2) and succinate. An iron atom in the catalytic 
center of the enzymes serves as catalyst during the redox reaction as 
intermediate oxygen binding partner and by mediating the electron transfer. 
The requirement for ascorbate (vitamin C) in the reaction remains enigmatic 
but seems to be an at least catalytically important factor for enzyme function 
(Schofield and Ratcliffe 2004; Dann and Bruick 2005; Hirota and Semenza 
2005) (Fig.5). 
 
 
 
Figure 3. Scheme for the reaction performed by the prolyl-4-hydroxylases. The reaction is catalyzed by 
iron in the active center of the enzymes. Apart from hydroxylated proline residues carbon dioxide and 
succinate are produced. The substrates for the reaction are oxygen and 2-oxoglutarat. Ascorbate (not 
shown here) is catalytically necessary to complete the enzymatic reaction. 
 
Thus, the absolute dependence of the dioxygenases on molecular oxygen 
links HIF activity with oxygen availability. Moreover, the reported Km 
(Michaelis-Menton) constant for all of the dioxygenases involved in HIF 
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activity regulation is higher than the molar concentration of oxygen dissolved 
in water at atmospheric pressure. Hence, enzyme activity is proportional to 
oxygen concentration and small deviations in the concentration of oxygen 
might affect enzyme activity linearly (Schofield and Ratcliffe 2005). 
FIH dictates HIF activity by controlling transcriptional co-factor (CBP/p300) 
binding to the heterodimer. However, stability of HIF is achieved largely by 
preventing prolyl hydroxylation, hence placing PHDs into the center of HIF 
regulation (Schofield and Ratcliffe 2004). 
The PHDs consist of three family members also known as HIF prolyl 
hydroxylases (HPH) 3, 2 and 1, or egg laying defective nine homolog (EGLN) 
2, 1 and 3, respectively (Bruick and McKnight 2001; Epstein et al. 2001; Ivan 
et al. 2002). The enzymatic properties of the three different enzymes have 
been widely investigated and found to be comparable for hydroxylation 
efficiency of a synthetic peptide containing the consensus sequence and for 
Km values of the co-substrates (Hirsila et al. 2003; Oehme et al. 2004; 
Tuckerman et al. 2004; McNeill et al. 2005; Wirthner et al. 2007) (Tab.1). 
 
 
 
Table 1. Km values for co-substrates. Whereas the PHDs have comparable values for oxygen the FIH 
differs. This might result in stable but transcriptional inhibited HIF.  
 
More discrepancy between the enzymes is observed in their tissue 
distribution. Whereas PHD1 is most abundant in testis and brain, PHD3 
expression is most prominent in the heart and PHD2 is found to be 
ubiquitously expressed (Soilleux et al. 2005; Stiehl et al. 2006). Likewise, also 
the intracellular distribution of the PHDs appears to be different. PHD1 seems 
to be restricted to the cytosol and PHD3 to the nucleus. PHD2 is detected 
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equally in both compartments (Metzen et al. 2003; Ke and Costa 2006). 
Interestingly, the response to hypoxia includes up-regulation of the PHD2 and 
PHD3 mRNA in a HIF-dependent way – with a pronounced PHD3 response 
(Stiehl et al. 2006). PHD1 is not induced by hypoxia. However, Siah2, a RING 
finger E3 ubiquitin ligase, targets PHD1 and PHD3 protein, adding another 
layer to HIFα regulation (Nakayama et al. 2004). 
The three PHDs share 42-59% sequence identity but no similarity to the 
collagen prolyl-4-hydroxylases. Structurally, the most unique of the three 
oxidoreductases is PHD3 with a molecular mass of only around 27 kDa 
compared to 45 kDa and 47 kDa for PHD1 and PHD2, respectively (Hirsila et 
al. 2003). However, PHD2 contains an additional zinc finger domain located in 
the first exon. X-ray crystallographic analyses of FIH revealed the typical jelly-
roll motif of eight β-strands folded into a double-stranded helix that is common 
for the 2-oxoglutarat dependent oxygenases. This motif comprises the three 
iron binding ligands which form a conserved two-histidine-one-carboxylate 
iron coordinating triad (Schofield and Ratcliffe 2004; Dann and Bruick 2005). 
1.2.1 Oxygen-independent HIFα stabilization 
Obviously, a large part of HIFα stabilization under normoxic conditions could 
be achieved by interfering with PHD function. Thus, several metals are known 
to induce HIF activity probably by direct replacement of iron in the catalytic 
center of the enzymes or by disturbing hydroxylation by preventing the 
completion of the enzyme’s redox cycle (Schofield and Ratcliffe 2004; Wenger 
et al. 2005; Ke and Costa 2006). Iron chelators (deferoxamine (DFX), 
cyclopirox olamine) are well-known for their stabilization of HIFα. Similar to 
the substitution of iron by other metals, the iron in the catalytic center of the 
hydroxylases is chelated, inactivating the enzymes and thereby stabilizing 
HIFα (Hirsila et al. 2005). Another possibility to block HIFα hydroxylation is the 
direct inhibition with designed inhibitors such as dimethyloxalylglycine, a 2-
oxoglutarat mimicking drug (Wirthner et al. 2007). Other potent inhibitors of 
the PHDs are succinate (the product of the enzyme reaction itself) and the 
chemically related fumarate, both compounds of the citric acid cycle (Isaacs et 
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al. 2005; Pollard et al. 2005; Selak et al. 2005; King et al. 2006) (Schofield 
and Ratcliffe 2004). 
1.2.2 Other means to modulate HIF activity 
In addition to the mechanisms governing HIF activity described above, various 
other stimuli dictate the outcome of HIF target gene activation. Several growth 
factors (PDGF, FGF-2, IGF-2, etc.) and cytokines (e.g. TFG-1β, TNFα, IL-1β) 
as well as oncogenes (ras, src) or tumor suppressor mutations (PTEN, pVHL, 
FH, SDH) have been shown to up-regulate HIF activity (Karni et al. 2002; 
Stiehl et al. 2002; Wenger 2002; Bilton and Booker 2003; Dery et al. 2005; 
Gort et al. 2006). One way of HIFα regulation by these factors may originate 
through direct phosphorylation of HIFα and thereby modulating HIF activity. 
As a matter of fact, HIF is strongly phosphorylated, but HIFα degradation 
seems not to be affected by these posttranscriptional modifications pointing to 
a mechanism different from HIFα protein stabilization (Bilton and Booker 
2003). Moreover, phosphorylation of threonine 796 was reported to prevent 
the inhibitory hydroxylation by FIH (Gradin et al. 2002), while MAPK pathway 
activation leads to increased transcriptional activity of HIF (Sang et al. 2003; 
Brahimi-Horn et al. 2005). However, the main impact of these factors on HIF 
regulation is through up-regulation of protein translation (Bilton and Booker 
2003; Bardos and Ashcroft 2004). Enhanced translation appears to be 
sufficient to overcome degradation or to titer out the PHDs, resulting in 
detectable HIFα protein (activity?) even under normoxic conditions.  
Basic levels of HIF-1α are subject to other control mechanisms, such as the 
multi-functional scaffold protein receptor for activated C-kinase 1 (RACK1) 
and the chaperone heat shock protein 90 (HSP90) (Liu and Semenza 2007). 
HSP90 has previously been recognized as HIF interactor and stabilizer 
(Katschinski et al. 2004). RACK1 in this scheme counteracts HIF-1α 
stabilization by HSP90 by competing for interaction with the PAS-A domain of 
HIF-1α. Upon binding to the PAS domain, RACK1 mediates the contact to the 
same ubiquitin-complex as pVHL, ultimately leading to HIF-
1α polyubiquitination and degradation (Fig.5). This oxygen-independent HIF-
1α degradation pathway could be stimulated in RCC4 cell lines (which are 
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pVHL deficient and therefore contain high endogenous HIFα levels) by the 
use of HSP90 inhibitors (Liu et al. 2007). The HSP90 inhibitors geldanamycin 
and 17-allylaminogeldanamycin (17-AAG) exert their action by binding and 
blocking the ATPase domain of the chaperone and thus abrogate the 
stabilizing interaction of HSP90 with its client proteins, in this case HIF-1α.  
 
Figure 4. Degradation of HIF-1α by the 26S proteasome. RACK1 binding to the transcription factor is 
independent of hydroxylation. RACK1 (analog to pVHL) mediates the interaction to the ubiqutin ligation 
complex. HSP90 competes with RACK1 for binding to HIF-1α. 17-AAG abrogates HSP90 interaction. 
This results in enhanced RACK1 dependent degradation of HIF-1α according to Liu (figure taken from 
Liu and Semenza 2007)  
1.3 HIF and tumor growth 
Considering the different ways of HIF regulation, it is not surprising that the 
HIFα subunit is detectable in the majority of human tumors in contrary to 
normal tissue of the same origin (Aebersold et al. 2001; Maxwell 2005).  
The enhanced HIFα levels in malignant tissues are accompanied by elevated 
expression levels of HIF-target genes (Wenger et al. 2005). These genes are 
central to the regulation of cellular metabolism, nutrition control, angiogenesis 
and pH (Semenza 2003). Thus, HIF helps to meet the high nutrition demand 
of highly proliferative tumor cells and contributes to equilibrate the cellular 
metabolism.  
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Clearly, HIF is at the heart of the regulatory systems controlling 
neovascularization (Pouyssegur et al. 2006). Vasculogenesis is primarily 
governed by oxygen supply and HIF activation leads to the expression of 
several angiogenic factors, among them the key regulator vascular endothelial 
growth factor (VEGF) (Vogelstein and Kinzler 2004). Moreover, the 
requirement of HIF for neovascularization and tumor growth has been shown 
Tang. (Tang et al. 2004). 
Besides its participation in the formation of new blood vessels, the uptake of 
nutrients (glucose, iron) is enhanced by HIF and glycolysis is up-regulated, 
whereas oxidative metabolism is reduced (Wenger 2002; Papandreou et al. 
2006). This leads to anaerobic ATP generation (Pasteur effect) and 
accumulation of lactate (Seagroves et al. 2001) and might explain the 
increased glycolysis by cancerous tissue when compared to their healthy 
counterparts; a phenomenon first described by O.H. Warburg. Lactate is 
transported by the H+/lactate monocarboxylate transporter (MCT) into the 
extra-cellular milieu and contributes to acidosis (Pouyssegur et al. 2006).  
Acidosis is another feature of solid tumors apart from angiogenesis or the 
Warburg effect. Cellular pH-control is governed by Na+/H+ exchanger (NHE) 
and NHE1 is HIF-dependently induced (Shimoda et al. 2006).(Cardone et al. 
2005). However, HIF dependent expression of membrane-bound, extra-
cellular carbonic anhydrase IX (CAIX) drives the alkalinization of the 
intracellular milieu but enforces the acidification of the extra-cellular milieu. 
CAIX converts water and carbon dioxide (formed during anaerobic glycolysis) 
to bicarbonate and protons, thereby up-regulates the extra-cellular pH. 
Bicarbonate, a weak base, buffers the intra-cellular milieu following transport 
into the cell by the sodium-bicarbonate co-transporter (NBC) or the anion 
exchanger (AE). Thus, HIF contributes to tumor acidosis and affects cellular 
pH-control (Pouyssegur et al. 2006). 
In summary, HIF activity might explain some of the characteristics of 
malignant tissues. In general, HIF contributes to tumor growth and drives the 
surrounding tissue to (re)-establish conditions suitable for cellular life. 
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1.3.1 
1.4.1 
HIF and malignant progression 
HIFs’ support of tumor development (and thus malignancy) is based largely on 
their ability to mitigate angiogenesis and nutrition supply (Pouyssegur et al. 
2006). However, during cancer progression other components of the HIF 
response may account for a more malignant state. Cell type specific HIF-
dependent effects on apoptosis or metabolism contribute to HIF-dependent 
malignant progression as well. 
The pathophysiological induction of HIF, as observed in neoplastic lesions, 
reflects the whole spectrum of HIF-target genes. (Wenger 2002; Greijer and 
van der Wall 2004). HIF target genes can be grouped in genes required for 
metabolism (glycolysis, mitochondrial respiration), nutrient supply (glucose 
uptake, iron uptake, angiogenesis, erythropoiesis),  cellular survival, 
apoptosis, proliferation, cytoskeletal structure, mobility etc. (Semenza 2003; 
Wenger et al. 2005). Many of these genes support cellular survival under 
harsh conditions. In short, HIF comes into action to sustain cell survival and 
tissue homeostasis. Intriguingly, under pathophysiological circumstances HIF 
helps neoplastic alterations to endure, giving time for clonal expansion of 
progressively more malignant cells.   
1.4 Tumors  
Tumor definition 
The term “tumor” originates from the Latin word tumor and is translated by 
“swelling”. Tumor characterizes every abnormal growth of tissue including 
masses due to inflammation or malformations as well as extrusions of tissues 
due to rigidifications (e.g. ingrown splinter). This definition includes tissues 
spawn by dysregulated cell proliferation known as neoplasia i.e. new types of 
tissue. Neoplasia or cancer is subdivided into benign or malignant according 
to their ability to invade the underlying tissue. Further histopathology 
classification enables cancer researcher to group the majority of human 
neoplasia into tumors of the ephitelial tissue, termed carcinomas; into tumors 
originating from the mesoderm of the embryo, termed sarcomas; into cancer 
derived from hematopoietic tissues (e.g. lymphomas, leukemia); and into 
tumors arising from cells with connection to the nervous system (sometimes 
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also referred to as neuroectodermal tumors e.g. glioblastoma, retinoblastoma) 
(Weinberg 2007). 
1.4.2 Tumor progression  
The recognition of tumors cells as being descendants of normal tissue cells 
hints to a malfunction of the progeny (Bickers and Lowy 1989). Hanahan and 
Weinberg concluded “...cancer to be a disease involving dynamic changes in 
the genome” and postulate the hallmarks of cancer as a multi-step process of 
genetic alterations which leads from normal human cells to malignant cancer 
cells (Preston-Martin et al. 1990; Hanahan and Weinberg 2000). 
In order to evolve into cancerous tissue, normal human cells have to 
circumvent several anti-cancer barriers that ensure the integrity of normal 
human tissue (Bartkova et al. 2005; Gorgoulis et al. 2005). 
Taken together, this signifies a halt for a proliferating tumor mass until the 
required abilities were achieved by a clone and therefore points to a clonal 
expansion in a Darwinian way. (Fig. 1A) 
 
 
Figure 5. (A) Expansion in a Darwinian way requires selection for the fittest cell followed by expansion 
of the population. Further clonal expansion after a beneficial mutation eliminates less adapted clones 
from the population. (B) Cancerous progression viewed as heterozygote clonal evolution (figure taken 
from Weinberg 2007). 
 
However the discovery of cancer stem cells, the contribution of epigenetic 
factors to malignant transformation and the possible rapid rate of de-
differentiation of cancer cells requires adapting this simplified classical 
perception of cancer cell selection to a contemporary view of cancer evolution 
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(Grady and Markowitz 2002; Lobo et al. 2007) (Fig. 1B).The road to a  fully 
developed malignant state might be different for any kind of human tissue but 
on the molecular level similar events have to take place to pass the barriers 
imposed by the metazoan evolution to allow for cancer progression (Lane 
2005; Weinberg 2007).These anti-cancer barriers were depicted as aberrant 
mitogenic signaling, loss of cell cycle control, avoidance of apoptosis, 
immortalization and the ability to trigger the angiogenic switch (Hanahan and 
Weinberg 2000). 
1.4.2.1 Aberrant mitogenic signalling 
For a human cell to proliferate, external growth stimuli are needed which are 
converted by transcriptional and translational induction into gain of mass and 
division cycles. The conversion of these stimuli into the corresponding cellular 
response is best characterized by the case of the RTK-ras-MAPK pathway 
(Chang and Karin 2001; Alberts 2002). Thus, every cell makes use of several 
distinct mitogenic signaling pathways that combine and control the adequate 
proliferation of each cell. However, every malfunction of each step of a given 
pathway has the potential to induce aberrant mitogenic signaling (Porter and 
Vaillancourt 1998) (Hunter 1997). 
1.4.2.2 Loss of cell cycle control  
During metazoan development, single cells had to learn to communicate 
together to ensure that a cell body will emerge out off a single cell (Lane 
2005). This communication yielded into a cell cycle clock which strictly 
depends on external permission signals to proceed (Tapon et al. 2001). 
Additionally, external anti-growth stimuli (e.g.TFG-β) are applied to keep or to 
bring a cell into a quiescent state. For a cancer cell to avoid this status means 
to neglect the superimposed cell cycle state (Blagosklonny and Pardee 2002). 
The cell cycle machinery is tightly controlled, but in a simplified view all 
signals finally converge in the phosphorylation status of pRB (and its cousins 
p107, p130, collectively called pocket proteins) (Weinberg 2007). pRB on the 
other hand controls the R point transition and only hyperphosphorylated and 
inactivated pocket proteins will lead to the passage of the G1 phase of the cell 
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cycle (Bartek et al. 1997) (Fig.2). Thus, de-regulated cell cycle control, vastly 
influenced by pRB, inexorably provokes cancer progression.  
 
 
Figure 6. Passage over the restriction point reflects pRB phosphorylation state. The cell cycle will be 
completed after R point transition regardless of exogenous signaling. Phosphorylation of the pocket 
protein is performed by cell cyclin dependent kinases initiated by mitogenic stimuli (figure modified from 
Weinberg 2007).  
1.4.2.3 Avoidance of apoptosis 
The master guardian over the cell state p53 is mutated or inactivated in most 
(if not all human cancers) (Weinberg 2007). This high rate of affected p53 in 
cancer progression underscores the prominent role of this protein in keeping 
tissue homeostasis in order. Upon inadequate stimuli such as: over-shooting 
proliferation signaling, loss of adherence to the extracellular matrix or 
damaged DNA, p53 is stabilized and thereafter induces cell cycle arrest, and 
by up-regulation of proapoptotic factors (e.g. bax, puma, noxa), shifts the 
balance of the cell fate towards apoptosis (Levine 1997; Giaccia and Kastan 
1998). In order to progress to a malignant state a precancerous cell therefore 
has to shift the balance of pro- and anti-apoptotic factors. As a result of the 
complex interactions, which determine the onset of apoptosis, and the 
abundant factors and signal pathways involved, avoidance of apoptosis 
seems most promising by targeting a key regulator such as p53 - but of 
course every factor influencing the execution of the death program or every 
contribution to one side of the balance of pro- vs. anti-apoptotic factors might 
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prohibit a cell to correctly engage into the cell death program (Green and 
Evan 2002; Igney and Krammer 2002). 
1.4.2.4 Immortalization 
Mammalian cells rely on a specific number of cell divisions after which they 
remain insensitive towards division stimuli but keep metabolic active. This 
process is termed replicative senescence and was traced back to an 
accumulation of DNA damage in the cell (Cristofalo et al. 2004). The cells thus 
will stop proliferating once the burden of DNA damage reaches a certain 
threshold. Apart from repeated replication rounds, other stresses are known to 
induce an indistinguishable cellular state. Among this stresses are DNA 
damage, aberrant mitogenic signaling (e.g. ras), oxidation or xenobiotic 
exposure (Weinberg 2007). Circumvention of senescence is made possible 
for rodent cells by inactivating key regulators (pRB, p53) by transfection with 
large T-antigen leading to immortalization. This state of unlimited replicative 
ability is also observed by spontaneous immortalization in cultured rodent 
fibroblasts. In this case, however, natural selection for inactivated key 
regulators results in immortalization (Katakura et al. 1998).  
Human cell lines, however, will not become immortalized as it is the case for 
cells with rodent origin but will result in a state called crisis, accompanied by 
heavy apoptosis after an additional number of cell doublings beyond the usual 
entrance into senescence (Weinberg 2007). Characteristic for cells in crisis is 
the appearance of fussed chromosomes and eroded telomeres. The 
molecular origin of the appearance of this phenotype is coupled to human 
telemorase regulation. Expression of the catalytic subunit of the enzyme 
hTERT is repressed in humans postembryonic cell lineages (in contrary to 
mice), resulting in telomerase independent telomere maintenance. Hence, 
telomeres in human cells shorten after each replication step until they are no 
longer able to protect the ends of the chromosomes (Stewart and Weinberg 
2006). 
1.4.2.5 The angiogenic switch 
The more a tumor gains mass the more distant from the vasculature some 
cells become. At some point in the growth of a tumor, support of nutrition (and 
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disposal of cell waste) will be restricted for those cells. This leads to a 
proliferation stop and slows down tumor progression. Large necrotic areas will 
form (Kaanders et al. 2002; Naumov et al. 2006). The sudden emergence of 
new capillaries inbetween the neoplastic tissue restores the cells with 
proliferative energy and gives rise to further tumor progression. For a healthy 
tissue, neoangiogenesis is restricted and cancer tissue has to pass this barrier 
in order to evolve further (Hanahan and Folkman 1996; Bergers and Benjamin 
2003). The onset of this process of increasing angiogenesis, “the angiogenic 
switch”, appears as the first milestone towards a highly vascularized tumor, 
paralleled by poor clinical outcomes (Heimann and Hellman 1998; Hlatky et al. 
2002; Weinberg 2007). To build up a dense network of new vessels, the tumor 
relies on macrophage and fibroblast recruitment and the subsequent 
infiltration of endothelial precursor cells attracted by the same cytokines 
(PDGF, FGF, VEGF, TGF-β etc.) as released by damaged vasculature (Bingle 
et al. 2002; Knowles and Harris 2007). 
The dramatic changes observed in neoplastic tissue, leading to new 
capillaries, are similar to the mechanisms observed during wound healing 
(Dvorak 1986; Singer and Clark 1999; Weinberg 2007). This ensures oxygen 
availability and cell survival for a cancerous mass since more distant areas 
from blood vessels experience an increasingly hypoxic environment (Brown 
and Giaccia 1998; Hockel and Vaupel 2001; Naumov et al. 2006). 
Paradoxically, tumors with large hypoxic regions are prone to develop an even 
more aggressive phenotype (Vaupel and Mayer 2007; Weinberg 2007). This 
might be explained by the function of the hypoxia-inducible factor (HIF) that 
up-regulates, amongst others, genes involved in neoangiogenesis. The 
protein levels of HIF strongly correlate with poor clinical prediction and tumor 
therapy resistance.(Wenger 2002; Linden et al. 2003; Tang et al. 2004; 
Manalo et al. 2005; Moeller and Dewhirst 2006; Pouyssegur et al. 2006). 
1.5 Cancer therapy 
The gold standard for cancer therapy is based on the three conventional 
methods: surgery, chemotherapy and radiotherapy (Lodish 2000; Stenner-
Liewen et al. 2006). Due to the progress in the development of these methods 
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and due to the increased sensitivity of early diagnosis, cancer therapy 
nowadays is able to cure a range of occurring malignant transformations 
(Alberts 2002). However, depending on localization and origin, some tumors 
are difficult to treat, resulting in a high rate of mortality and an increase of 
therapeutic side-effects. Modern clinical approaches try to lower treatment 
burden and enhance therapeutic efficiency by complementing classical 
therapies (Alberts 2002). The goal of these attempts towards more specific 
cures is to discover characteristic attributes of transformed tissue. These 
unique traits serve as molecular targets to directly induce tumor regression or 
render cancerous cells more sensitive to therapy (Balis 2002; Stenner-Liewen 
et al. 2006). Therefore, the prerequisite to designed drugs is a fundamental 
understanding of the molecular processes in the cancerous lesions as well as 
in healthy tissues. Unfortunately, molecular action of the conventional 
remedies remains only partially resolved and modern approaches, besides 
success in a few rare cases, are rather ineffective (Weinberg 2007). 
In general, traditional nonsurgical strategies to eliminate cancer cells induce 
cell death by activation of the apoptosis program in one or the other way but 
do not specifically target malignant cells (Fisher 1994; Lowe and Lin 2000; 
Johnstone et al. 2002). Some degree of selection is achieved by applying 
treatments that preferentially affect (fast) proliferating cells. One way is to 
disrupt DNA to such extend as to overrule repair. Proliferation of cells with 
damaged DNA is abrogated leading to cell cycle stop and apoptosis (Lodish 
2000; Alberts 2002) 
1.5.1 Etoposide  
Etoposide is one of the most important drugs in cancer chemotherapy and is 
used to treat different type of cancers, including testicular, ovarian, lung and 
stomach cancer. In the clinics, etoposide is intravenously applied. Side-effects 
include lowered resistance to infection due to reduced white blood cell 
production, anemia due to reduced red blood cell production, bleeding due to 
reduced platelet production and hair loss. Chemically, the compound is 
derived from podophyllotoxin a substance isolated from the American 
mayapple tree (podophyllum peltatum). The semi-synthetically modified toxin 
is also known as eposin, vepeside or VP-16. Etoposide exerts its action by 
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inhibition of topoisomerase II, an enzyme used to unwind curled DNA-strands. 
Topoisomerase II is needed for replication of the DNA as well as for 
transcription to RNA by the respective polymerases. In order to unwind the 
DNA strand, the enzyme cuts one side of the DNA double-strand and passes 
the other strand through the newly formed gap before relegation. The 
etoposide inhibited isomerase yields a DNA-topoisomerase intermediate that 
collapses by a polymerase complex, leading to DNA double-strand breaks. 
Therefore, the cellular concentration of topoisomerase II is critical to the 
toxicity of the drug and the more topoispomerases II, as observed in 
proliferating cells (of a neoplastic tissue), the more detrimental the drug 
(Meresse et al. 2004). 
1.5.2 Hypoxia, HIF and therapy resistance 
During solid tumor growth, hypoxic to anoxic areas are commonly 
encountered owing to inadequate vasculature of the growing malignant 
transformation and the resulting imbalance in oxygen supply and demand 
(Brown and Giaccia 1998). Thus oxygen-deprived cells will become apoptotic 
and necrotic regions will form in the tumor, as well (Kaanders et al. 2002). 
Therapy outcome of tumors with alternating areas of hypoxia and normoxia is 
difficult to predict and hypoxic regions correlate with therapy resistance 
(Hockel and Vaupel 2001; Vaupel and Mayer 2007). 
Hypoxic therapy resistance is a well-established aspect in solid tumor 
treatment, however, the underlying mechanisms are not completely 
understood. When it comes to HIF function, as master controller of the 
hypoxic response, things are even more uncertain.  
Based on HIF function in vascularization it is evident that this transcription 
factor is a strong, tumor-growth promoting element. Other important aspects 
of HIF function, regulation of cellular metabolism (glycolysis, oxidative 
phosphorylation) and its involvement in apoptosis seem to contribute to the 
tumor promoting action of HIF but still need clarification (Pouyssegur et al. 
2006). The very same reasons that suggest HIF as a tumor promoter are 
discussed as reasonable arguments for HIF’s role in cancer therapy 
resistance (Moeller and Dewhirst 2006). 
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HIF might impact on therapy resistance by mediating vascularization and 
ensuring tumor growth by stimulation of endothelial cell survival. This, 
however, does not explain the cellular effects of HIF on therapy resistance 
observed in cell culture studies (Zhang et al. 2004; Williams et al. 2005; 
Brown et al. 2006; Hussein et al. 2006; Song et al. 2006). According to these 
studies HIF is a negative factor in tumor therapy, possibly acting as “survival 
factor”. Indeed, some authors try to establish an effect of HIF on apoptosis, 
leading to enhanced resistance through a shift from pro- to anti-apoptotic 
factors (BID, BAX) (Erler et al. 2004). However, contradictory reports question 
the findings (Biju et al. 2004). Moreover, the use of anoxic conditions, that 
induce p53 and thereby a presumable effect of p53, diminish the importance 
of these observations (Schmid et al. 2004). The exact role of HIF in induction 
of apoptosis is not clear and might even depend on the oxygen partial 
pressure or glucose abundance (Greijer and van der Wall 2004; Kilic et al. 
2007). 
Another approach to explain HIF’s role in cancer therapy resistance was to 
circumvent the possible implication of p53 in apoptosis by the use of p53 
inactivated cell lines. By comparison of two p53 inactivated cell lines, one 
wild-type and the other deficient for HIFα, a difference in the sensitivity 
towards DNA double-strand break-inducing drugs could be observed (Unruh 
et al. 2003). Surprisingly other compounds did not provoke the same 
differential cell kill. Together with a plasmid rejoining assay this data led to the 
assumption that factors involved in the maintenance of DNA, more precisely in 
the re-ligation of DNA double-strand breaks, may depend on HIF for proper 
action. 
1.6  DNA-repair 
The construction plan of every single cell in our body is located in the nucleus 
itself. Wrapped around proteins, tangled together and fixed to a scaffold, but 
altogether nicely protected, the DNA serves as encoded sketch for its own 
duplication (Richmond 2006). In this way DNA templates are passed from one 
generation to another. Shelter from possible harm is one mean to assure the 
integrity of the genome. In spite of this protecting architecture, DNA is 
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subjected to chemical and physical damage (Weinberg 2007). Therefore, 
without surveillance and restoration the code would soon be mutated to such 
an extent as to abrogate genome duplication or to enhance the rate of tumor 
incidence and progression. Thus, a cell has developed “care keeper” enzymes 
to survey and fix DNA (Scharer 2003).  
1.6.1 
1.6.2 
Double-strand breaks 
DNA double-strand breaks (DSBs) are one of the many DNA damages a cell 
has to suffer from and is believed to be one of the most severe types of 
lesions (Valerie and Povirk 2003). DSBs arise from exogenous agents such 
as ionizing radiation or radio-mimetic compounds (chemotherapeutic agents: 
etoposide, cisplatin). DSBs are also formed by reactive oxygen species (ROS) 
generated by endogenous sources (peroxisomal, mitochondrial) (Pierce et al. 
2001). Furthermore DSBs are caused by mechanical stress on chromosomes 
or by collapse of replication forks when the replication machinery encounters 
a DNA single-strand break or other DNA distortions and by programmed 
cleavage during various biological events such as V(D)J recombination during 
immunoglobulin gene rearrangement  or meiotic recombination or in the 
course of an inflammatory response. DSBs lead to cell cycle arrest and, if 
unrepaired, to cell death (Collis et al. 2005). Errors during repair may lead to 
insertion or deletion mutations or to genomic instability through chromosomal 
translocation. The DSB response activates the repair machinery and 
transiently arrests cell cycle progression which involves distinct enzymes, 
many of which assemble at the damaged site (Jackson 2002; Valerie and 
Povirk 2003).  
Histone H2AX 
 One of the earliest events in the DSB response is the rapid and massive 
phosphorylation of H2AX a histone variant of H2A (Olive and Banath 2004) 
The isoform H2AX accounts for 2%-25% of the total histone H2A of a cell and 
is ubiquitously distributed throughout the genome (Rogakou et al. 1998). A 
few minutes after DSB insult and several hundred of kilobases around the 
break, phosphorylation of serine 139 on the carboxy-terminal end of the 
histone takes place (Rogakou et al. 1999; Pilch et al. 2003; Tsukuda et al. 
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2005). Phosphorylated H2AX is termed γH2AX. Immunohistochemical 
detection of γH2AX reveals the formation of visible foci proportional to the 
irradiation dose and overlaps with break sites (Limoli and Ward 1993; 
Rogakou et al. 1998; Rogakou et al. 1999; Banath and Olive 2003; Banath et 
al. 2004). The role of γ-H2AX in DSB repair is not entirely understood but is 
necessary for sustained recruitment of repair factors and to restructure 
chromatin (Celeste et al. 2003; Chowdhury et al. 2005; Franco et al. 2006). 
H2AX knock-out mice are viable but inonizing radiation (IR) sensitive, 
immunocompromised and suffer from increased genomic instability, 
underscoring the involvement in DNA repair. DNA damage-induced 
phosphorylation is attributed to at least three members of the PIKK 
(phosphatidyl inositol kinase related kinase) group of kinases DNA-activated 
protein kinase (DNA-PK), Ataxia-telangiectasia mutated (ATM), ATM- and 
rad3-related (ATR) (Pilch et al. 2003; Fernandez-Capetillo et al. 2004; Kurose 
et al. 2005; Reitsema et al. 2005). 
1.6.3 The phosphatidyl inositol 3-kinase related kinases (PIKK)   
The PIKKs form a family of six members (ATM, ATR, DNA-PK, mammalian 
target of rapamycin (mTOR), suppressor of morphogenesis in genitalia-1 
(hSMG-1), transformation/transcription domain-associated protein (TRRAP)) 
of high molecular weight proteins. Five of them bear serine-threonine kinase 
activity, whereas TRRAP has a catalytic domain, although without 
phosphotransferase activity. The element that groups the enzymes into the 
large superfamily of the PIKKs is the catalytic domain with a high similarity in 
the DNA sequence, although the phosphorylation of proteins and not lipids is 
favored. Characteristic for the family of PIKKs, apart of the catalytic domain, 
are two domains termed FAT (FRAT, ATM, TRAPP) and FATC (FRAT, ATM, 
TRAPP, C-terminal) which flank the catalytic core and which are necessary for 
the catalytic efficiency of the enzymes, and finally a N-terminally located 
domain of α-helical repeat subunits called HEAT (huntingtin, elongation factor 
3, a subunit of protein phosphatase 2A and TOR1) presumably used for 
protein-protein interaction (Abraham 2004). 
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1.6.3.1 ATM- and rad3-related (ATR) 
ATR is an essential member of the PIKK family since homozygous mutation of 
the ATR locus in mice not only leads to embryonic lethality, but even cells 
could not be cultivated (Bakkenist and Kastan 2004). Therefore, ATR is 
needed for the survival of a cell and the organism, hinting to roles in 
development and/or cell cycle progression. Established is the requirement of 
ATR for appropriate signaling after DNA damage in course of replication or 
after disruption of proceeding replication events (Shechter et al. 2004). ATR 
seems to be activated by various DNA-damaging agents, replication inhibitor, 
UV irradiation, single-stranded DNA (ssDNA) gaps, severe hypoxia, and 
during ATMs response to DNA DSB (Yang et al. 2003; Bakkenist and Kastan 
2004). Apparently, ATR is activated by replication protein A (RPA) covered 
ssDNA (Shechter et al. 2004). ATR interacting protein (ATRIP) binds RPA-
ssDNA intermediates and thereby recruits ATR (Falck et al. 2005). Activated 
ATR will slow down or halt cell cycle progression by targeting several proteins 
implicated in cell cycle control (Shechter et al. 2004). 
 
A                                                                       B 
igure 7. Inactivation of active cyclin-CdK dimers (A) CDKI inhibitor binds to the complex and keeps it 
inactive, here shown for p27 (a cousin to p21) (B) Activation of the kinase complex is possible by 
removing a phosphate group. The activating phosphatase is called cdc25. Degradation of cdc25 results 
in inhibited cyclin-Cdk dimers and cell cycle arrest (figure taken from Alberts 2002). 
ell-cycle progression depends largely on the activity of dimeric complexes 
 
 
F
 
C
with kinase activity. Cell cycle halt signifies to inactivate these complexes or to 
keep these complexes in an inactive state. One possibility is to physically 
block the kinase, like the cyclin-dependent kinase inhibitors (CDKI) do, by 
complexing with the cyclin-Cdk dimer (Weinberg 2007) (Fig.6A). Other means 
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to kinase inactivation include allosteric interaction or modification. Indeed 
control over S-phase transition is achieved by the interplay of inactivating 
phosphorylation of the Cdk complexes and activating removal of the 
phosphate group by a phosphatase (cdc25) (Alberts 2002) (Fig.6B). ATR 
triggers cell cycle arrest by phosphorylation of p53 which in turn up-regulates 
p21waf1/cip, a CDKI, and by activation of Chk1 a cell cycle regulatory kinase 
resulting in phophorylation and degradation of cdc25 (Chen and Sanchez 
2004; Shechter et al. 2004). 
1.6.3.2 Ataxia-telangiectasia mutated (ATM)  
onse. In undamaged cells ATM is the key transducer of the DNA DSB resp
ATM resides as inactive dimer. Upon insult, dimer dissociation and 
autophosphorylation on serine 1981 result in activation of the large kinase and 
subsequent phosphorylation of ATM target proteins in the surrounding of the 
break (Bakkenist and Kastan 2004). Active ATM is recruited to DSB by 
Nijmegen breakage syndrome 1 (Nbs1), a part of the evolutionarily conserved 
Mre11, Rad50, Nbs1 (MRN) complex (Falck et al. 2005; Lee and Paull 2005). 
Autophosphorylation is defective in Nbs1 or Mre11 compromised cells. Thus, 
MRN is needed for the initial activation and amplification of the ATM signal. In 
addition, Nijmegen breakage syndrome, A-T like Disorder (ATLD), caused by 
mutation in the MRE11 gene, and ataxia-telangiectasia share common clinical 
manifestations and overlapping cellular characteristic (Paull and Lee 2005). 
AT patients are deficent for ATM function and exhibit, amongst others, a 
pronounced radiosensitivity, increased risk of cancer, premature aging and 
immune deficiencies. Cells from AT patients do not respond appropriately to 
ionizing radiation, as reflected by enhanced cell death, enhanced 
chromosomal breakage and defective cell cycle checkpoints (Bakkenist and 
Kastan 2004). Similar to its cousin ATR, cell-cycle control is obtained by 
phosphorylation of p53 and inactivation of cdc25. However Chk2 rather then 
Chk1 is the mediator in the ATM response to DSB (Ahn et al. 2004; Kurz and 
Lees-Miller 2004). 
 21
INTRODUCTION 
 
1.6.3.3 DNA depended protein kinase (DNA-PK)  
The function of the third PIKK involved in DSB repair clearly deviates from the 
mediator kinases ATM or ATR that organize the DSB-response. DNA-PK, 
however, is directly implicated in the repair event as part of the end-fixing and 
relegation machinery (Weterings and van Gent 2004). Even though p53 
phosphorylation by DNA-PK may be observed in vivo and thus contributes to 
cell cycle regulation and apoptosis, the main task remains in soiling two DNA 
ends together (Collis et al. 2005). When DNA breaks, the large kinase 
complex is located on the DNA ends, acting as a scaffold for other repair 
proteins. The repair event is additionally directed by the kinase through the 
addition of phosphate groups to several key proteins. End-ligation presumably 
is supported by directly promoting pairing of the broken ends (Spagnolo et al. 
2006). DNA-PK consists of three components: the heterodimeric Ku complex 
with its two subunits of approximately 70 and 80 kDa and the catalytic part 
called DNA-PKcs (catalytic subunit) (Spagnolo et al. 2006). The Ku complex 
has been originally discovered as autoantigen (“Ku” is derived from the first 
two letters of the original patient`s name) (Downs and Jackson 2004). The Ku 
complex is conserved in eukaryotes and the core complex of the dimer was 
discovered in archaea as well as bacteria (Doherty and Jackson 2001). The 
cellular localization of the dimer appears restricted primarily to the nucleus, 
both subunits having a nuclear localization signal (NLS). However, cytosolic 
Ku70 has been attributed a bax binding ability, exerting a possible anti-
apoptotic function, as well (Koike et al. 2001; Sawada et al. 2003; Downs and 
Jackson 2004). Nevertheless, the principal form detected in the cell is the 
stable Ku70-Ku80 dimer, indicating a stabilizing effect off the subunits upon 
complex formation (Downs and Jackson 2004). The observed 
interdependence is further underscored by Ku80 deficient cell lines, 
possessing only little Ku70 (and vice versa) as well as by the reconstitution of 
a Ku80-lacking phenotype with Ku80 that leads to the restoration of both 
(Downs and Jackson 2004). The homology between the two proteins hints to 
a common ancestor. The major difference is found in the C-terminal part. 
Whereas Ku70 possesses a SAP domain with low DNA binding affinity, Ku80 
has a DNA-PKcs binding-site (Downs and Jackson 2004). Three dimensional 
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analyses revealed a ring-like structure for the Ku complex which may encircle 
DNA ends without any further sequence specificity - but with Ku70 aligned 
distal to the end when compared to Ku80 (Walker et al. 2001). Recruitment of 
the large catalytic subunit by the Ku-complex to free DNA ends then follows, 
since the trimeric complex requires the presence of free DNA ends for strong 
and stable interaction (Weterings and van Gent 2004). Association of the 
catalytic subunit with the Ku complex on DNA stimulates the activity of the 
kinase and leads to phosphorylation of downstream targets – eventually the 
Ku ring winds interior, placing the DNA-PKcs at the edge of the DNA strand, 
thereby protecting the ends from nucleases or physical damage (Meek et al. 
2004). Two DNA-PKcs proteins on two opposite ends then contact each other, 
possibly yielding a synaptic complex which is a prerequisite for ligation 
(Spagnolo et al. 2006). In contrary to the Ku complex DNA-PKcs is only found 
in vertebrates. Thus, it has been speculated that other homologous of PIKKs 
exist in lower eukaryotes or that functions of DNA-PKcs are specific to higher 
organisms e.g. repair-dependent chromatin remodeling (Khanna and Jackson 
2001; Jackson 2002; Lees-Miller and Meek 2003). Mice deficient for DNA-
PKcs have defective immune systems caused by a disturbed B- an T-cell 
maturation due to its role in V(D)J-rejoining. These mice are not only 
comprised in their immune system but are also hypersensitive to IR (Lees-
Miller and Meek 2003). Both events require the ligation of two opposed DNA 
ends. Owing to the central role of DNA-PKcs in religation of DNA ends, this 
process is abolished in the knock-out mouse, resulting in the observed 
phenotype (Lieber et al. 2004). The phenotype of Ku-deficent mice is similar 
to DNA-PKcs mutants but additionally marked by reduced body weight at 
birth, slow growth and shorter life expectancy. Therefore, additional functions 
of the Ku heterodimer e.g. in telomere maintenance are expected (Lees-Miller 
and Meek 2003; Downs and Jackson 2004). 
1.6.4 Homologous recombination repair versus non-Homologous 
end joining 
A vertebrate cell relies on two major pathways when it comes to fixation of 
DNA DSB: HR or NHEJ (Pierce et al. 2001). 
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Even though both pathways lead to fixed DNA ends, the two mechanisms are 
different. Whereas HR relies on a template to keep the original sequence 
preserved in an error-free process, NHEJ religates broken DNA ends without 
sequence consideration and therefore is per se an error-prone process (Lisby 
and Rothstein 2005). Due to the dependence on a template for action, HR is 
restricted to the late S/G2 phase of the cell cycle when sister chromatids are 
aligned and recombination is possible. On the other hand, NHEJ ligates 
broken DNA ends as the major mechanism during G0/G1 phase of the cell 
cycle but still persists in the later cell cycle phases (Lees-Miller and Meek 
2003; Lieber et al. 2004). 
1.6.4.1 Homologous recombination repair (HR) 
HR is performed by a multitude of proteins including RPA, Rad51, Rad52, 
Rad54, MRN, BRCA1 and BRCA2 which are directly involved in the repair 
event or direct the repair event by acting as scaffold proteins.  
 
 
Figure 8. Homologous 
recombination repair. After strand 
alignment of the broken strand 
with the corresponding template, 
HR starts with nucleolytic 5`to 3` 
resection of the strand. Rad51 
assists strand invasion and 
homologous pairing in concert 
with numerous additional proteins 
leading to a recombination 
intermediate. After DNA synthesis 
the restored strands are re-igated. 
Final resolution of the 
recombination intermediate by 
cleavage and ligation results in 
two intact DNA double helices 
(figure taken from Jackson 2002). 
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Mediator proteins which promote the repair event are ATM and ATR. In short, 
after DSB recognition the helix is cut partially, leading to single-stranded DNA 
coated by RPA protein. This will subsequently be complexed by Rad51 which 
is necessary for strand invasion and exchange. Further unwinding of the 
double-strand is assisted by the Rad51 homologous and Rad52 as well as by 
Rad54 and helicases such as WRN or BLM helicase, leading to a 
recombination intermediate. Finally, strand replication by a polymerase and 
ligation of the resulting gap restores the DNA strand and completes repair 
(Jackson 2002) (Fig.7).  
1.6.4.2 Non-homologous end joining  
The mediator kinase ATM and the MRN complex have a function in the early 
steps of DSB repair by NHEJ, probably in signaling the break to the cell and in 
trimming the ends for subsequent repair. However, NHEJ does not strictly 
depend on these factors. The process is initiated by the Ku heterodimer 
binding to the ends of the break point. This leads to DNA-PKcs recruitment to 
the damaged site. 
 
 
Figure 9. Non-homologous end joining. The 
broken DNA ends are immediately fixed 
and bound by the Ku-dimer. The Ku-DNA 
intermediate atractes and activates DNA-
PKcs. The DNA-PK holoenzyme then 
physically bridges and stabilizes the break 
and phosphorylates other targets, probably 
to direct repair. Depending on the damage 
some broken ends need to be trimmed prior 
to ligation. The completed process results in 
a repaired DNA strand. However changes 
in the sequence are likely to occur. Thus, 
NHEJ is an error-prone process (figure 
taken from Jackson 2002). 
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In principal, the stabilized DNA ends could now be ligated by a ligase, but 
most often the DNA ends need to be processed first. Artemis, a nuclease is 
the most likely candidate for this function. After end resection and addition of a 
phosphate group by the terminal deoxynucleotidyl transferase (TdT), most 
probably polymerase µ fills up the existing gap and ligase IV in complex with 
XRCC4 (an adapter protein) connect the ends together (Jackson 2002) 
(Fig.8). 
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2.1.1 Abstract 
 The prolyl-4-hydroxylase domain (PHD) oxygen sensor proteins 
hydroxylate hypoxia-inducible transcription factor (HIF) α-subunits, leading to 
their subsequent ubiquitinylation and degradation. Because oxygen is a 
necessary co-substrate, a reduction in oxygen availability (hypoxia) decreases 
PHD activity and subsequent HIFα hydroxylation. Non-hydroxylated 
HIFα cannot be bound by the ubiquitin ligase von Hippel-Lindau tumor 
suppressor protein and HIFα proteins thus become stabilized. HIFα then 
heterodimerizes with HIFβ to form the functionally active HIF transcription 
factor complex which targets approx. 200 genes involved in adaptation to 
hypoxia. The three HIFα prolyl-4-hydroxylases are clearly of different nature 
compared with the prototype collagen prolyl-4-hydroxylase which hydroxylates 
a mass protein rather than a rare transcription factor. Thus, novel assays had 
to be developed to express and purify functionally active PHDs and to 
measure PHD activity in vitro. There is also a need for such assays to 
functionally distinguish the three different PHDs in terms of substrate 
specificity and drug function. We provide a detailed description of the 
expression and purification of the PHDs, as well as of a HIFα-dependent and 
a HIFα-independent PHD assay. 
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2.1.2 Introduction 
 Cells sense changes in environmental oxygen availability by a group of 
enzymes which directly control the cellular response to low oxygen by 
destabilizing hypoxia-inducible factor (HIF) α subunits, the master 
transcriptional regulators of the hypoxic response. These oxygen sensing 
enzymes have alternatively been termed prolyl-4-hydroxylase domain (PHD), 
HIF prolyl hydroxylase (HPH) or egg laying defective nine homolog (EGLN). 
Three family members are known up to date: PHD1/HPH3/EGLN2, 
PHD2/HPH2/EGLN1 and PHD3/HPH1/EGLN3 (Bruick 2000; Epstein et al. 
2001; Ivan et al. 2002). PHDs hydroxylate HIF-1α and HIF-2α at two distinct 
proline residues within the HIFα oxygen-dependent degradation (ODD) 
domain (Fig. 1A). Under normoxic conditions, prolyl-4-hydroxylation allows 
binding of the von Hippel-Lindau tumor suppressor protein (pVHL), leading to 
polyubiquitinylation and proteasomal destruction (Wenger 2002; Schofield and 
Ratcliffe 2004). Under hypoxic conditions, prolyl-4-hydroxylation is reduced, 
HIF-1α and HIF-2α become stabilized, heterodimerize with the constitutively 
expressed HIF-1β subunit aryl hydrocarbon receptor nuclear translocator 
(ARNT), and regulate the expression of a large number of effector genes 
involved in adaptation to low oxygen (Wenger et al. 2005). In addition, factor 
inhibiting HIF (FIH) hydroxylates an asparagine residue within the C-terminal 
transactivation domain. Oxygen-dependent asparagine hydroxylation blocks 
the recruitment of the CBP/p300 transcriptional co-activators and thereby 
regulates the transcriptional activity of HIFs (Hewitson et al. 2002) (Mahon et 
al. 2001; Lando et al. 2002) 
 PHDs do not represent static oxygen sensor molecules but rather are 
highly regulated themselves. Importantly, PHD2 and PHD3, but not PHD1, 
have been reported to be hypoxically induced at both the mRNA and protein 
levels (Epstein et al. 2001). Accordingly, elevated PHD2 and PHD3 levels 
have been demonstrated in a broad panel of established cancer cell lines 
(Appelhoff et al. 2004). Functional hypoxia response elements (HREs) are 
located in the promoter region of the human PHD2 gene as well as in the first 
intron of the human PHD3 gene, demonstrating that PHD2 and PHD3 are HIF 
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target genes themselves (Metzen et al. 2005; Pescador et al. 2005). Because 
the essential co-factor oxygen is basically lacking under hypoxic conditions, 
the HIF-dependent hypoxic increase in PHD abundance is somehow 
paradoxical and it has been suggested that PHD induction plays a role in 
accelerating the termination of the HIF response following re-oxygenation 
(Epstein et al. 2001; Appelhoff et al. 2004; Aprelikova et al. 2004; Marxsen et 
al. 2004). Indeed, biochemical in vitro studies revealed Km values of purified 
PHDs for oxygen close to the oxygen partial pressure (pO2) in air, suggesting 
that the kinetics of specific HIFα hydroxylation under hypoxic conditions are 
rather slow (Hirsilä et al. 2003; Ehrismann et al. 2006). However, tissues in 
situ have to deal with a great variability of generally very low pO2 values, even 
when the inspiratory pO2 is considered to be “normoxic”. We recently showed 
that HIF-dependent regulation of PHD levels adapts the PHD-HIF oxygen 
sensing system to a given tissue pO2, rather than simply accelerating HIFα 
destruction following re-oxygenation (Stiehl et al. 2006). Such a self-regulatory 
loop might define a tissue-specific threshold for HIFα-activation as a function 
of local pO2.  
 In addition to transcriptional regulation, PHD levels are also regulated 
by protein-protein interactions: the ubiquitin ligase Siah2 regulates PHD1 and 
PHD3, but not PHD2, protein stability (Nakayama et al. 2004); PHD3, but not 
PHD1 or PHD2, appears to be a substrate for the TRiC chaperonin (Masson 
et al. 2004); OS-9 apparently is simultaneously interacting with both HIFα and 
PHD2 or PHD3, but not PHD1, thereby enhancing HIFα hydroxylation and 
degradation (Baek et al. 2005); MORG might provide the molecular scaffold 
for HIFα interaction specifically with PHD3 (Hopfer et al. 2006); and ING4, a 
likely component of a chromatin-remodeling complex, might be recruited via 
PHD2 to enhance HIF transcriptional activity (Ozer et al. 2005). On the other 
hand, PHD2 has been shown to inhibit the transactivation function of HIF-1α 
in VHL-deficient cells (To and Huang 2005) 
 These findings suggest two additional layers in oxygen signalling: first, 
abundance and function of PHDs can indeed be regulated; and second, the 
three different PHDs are regulated in non-identical ways, further supporting 
 29
RESULTS 
 
their non-redundant roles in oxygen sensing. In fact, while all three PHDs can 
hydroxylate HIFα with similar efficiency, PHD2 has been suggested to play 
the main role for normoxic HIFα turnover (Berra et al. 2003). Consistent with 
these in vitro findings, PHD2 but neither PHD1 nor PHD3 knock-out mice die 
during embryonic development (Takeda et al. 2006). Interestingly, a family 
with erythrocytosis due to a mutation in the gene encoding PHD2 has recently 
been reported (Percy et al. 2006). The three PHDs are expressed in most 
organs but there are strikingly high levels of PHD3 mRNA expressed in the 
heart and of PHD1 mRNA expressed in the testis (Stiehl et al. 2006; Willam et 
al. 2006) 
 PHD function can also be regulated by a number of endogenous small 
molecules as well as by a number of clinically relevant drugs: ascorbate 
(Knowles et al. 2003), transition metals (Hirsila et al. 2005; Martin et al. 2005), 
Krebs cycle intermediates (Dalgard et al. 2004; Lu et al. 2005; Selak et al. 
2005) and reactive oxygen species (ROS) including NO (Metzen et al. 2003; 
Gerald et al. 2004; Berchner-Pfannschmidt et al. 2006) has been shown to 
influence or completely block the activity of the PHDs. Thus, there appear to 
exist molecular cross-talks between oxygen homeostasis and transition metal 
homeostasis as well as cellular metabolism. However, it is not completely 
understood how various transition metals and ascorbate interfere with PHD 
and FIH function. The transition metals do not simply replace or oxidize the 
ferrous iron in the active center of the hydroxylases (Hirsila et al. 2005; Martin 
et al. 2005). More likely, transition metals might decrease the availability of 
ascorbate by catalysing oxygen-dependent ascorbate oxidation (Salnikow et 
al. 2004; Karaczyn et al. 2006). As known for collagen hydroxylation, 
ascorbate might be required for reducing ferric iron in the active center of 
PHDs and FIH which occurs when oxidative decarboxylation of 2-oxoglutarate 
is uncoupled from target hydroxylation (Myllyla et al. 1984; McNeill et al. 2005) 
 In addition to kinase signalling pathways, numerous reports appeared 
about an involvement of ROS in HIFα protein stabilization by either growth 
stimuli or hypoxia. Non-conclusive data were obtained so far about the 
source(s) of the ROS and whether hypoxia leads to an increase or decrease 
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in ROS levels (Wenger 2000). However, ROS do have the potential to 
interfere with the complex process of protein hydroxylation. Indeed, the 
increase in ROS in junD-/- cells leads to a decrease in PHD activity and hence 
to HIF-1α accumulation (Gerald et al. 2004). Apart from direct interference of 
ROS with the active center of oxygen sensing protein hydroxylases, also the 
re-direction of oxygen from mitochondria towards the protein hydroxylases 
might contribute to these effects (Wenger 2006) 
 Due to the large therapeutical potential of PHD inhibitors in the 
treatment of anemic and ischemic diseases, several attempts to develop PHD 
antagonists are in progress. Currently, N-oxyalylglycine (N-OG) and its cell-
permeable derivative dimethyloxalylglycine (DMOG) are the commercially 
available PHD inhibitors of choice for experimental purposes. Apart from 
these co-substrate competitive inhibitors, iron chelators are very well known to 
induce HIF by PHD inhibition. These include desferoxamine (DFX) and 
ciclopirox olamine (CPX), two clinically relevant hydroxamic acid iron 
chelators (Linden et al. 2003). In order to functionally investigate the potency 
and mechanisms of available and future PHD inhibitors, there is a clear need 
for reliable methods to generate PHD proteins and to determine their activity. 
2.1.2.1 Production of functionally active PHDs 
 Since bacterially expressed PHDs retain only little hydroxylase activity, 
PHDs were expressed and purified from baculovirally infected insect cells. To 
facilitate purification, the PHDs were tagged with either glutathione-S-
transferase (GST) or His6. According to our experience, best results were 
obtained with GST-tagged PHD proteins. Thus, GST-tagged expression 
vectors were prepared by LR clonase-mediated homologous recombination of 
the corresponding pENTR vector, containing PHD1, PHD2 or PHD3 cDNA 
inserts, with the pDEST20 vector (Invitrogen). Recombined plasmids were 
transfected into the E. coli strain Top10 and the resulting bacmid plasmids 
were used to generate baculovirus stocks according to the manufacturer's 
instructions (Invitrogen). Spodoptera frugiperda (Sf) 9 cells were infected with 
baculovirus and cultured in Grace's insect medium (Invitrogen) at 25°C in a 
humidified incubator. Infected cells were grown for 80 to 110 hours, collected 
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by centrifugation at 700 × g for 10 minutes at 4°C and washed with ice-cold 
PBS. Lysis was performed on ice for 10 minutes with 0.1% NP-40 in a buffer 
containing 10 mM Tris-HCl pH 7.4, 100 mM NaCl, 100 mM glycine and 100 
µM dithiothreitol (DTT). Crude lysate was cleared by centrifugation at 20,000 
× g for 20 minutes at 4°C and the supernatant was incubated with glutathione-
sepharose beads (previously washed with PBS) for at least 2 hours at 4°C 
with gentle agitation. After washing three times with PBS the protein was 
eluted with 15 mM reduced glutathione (GSH) in 50 mM Tris-HCl pH 8.0, 5% 
glycerol and 2 µM FeSO4. Purity was checked by SDS-PAGE followed by 
coomassie staining or immunoblotting (Fig. 1B). Activity was routinely 
determined by the VHL binding assay described below (Fig. 1C).  
2.1.2.2 Determination of prolyl-4-hydroxylation by VHL binding to 
peptides derived from the HIF-1α ODD domain 
 Enzymatic activities of recombinant PHD proteins were determined by 
an in vitro hydroxylation assay based on a 96-well format as described 
previously (Oehme et al. 2004; Martin et al. 2005). Briefly, biotinylated 
synthetic peptides derived from human HIF-1α amino acids 556 to 574 (biotin-
DLDLEALAPYIPADDDFQL; either wild-type, P564A mutant or Hyp564 
modified) were bound to NeutrAvidin-coated 96-well plates (Pierce). All 
methionine residues were mutated to alanine residues in these peptides 
(M561A, M568A). Hydroxylase reactions using purified recombinant GST-
tagged PHDs or cellular extracts were carried out for 1 hour at room 
temperature. A polycistronic bacterial expression vector for His6-tagged and 
thioredoxin-tagged pVHL/elongin B/elongin C (VBC) complex (kindly provided 
by S. Tan, Pennsylvania, PA) was used to express VBC in E. coli strain 
BL21AI followed by purification using nickel affinity chromatography 
(Amersham-GE Healthcare). The VBC complex was allowed to bind to the 
hydroxylated peptides for 15 minutes, anti-thioredoxin antibodies were added 
for 30 minutes, and horseradish peroxidase-coupled anti-rabbit antibodies 
(Sigma) were added for 30 minutes. Bound VBC complex was detected using 
the TMB (3,3’,5,5’-tetramethylbenzidine) substrate kit (Pierce). The 
peroxidase reaction was stopped by adding one volume 2 M H2SO4 and 
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absorbance was determined at 450 nm in a microplate photometer. This 
assay is routinely used to determine the activity of the three GST-tagged PHD 
enzymes purified from Sf9 insect cells (Fig. 1C). Inter-assay comparability 
was guaranteed by calibration of each experiment to an internal standard 
curve using increasing fraction of synthetic hydroxyproline-containing peptides 
(Fig. 2A). When performed with pre-equilibrated solutions in a hypoxic glove 
box (Invivo2 400, Ruskinn Technology), this assay nicely demonstrates that 
PHD2 and PHD3 hydroxylase activities are functional over a wide range of 
physiologically relevant oxygen concentrations (Fig. 2B). Furthermore, this 
assay is strictly dependent on the presence of P564 within the substrate 
peptide, and the iron chelator DFX as well as the substrate analog N-OG 
inhibit PHD-dependent prolyl-4-hydroxylation (Fig. 2C).  
 Apart from purified recombinant PHDs, also crude cellular extracts are 
suitable sources of PHD activity for the VBC binding assay. Therefore, Hep3B 
cells were lysed by dounce homogenization in 100 mM Tris-HCl pH 7.5, 1.5 
mM MgCl2, 8.75% glycerol, 0.01% Tween20 and EDTA-free protease inhibitor 
cocktail (Roche). Cell lysates were cleared by centrifugation at 20,000 × g for 
30 minutes at 4°C. As shown in Fig. 2D, these extracts stimulated VBC 
binding to wild type but not P564A mutant HIF-1αODD-derived peptides. The 
specificity of the PHD activity was further demonstrated by inhibition with N-
OG and by culturing the Hep3B cells under hypoxic conditions (0.4% O2 for 16 
hours). Consistent with the known hypoxic induction of PHD2 and PHD3, 
extracts derived from hypoxic Hep3B cells showed an increased PHD activity 
(Fig. 2D). Similar results were obtained with HeLa cells (data not shown). 
2.1.2.3 Determination of prolyl-4-hydroxylation by oxidative 
decarboxylation of 2-oxoglutarate 
 While the VHL binding assay is well suited to investigate PHD function, 
it is strictly dependent on HIFα-derived peptides as hydroxylation substrates 
and hence does not allow to investigate the hydroxylation of potential novel 
non-HIFα targets. To overcome this problem, a 2-oxoglutarate to succinate 
conversion assay, originally developed to study collagen hydroxylation (Kaule 
and Gunzler 1990), was adapted to HIFα hydroxylation. There are basically 
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two possibilities to label the 2-oxoglutarate co-substrate: when [5-14C]2-
oxoglutarate is used, the resulting [14C]succinate can be measured (D'Angelo 
et al. 2003; D'Angelo et al. 2003); when [1-14C]2-oxoglutarate is used, the 
resulting [14C]CO2 must be captured and quantified (Hirsila et al. 2003). 
Because it is technically less demanding, the former technique is used in our 
laboratory. This assay was first applied for PHD measurements by Frelin and 
co-workers using "light mitochondrial rat kidney fractions" (D'Angelo et al. 
2003; D'Angelo et al. 2003). We measured oxidative decarboxylation of 2-
oxoglutarate by purified PHDs, because kidney extracts prepared according to 
Frelin and co-workers in fact solely showed high background activities, but did 
not contain measurable quantities of specific PHD activity (see below). 
Peptide or protein substrates (about 5 µM) were incubated with 0.1 µg GST-
tagged PHD enzymes in 100 µl 50 mM Tris-HCl pH 7.4, 10 µM 2-oxoglutarate, 
2 mM ascorbate, 100 µM DTT, 1 mg/ml BSA, 0.6 mg/ml catalase, 5 µM 
freshly prepared FeSO4 and 50,000 - 100,000 dpm [5-14C]2-oxoglutarate with 
a specific activity of 50 mCi/mmol (Hartmann-Analytic). Hydroxylation 
reactions were carried out for 24 hours at 37°C. To separate 2-oxoglutarate 
from succinate, 25 µl 20 mM succinate and 20 mM 2-oxoglutarate were added 
and mixed by vortexing. Subsequently, 25 µl 0.16 M 2,4-dinitrophenyl 
hydrazine in 30% HClO4 were added. After incubation at room temperature for 
30 minutes, 50 µl of 1 M 2-oxoglutarate was added to remove residual 2,4-
dinitrophenyl hydrazine, and the reaction was allowed to proceed for another 
30 minutes at room temperature. Following centrifugation at 20,000 × g for 15 
minutes at 4°C, 150 µl supernatant was carefully removed, mixed with 3 ml 
scintillation cocktail (PerkinElmer), and the amount of [14C]succinate was 
determined by liquid scintillation counting in a β-counter (TRI-CARB 2900TR, 
Packard).  
 As depicted in Fig. 3A, using recombinant GST-PHD2 this assay shows 
a linear relationship between the availability of a HIF-1α ODD domain-derived 
synthetic peptide substrate and [14C]succinate production in the range from 8 
to 50 µM peptide. Below 5 µM, however, only background values were 
obtained. This assay is strictly dependent on the presence of 1 mM ascorbate 
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as well as a peptide substrate containing the wild-type P564 (Fig. 3B). The 
lack of a substrate peptide or the mutation of the critical proline (P564A) 
results in background 2-oxoglutarate conversion.  
2.1.2.4 Crude tissue extracts are not a suitable source of PHD activity 
for the 2-oxoglutarate conversion assay. 
 Earlier reports suggested the use of "light mitochondrial rat kidney 
fractions" as a source for PHD activity in this type of assay (D'Angelo et al. 
2003; D'Angelo et al. 2003). We therefore prepared rat kidney extracts 
according to this protocol and tested them for PHD activity. As shown in Fig. 
4A, 2-oxoglutarate conversion was indeed stimulated by these extracts. 
However, a very high background activity was also observed in the absence 
of the HIF-1α ODD domain-derived peptide and the presence of the wild-type 
peptide stimulated 2-oxoglutarate conversion only moderately. To ensure 
PHD-dependent 2-oxoglutarate conversion, ample amounts of the known 
PHD inhibitors DFX and N-OG (see Fig. 2C) or CuCl2 (Martin et al. 2005) 
were added to the reaction mix. Surprisingly, none of these PHD inhibitors 
blocked 2-oxoglutarate conversion, whether the substrate peptide was present 
or not (Fig. 4A, left panel). Moreover, the presence of a P564A mutant peptide 
stimulated 2-oxoglutarate conversion as well as the wild-type peptide (Fig. 4A, 
right panel). The P564A mutant peptide cannot be hydroxylated and shows no 
VBC complex binding after incubation with purified PHDs (Figs. 2C and 3B). 
Therefore, these experiments clearly demonstrate that "light mitochondrial rat 
kidney fractions" do not represent a source of specific PHD activity but rather 
contain high levels of enzymes unspecifically metabolising 2-oxoglutarate. A 
similar lack of specific (i.e. PHD-dependent) 2-oxoglutarate conversion was 
observed with crude extracts derived from HeLa, Hep3B/Hek293 and Sf9 cells 
(data not shown). 
2.1.2.5 Thin layer chromatography to assess the purity of [5-14C]2-
oxoglutarate 
 A major problem in the optimisation of the 2-oxoglutarate conversion 
method is the high proportion of background activity when non-purified PHD 
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preparations are used as source of the enzymatic activity. Indeed, cellular 
extracts usually contain too high background activities to be suitable as PHD 
source, even when the PHDs are exogenously overexpressed. Another 
background-causing problem was the quality of the radioactively labelled [5-
14C]2-oxoglutarate. To analyse the [5-14C]2-oxoglutarate preparations for 
impurities, it was diluted in 1.5 mM non-labeled 2-oxoglutarate and spotted 
onto thin layer chromatography (TLC) plates (Silica gel 60 F254, Merck). 
Following drying, the TLC plate was placed in a chromatography chamber 
containing a 120:70:15 mixture of diethyl ether/hexane/formic acid. When the 
eluent reached the top of the TLC plate, it was dried and the radioactivity 
quantitated by phosphorimaging (BioRad). Non-labeled 2-oxoglutarate and 
succinate were used as standards. They were visualized as bright yellow 
spots by immersing the TLC plates in a 0.04% bromcresol purple solution in a 
1:1 mixture of ethanol and water (adjusted to pH 10.0 with NaOH) and dried 
with a hair-dryer. Rf values for succinate and 2-oxoglutarate were 0.45 and 
0.12, respectively. As shown in Fig. 4B, there are considerable differences in 
the quality of the available [5-14C]2-oxoglutarate preparations. While some 
batches were of acceptable purity (Fig. 4B, left panel), others contained up to 
30% of an impurity that co-migrated with the succinate standard (Fig. 4B, right 
panel). Regarding the relatively low specific PHD activities and the rather high 
unspecific background 2-oxoglutarate conversion, such high impurities are not 
acceptable in this type of assay. 
2.1.2.6 Application of the 2-oxoglutarate conversion assay to protein 
targets 
 In order to be useful for putative novel PHD substrate proteins without 
prior knowledge of the actual target prolyl residue, the 2-oxoglutarate 
conversion assay needs to work also with proteins rather than only with 
synthetic peptides. To demonstrate the feasibility of this approach, wild-type 
GST-HIF2αODD (aa 404-569, MW = 46 kDa) and P405A/P531A double-
mutant GST-HIF2αODD protein fragments were expressed in E.coli BL21AI 
by induction with 0.2% arabinose for 4 hours at 37°C. After harvesting by 
centrifugation, the bacteria were lysed with a high pressure cell disrupter 
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(Basic-Z, Constant Systems) in the prescence of an EDTA-free protease 
inhibitor cocktail (Roche). Purification of the GST-tagged protein was carried 
out using affinity chromatography on glutathione sepharose beads  
(Amersham-GE Healthcare) as described above (see Fig. 1B). Purity of the 
recombinant protein fragments was checked by SDS-PAGE followed by 
coomassie staining or immunoblotting (Fig. 5A). When compared with a HIF-
1αODD-derived wild-type peptide, equimolar concentrations of the HIF2αODD 
protein fragment also stimulated PHD1-dependent 2-oxoglutarate conversion, 
albeit to a somewhat lower extent (Fig. 5B). 
2.1.3 
2.1.4 
Conclusions 
 The PHD-dependent hydroxylation assay presented here works 
independently of already known peptide sequences or VHL binding. It should 
thus be possible to use this assay for the investigation of putative novel, non-
HIFα PHD substrates as well. In addition, even if not shown here, the same 
assay should principally also be applicable to novel FIH substrates and might 
become useful for screening for novel hydroxylation targets. Whereas no non-
HIFα PHD targets have been reported thus far, FIH has recently been shown 
to hydroxylate a number of proteins containing ankyrin repeats, including NF-
κB and IκBα (Cockman et al. 2006). We expect a similar widening of the 
spectrum of PHD targets. In addition, PHD-dependent hydroxylation assays 
will be required to study novel drugs that modulate PHD activity and hence will 
become important for the treatment of anemic and ischemic disease. 
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Figure 1. (A) Reaction mechanism of PHD-mediated oxygen-dependent prolyl-4-hydroxylation by 
oxidative decarboxylation of the co-substrate 2-oxoglutarate. Inhibitors of this reaction are indicated. N-
OG, N-oxalylglycine; DMOG, dimethyloxalylglycine. (B) Purification of GST-tagged PHD1, PHD2 and 
PHD3 expressed in baculovirus-infected Sf9 insect cells by glutathione affinity chromatography. The 
purified GST-PHD proteins were analyzed by SDS-PAGE and coomassie blue staining ("CBS") or 
immunoblotting ("IB") using anti-GST antibodies. (C) Hydroxylation activities of GST-PHD preparations 
determined by a VBC-binding assay as described in the text. Wild-type ("Pro") and P564A mutant ("Ala") 
HIF-1α ODD domain-derived peptides were used as hydroxylation substrates. 
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Figure 2. (A) VBC (pVHL/elongin B/elongin C) complex binding to prolyl-4-hydroxylated HIF-1α ODD 
domain-derived peptides. Biotinylated peptides containing increasing proportions of synthetically 
generated hydroxyproline peptides were allowed to bind to neutravidin-coated 96 well ELISA plates. 
Immunodetection of bound VBC complex was performed as described in the text. (B) Oxygen-
dependent activity of recombinant GST-PHD2 and GST-PHD3. Purified PHD proteins were used to 
hydroxylate HIF-1α ODD domain-derived peptides under the indicated oxygen concentrations (% vol/vol 
in the gas phase). The extent of prolyl-4-hydroxylation was quantitated as described above. (C) PHD3 
as well as the wild-type peptide substrate ("Pro") are required for VBC binding. The lack of peptide ("-"), 
a P564A mutation ("Ala"), iron chelation by desferrioxamine ("DFX") or N-oxalylglycine ("N-OG") all 
completely inhibited VBC binding. (A-C) Shown are mean values ± SEM of triplicates. (D) Hypoxia 
stimulates PHD activity in Hep3B cells. Crude cellular lysates were used to hydroxylate HIF-1α ODD 
domain-derived peptides as described above. Shown are mean values ± SEM of triplicates normalized 
to protein content. 
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Figure 3. (A) Determination of prolyl-4-hydroxylation by oxidative decarboxylation of [5-14C]2-
oxoglutarate. Recombinant GST-PHD2 was incubated with increasing concentrations of a HIF-1α ODD 
domain-derived peptide as indicated. PHD-dependent generation of [14C]succinate was determined as 
described in the text. Background activity was determined in control reactions without substrate peptide 
and the obtained value subtracted from the peptide-containing reactions. (B) Recombinant GST-PHD2 
was incubated with increasing concentrations of ascorbate as indicated and either a wild-type, P564A 
mutant or no peptide substrate. 
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Figure 4. (A) Lack of specific 2-oxoglutarate-to-succinate conversion by "light mitochondrial rat kidney 
fractions". Left panel: peptide-stimulated activity in these extracts could not be inhibited by DFX, CuCl2 
or N-OG. Right panel: a P564A mutant ("Ala") HIF-1α ODD domain-derived peptide stimulated 2-
oxoglutarate conversion as well as the wild-type ("Pro") peptide. (B) Quality control of [5-14C]-2-
oxoglutarate by thin layer chromatography. The amount of [5-14C]-2-oxoglutarate spotted corresponded 
to 30 kdpm, 15 kdpm, 7.5 kdpm and 3.8 kdpm, respectively (from left to right). Two [5-14C]-2-
oxoglutarate batches of different quality are shown. Pure 2-oxoglutarate and succinate served as 
migration markers (positions indicated at the right margin).  
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Figure 5. (A) Purification of wild-type and P405/531A double mutant GST-HIF-2α ODD (human HIF-2α 
amino acids 404-569) protein fragments expressed in bacteria and purified by glutathione affinity 
chromatography. The purified proteins were analyzed by SDS-PAGE and coomassie blue staining 
("CBS") or immunoblotting ("IB") using anti-GST antibodies (B) Determination of prolyl-4-hydroxylation 
by oxidative decarboxylation of [5-14C]2-oxoglutarate. Recombinant GST-PHD1-dependent generation 
of [14C]succinate was promoted by HIF-1αODD-derived wild-type ("wt") but not by P564A mutant ("mt") 
peptides (human HIF-1α amino acids 556-574). Generation of [14C]succinate was also promoted by 
wild-type GST-HIF-2αODD protein but not by GST alone and to a much lower extent by the  
GST-HIF-2αODD P405/531A double mutant. Equimolar concentrations (5 µM) of the substrate peptides 
and protein fragments were used. Where indicated, the reactions could be blocked by 5 mM N-
oxalylglycine ("N-OG"). Shown are mean values ± SEM of three independent experiments performed in 
duplicates. 
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2.2.1 Abstract 
Prolyl-4-hydroxylase domain (PHD) proteins are oxygen-dependent enzymes 
that hydroxylate hypoxia-inducible transcription factor (HIF) α-subunits, 
leading to their subsequent ubiquitinylation and degradation. Paradoxically, 
the expression of two family members (PHD2 and PHD3) is induced in 
hypoxic cell culture despite the reduced availability of oxygen co-substrate, 
and it has been suggested that they become functionally relevant following re-
oxygenation to rapidly terminate the HIF response. Here we show that PHDs 
are also induced in hypoxic mice in vivo, albeit in a tissue-specific manner. As 
demonstrated under chronically hypoxic conditions in vitro, PHD2 and PHD3 
show a transient maximum but remain upregulated over more than 10 days, 
suggesting a feedback downregulation of HIF-1α which then levels off at a 
novel setpoint. Indeed, hypoxic induction of PHD2 and PHD3 is paralleled by 
the attenuation of endogenous HIF-1α. Using an engineered oxygen-sensitive 
reporter gene in a cellular background lacking endogenous HIF-1α and hence 
inducible PHD expression, we could show that increased exogenous PHD 
levels can compensate for a wide range of hypoxic conditions. Similar data 
were obtained in a reconstituted cell-free system in vitro. In summary, these 
results suggest that due to their high O2 Km values PHDs have optimal 
oxygen-sensing properties under all physiologically relevant oxygen 
concentrations: increased PHDs play a functional role even under oxygen-
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deprived conditions, allowing the HIF system to adapt to a novel oxygen 
threshold and to respond to another hypoxic insult. Furthermore, such an 
autoregulatory oxygen-sensing system would explain how a single 
mechanism works in a wide variety of differently oxygenated tissues.  
2.2.2 Introduction 
Biological systems tightly monitor acute changes in environmental 
conditions, initiate regulatory responses, and use negative feedback loops to 
limit the extent of these responses. To adapt to chronic changes, many 
environmental sensors are capable of adjusting their threshold values, 
allowing to respond again to acute deviations of a now different setpoint.  
Cells sense changes in environmental oxygen availability by a group of 
enzymes which directly control the cellular response to lowered oxygen by 
destabilizing hypoxia-inducible factor (HIF) α subunits, the master 
transcriptional regulators of the hypoxic response. These oxygen-sensing 
enzymes have alternatively been termed prolyl-4-hydroxylase domain (PHD), 
HIF prolyl hydroxylase (HPH) or egg laying defective nine homolog (EGLN). 
Three family members are known up to date: PHD1/HPH3/EGLN2, 
PHD2/HPH2/EGLN1 and PHD3/HPH1/EGLN3 (Bruick 2000; Epstein et al. 
2001; Ivan et al. 2002). PHDs hydroxylate HIF-1α and HIF-2α at two distinct 
proline residues within the HIFα oxygen-dependent degradation (ODD) 
domain. Under normoxic conditions, prolyl-4-hydroxylation allows binding of 
the von Hippel-Lindau tumor suppressor protein (pVHL), leading to 
polyubiquitinylation and proteasomal destruction (Wenger 2002). Under 
hypoxic conditions, prolyl-4-hydroxylation is reduced, HIF-1α and HIF-2α 
become stabilized, heterodimerize with the constitutively expressed HIF-1β 
subunit aryl hydrocarbon receptor nuclear translocator (ARNT), and regulate 
the expression of a large number of effector genes involved in adaptation to 
low oxygen (Wenger et al. 2005). In addition, factor inhibiting HIF (FIH) 
hydroxylates a C-terminal asparagine residue, thereby regulating the 
transcriptional activity of HIFs (Mahon et al. 2001; Hewitson et al. 2002; Lando 
et al. 2002). 
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 Upon re-oxygenation, the PHD oxygen sensing system must be rapidly 
reversed. Interestingly, PHD2 and PHD3, but not PHD1, have been reported 
to be hypoxically induced at both the mRNA and protein levels (Epstein et al. 
2001). Accordingly, elevated PHD2 and PHD3 levels have been demonstrated 
in a broad panel of established cancer cell lines (Appelhoff et al. 2004). 
Functional hypoxia response elements (HREs) are located in the promoter 
region of the human PHD2 gene as well as in the first intron of the human 
PHD3 gene, suggesting that PHD2 and PHD3 are HIF target genes 
themselves (Metzen et al. 2005; Pescador et al. 2005). Because the essential 
co-factor oxygen is basically lacking under hypoxic conditions, the HIF-
dependent hypoxic increase in PHD abundance has been suggested to play a 
role in accelerating the termination of the HIF response following re-
oxygenation (Epstein et al. 2001; Appelhoff et al. 2004; Aprelikova et al. 2004; 
Marxsen et al. 2004). Indeed, biochemical in vitro studies revealed Km values 
of purified PHDs for oxygen close to the oxygen partial pressure (pO2) in air, 
suggesting that the kinetics of specific HIFα hydroxylation under hypoxic 
conditions are rather slow(Hirsilä et al. 2003). However, tissues in situ have to 
deal with a great variability of generally very low pO2 values, even when the 
inspiratory pO2 is considered to be “normoxic”. We therefore raised the 
question, whether HIF-dependent regulation of PHD levels might lead to the 
adaptation of the PHD-HIF oxygen sensing system to a given tissue pO2, 
rather than simply accelerating HIFα destruction following re-oxygenation. 
Such a self-regulatory loop might define a tissue-specific threshold for HIFα-
activation as a function of local pO2.  
2.2.3 Materials and Methodes 
2.2.3.1 Cell culture 
All cells were maintained in DMEM high glucose, containing 4.5 mg/ml 
glucose (Sigma, Buchs, Switzerland) to maintain cellular energy metabolism 
during prolonged hypoxic culturing. Culturing media were supplemented with 
10% heat-inactivated fetal calf serum, 50 IU/ml penicillin and 50 µg/ml 
streptomycin (Invitrogen, Basel, Switzerland). Mouse embryonic fibroblast 
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(MEF)-Hif1a+/+ and MEF-Hif1a-/-, and mouse hepatoma Hepa1 and Hepa1c4 
were cultured as described before (Chilov et al. 1999; Unruh et al. 2003). For 
long-term hypoxia, MEFs were grown under 2% O2 for up to 256 hours in a 
gas-controlled glove box to allow for handling of the cells under constant pO2 
(InvivO2 400, Ruskinn Technologies, Leeds, UK). Cells were grown on 145 
mm culture dishes and splitted every 48 hours. Reagents used for splitting 
and permanent culturing were pre-equilibrated to the pO2 in the glove box 
before use. For oxygen titration, a single batch of transfected MEF-Hif1a-/- 
cells was distributed into different hypoxic incubators (Binder, Tuttlingen, 
Germany) and simultaneously cultured for the indicated time periods. 
2.2.3.2 Protein extractions and immunoblot analyses 
Cells were washed twice and scraped into ice-cold PBS. Soluble cellular 
protein was extracted with a high-salt extraction buffer containing 0.1% NP-40 
essentially as described before (Martin et al. 2005). Protein concentrations 
were determined by the Bradford method and 50 to 80 µg protein was 
subjected to immunoblot analysis. Antibodies were obtained from the following 
sources: anti-human HIF-1α mouse monoclonal antibody (mAb), Transduction 
Laboratories (BD Biosciences, Basel, Switzerland); anti-human PHDs rabbit 
polyclonal antibodies, Novus Biologicals (Littleton, CO); anti-V5-tag mAb, 
Invitrogen; anti-β-actin mAb, Sigma; Horseradish peroxidase-coupled 
secondary antibodies, Pierce (Perbio, Lausanne, Switzerland). Anti-human 
PHD3 mAb was kindly provided by P.J. Ratcliffe (Oxford, UK). Bound 
antibodies were detected with ECL substrate (Pierce) and chemiluminescence 
was quantified with a CCD-camera-based light imaging system 
(FluorChem8900, AlphaInnotech, Witec, Littau, Switzerland) using 
QuantityOne software (Biorad, Reinach, Switzerland).  
2.2.3.3 mRNA quantification 
Exposure of mice to inspiratory 0.1% carbon monoxide or 7.5% oxygen and 
serum erythropoietin quantification by RIA have been published previsously 
(Wenger et al. 1996; Wenger et al. 1998; Wenger and Gassmann 1999). Total 
RNA from tissue and cells was purified as described previously (Martin et al. 
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2005). RNA concentrations were determined spectrophotometrically and RNA 
integrity was monitored by denaturing formaldehyde/agarose gel 
electrophoresis. Total RNA (5 µg) was reverse transcribed (RT) using oligo-dT 
and Stratascript reverse transcriptase (Stratagene, LaJolla, CA). mRNA levels 
for mouse carbonic anhydrase (CA) IX, glucose transporter (GLUT) 1, 
erythropoietin, PHD1, PHD2 and PHD3 were quantified with 2 µl of diluted 
cDNA reaction (corresponding to 1% of cDNA reaction) by real-time RT-PCR. 
A SybrGreen qPCR reagent kit (Sigma) was used in combination with a 
MX3000P light cycler (Stratagene). Initial template concentrations of each 
sample were calculated by comparison with serial dilutions of a calibrated 
standard. To control for equal input levels, ribosomal protein S12 mRNA was 
determined and data expressed as ratios relative to S12 levels. Melting point 
analyses of amplified PCR products were performed after each run to verify 
specific amplification. For primer sequences see Supplemental Data. 
2.2.3.4 Plasmid constructions 
Plasmids encoding full-length mouse HIF-1α, both wild-type and P402A 
and/or P563A mutants (note that all amino acid numbering correspond to 
mouse HIF-1α sequences), were a kind gift of L. Poellinger (Stockholm, 
Sweden). A PCR-product spanning the HIF-1α ODD region (amino acid 359 
to 685) was cloned into the EcoRI site of pM3-VP16 (Clontech, BD 
Biosciences) to obtain one-hybrid constructs harboring a N-terminal GAL4 
DNA-binding domain and a C-terminal VP16 transactivation domain. Resulting 
plasmids were termed G4.mHIF(359-685).VP16_wt, G4.mHIF(359-
685).VP16_P402A, G4.mHIF(359-685).VP16_P563A and G4.mHIF(359-
685).VP16_PP/AA. For overexpression in mammalian cells, full-length human 
PHD2 and PHD3 (kindly provided by W. Kaelin Jr., Boston, MA, and I. 
Flamme, Wuppertal, Germany, respectively) were subcloned into pENTR4 
and recombined into pcDNA3.1/nV5-DEST using Gateway technology 
(Invitrogen). Similarly, vectors for expression of GST-tagged PHD isoforms in 
Sf9 insect cells were constructed by recombining coding sequences for PHD2 
and PHD3 into pDEST20 (Invitrogen). All primary cDNA inserts were 
sequenced (Microsynth, Balgach, Switzerland). 
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2.2.3.5 Transient transfections 
Cells were co-transfected with the indicated amounts of DNA using 
polyethylenimine (PEI, Polysciences, Warrington, PA). Therefore, cells were 
grown on 100 mm dishes to subconfluency and 200 µl 150 mM NaCl 
containing a DNA-PEI mixture (1:5, w/w) was added. For co-transfections, 
total DNA was kept constant by adding empty vector. Following over-night 
incubation, the cells were trypsinized and divided onto 12-well plates for 
luciferase assays and 100 mm dishes for immunoblotting.  
2.2.3.6 Luciferase assays 
MEF-Hif1a-/- cells were transiently co-transfected with 2 µg of indicated 
G4.mHIF(359-685).VP16 fusion constructs and up to 8 µg of the respective 
V5.PHD isoform, along with 1 µg of the GAL4-responsive reporter plasmid 
pGRE5xE1b, containing the firefly luciferase gene under control of E1b 
promoter and five GAL4 response elements (kind gift of D. Peet, Adelaide, 
Australia). Identical amounts of total DNA were transfected in each 
experimental setting. Following transfection, cultures were grown for 
additional 24 hours at the indicated oxygen concentration and lysed in 100 µl 
passive lysis buffer (Promega, Madison, WI). Luciferase reporter gene activity 
was determined in a microplate luminometer (Berthold, Regensdorf, 
Switzerland) using luciferase firefly substrate (Promega). Protein 
concentration in the lysates was determined by a Bradford assay and relative 
luciferase activity was calculated from the ratio between relative light units and 
µg protein.  
2.2.3.7 RNA interference 
HeLa cells were plated at a density of 2×105 cells per single well of a 6-well 
plate. The day after, cells were transfected in fresh media with 80 nM siRNA 
duplexes targeting either human PHD2 (5’-ggacgaaagccaugguugcuuguua-3’, 
sense strand) or PHD3 (5’-gcuauccgggaaauggaacagguua-3’ sense strand) 
using Lipofectamin 2000 according to the manufacturer’s protocol (Invitrogen). 
After 4 hours of culturing at 20% oxygen, cells were subjected to the indicated 
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oxygen concentrations and grown for an additional period of 24 hours prior to 
lysis.  
2.2.3.8 Expression and purification of PHDs 
GST.PHD2 and GST.PHD3 were expressed in baculovirus-infected Sf9 insect 
cells according to the manufacturer's instructions (Invitrogen). After 80 hours 
of infection, Sf9 cells were lysed in ice-cold 0.1% NP-40, 10 mM Tris-HCl, pH 
7.5, 100 mM NaCl, 100 mM glycine and 10 µM DTT. Crude lysate was 
cleared by centrifugation at 20,000×g for 20 minutes and supernatants were 
incubated with equilibrated glutathione-sepharose beads (Amersham, 
Dübendorf, Switzerland) for 2 hours at 4°C with gentle agitation. Beads were 
washed three times with PBS and bound protein was eluted with 15 mM 
reduced glutathione, 50 mM Tris-HCl, pH 8.0, 5% glycerol and 2 µM FeSO4. 
Purity of recombinant proteins was estimated by SDS-PAGE and coomassie 
blue staining.  
2.2.3.9 In vitro prolyl-4-hydroxylation assays 
Enzymatic activity of recombinant PHD2 and PHD3 was determined by an in 
vitro hydroxylation assay performed essentially as described before (Oehme 
et al. 2004; Martin et al. 2005). Briefly, biotinylated mouse HIF-1α-derived 
peptides (aa 555 to 573, either wild-type or P563A mutant) were bound to 
NeutrAvidin-coated 96-well plates (Pierce). Hydroxylase reactions using 
purified recombinant GST.PHD2 or GST.PHD3 enzyme were carried out for 1 
hour at room temperature. A polycistronic expression vector for His6- and 
thioredoxin-tagged pVHL/elongin B/elongin C (VBC) complex was kindly 
provided by S. Tan (Pennsylvania, PA). VBC was expressed in bacteria, 
purified by nickel affinity chromatography followed by ion exchange 
chromatography (Amersham), and allowed to bind to the hydroxylated 
peptides. Bound VBC complex was detected by rabbit anti-thioredoxin 
antibodies and secondary horseradish peroxidase-coupled anti-rabbit 
antibodies (Sigma) using the TMB (3,3’,5,5’-tetramethylbenzidine) substrate 
kit (Pierce). The peroxidase reaction was stopped by adding H2SO4 and 
absorbance was determined at 450 nm in a microplate reader. For oxygen 
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titration experiments, the assay was performed in the hypoxic glove box. All 
reagents and solutions were allowed to equilibrate to the indicated oxygen 
concentration. Inter-assay comparability was guaranteed by calibration of 
each experiment to an internal standard curve using hydroxyproline-
containing peptides.  
2.2.4 Results 
2.2.4.1 mRNA levels of inducible PHD isoforms show a transient 
maximum and remain upregulated during prolonged hypoxia in cell 
culture. 
To study the kinetics of PHD expression during prolonged hypoxia (2% 
O2 for up to 256 hours), mRNA levels of all three PHDs were determined in 
MEF-Hif1a+/+ and MEF-Hif1a-/- cells. PHD2 and PHD3 but not PHD1 mRNA 
levels were efficiently upregulated under hypoxic conditions, peaked after 64 
to 112 hours, and remained elevated over the entire time-course (Fig. 1A). As 
positive controls, mRNA levels of GLUT1 and CAIX, two well established HIF-
1 target genes, were measured in the same time-course. Interestingly, 
hypoxic GLUT1 upregulation followed a similar kinetics as PHD2 mRNA 
expression, while CAIX levels were maximally induced 48 hours later, like it 
was observed for PHD3 (Fig. 1A). Because both PHDs were readily induced 
after four hours, we investigated the early onset of induction in a shorter time-
course. Induction of PHD2 and PHD3 mRNA was detectable as early as 60 to 
120 minutes after hypoxic stimulation (Fig. 1B). None of the PHD isoforms 
was induced in hypoxic MEF-Hif1a-/- cells, suggesting a non-redundant role of 
HIF-1α for hypoxic upregulation of PHD mRNA in these cell lines. In addition, 
a lack of PHD2 and PHD3 mRNA induction was also observed in functionally 
HIF-1β/ARNT-deficient mouse Hepa1c4 but not wild-type Hepa1 hepatoma 
cells after 38 hours of hypoxic stimulation (Fig. 1C). Thus, these genetically 
altered cellular models confirm HIF-1-dependent PHD2 and PHD3 gene 
expression in both acute and chronic hypoxia, which has previously been 
demonstrated mainly in siRNA experiments (Berra et al. 2003; Aprelikova et 
al. 2004; Marxsen et al. 2004).  
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2.2.4.2 Tissue-dependent hypoxic induction of PHD2 and PHD3 mRNA 
in mice. 
Up to date, no systematic investigation on hypoxic PHD mRNA 
induction in vivo was available. Thus, we assessed the grade of hypoxic 
PHD2 and PHD3 mRNA induction in acutely and chronically hypoxic mice.  
 To examine the effects of acute hypoxia, mice were treated for 4 hours 
with an inspiratory gas-mixture containing 0.1% carbon monoxide (CO) which 
induced a rapid onset of severe hypoxia by blocking approximately 50% of the 
oxygen-binding sites in hemoglobin (data not shown). Strong hypoxic 
induction of erythropoietin mRNA content in kidney as well as erythropoietin 
and GLUT1 mRNA in liver and brain confirmed the activation of the HIF 
system in these mice (Fig. 2). The various PHD mRNA isoforms showed a 
broad disparity of hypoxic activation: PHD1 was not markedly regulated by 
hypoxia in most tissues; PHD2 was widely induced by hypoxia, albeit at rather 
low levels; and PHD3 was strongly induced already following four hours tissue 
hypoxia in the lung (15.6-fold), liver (5.2-fold), kidney (3.8-fold), but only 
moderate induction factors similar to PHD2 were observed in other organs. Of 
note, striated muscle tissue (heart and to some extent tongue) showed 
highest normoxic expression values for the inducible PHD2 and PHD3 
isoforms. 
 To investigate the kinetics of PHD mRNA induction under chronically 
hypoxic conditions, mice were exposed to inspiratory hypoxia (7.5% O2) for 24 
up to 72 hours and mRNA levels were determined in liver, kidney and brain. 
While erythropoietin mRNA expression was induced to a similar extent in 
kidney and brain already after 24 hours of hypoxia, erythropoietin mRNA in 
liver increased not until 72 hours of hypoxic exposure (Fig. 3A). Consistent 
with previous findings, serum levels of erythropoietin protein in these animals 
highly correlated with mRNA levels in kidney (Fig. 3B). Unexpectedly, the 
hypoxic inducibility of the known HIF target genes GLUT1 and CAIX was 
rather small. While strong hypoxic induction of both proteins in tumors and 
tumor-derived cell lines is well established, they were not induced in liver, only 
one of them (CAIX) was induced after prolonged hypoxia in kidney and both of 
them showed a transient induction in brain (Fig. 3C). Nevertheless, these 
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results confirmed the hypoxic status of the animals. Comparable results were 
obtained with the inducible PHD2 and PHD3 isoforms: only PHD2 showed a 
small, transient increase in the liver; only PHD3 was induced after prolonged 
hypoxia in the kidney; and both of them were transiently induced in the brain. 
Thus, under physiological inspiratory hypoxia, regulation of these genes 
appears to be more subtile than under in vitro conditions, in tumor hypoxia or 
following severe tissue hypoxia in CO-treated mice. 
2.2.4.3 Hypoxic induction of PHD2 and PHD3 proteins is accompanied 
by decreased HIF-1α protein levels.  
Hypoxic upregulation of PHD2 and PHD3 has the potential to affect 
protein abundance of HIF-1α during prolonged hypoxia. To further elaborate 
this hypothesis, we quantified protein levels of HIF-1α as well as PHD2 and 
PHD3 in different cell lines. As shown exemplarily for HEK293 cells, 
endogenous HIF-1α protein levels decreased concomitantly with the hypoxic 
increase of endogenous PHD2 and PHD3 levels when cells were cultured for 
up to 72 hours at 1% O2 (Fig. 4A). Similar results were obtained from lysates 
that were prepared under strictly hypoxic conditions, ruling out the possibility 
that increased levels of induced PHD enzymes might have influenced the 
protein levels of HIF-1α during lysis. HIF-1α mRNA levels in HEK293 were not 
significantly altered under the same hypoxic conditions, while PHD2 and 
PHD3 mRNAs were readily induced after 4 hours hypoxia (Fig. 4B). 
Interestingly, hypoxic PHD3 mRNA induction was steadily induced during the 
entire hypoxic incubation, whereas PHD2 mRNA levels reached maximal 
induction already before 4 hours of hypoxia and remained constant for up to 
72 hours of hypoxia.  
A similar pattern of HIF-1α and PHD protein levels was observed in HeLa and 
Hep3B cells at oxygen concentrations as low as 0.2%, supporting the idea of 
a widespread regulative mechanism (see Supplemental Fig. 1). These 
observations suggest that even under very limited oxygen supply HIF-1α 
hydroxylation by PHDs functionally persists, implicating that HIF-1α turn-over 
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might be controlled by the PHD sensor system not only under normoxic 
conditions but also under severely hypoxic conditions. 
2.2.4.4 A second hypoxic insult activates another HIF-1α  response in 
cells adapted to chronic hypoxia.  
If the novel HIF-1α protein baseline following adaptation to chronic 
hypoxia indeed resulted from an altered steady-state of the HIF-PHD oxygen 
sensing circuit, the adapted cells should react to a second, more severe 
hypoxic insult by acutely inducing HIF-1α to a similar extent as at the first 
hypoxic insult. To test this hypothesis, HEK293 cells were allowed to adapt to 
1% oxygen for 72 hours before they were exposed to 0.2% oxygen for up to 4 
hours. While HIF-1α levels markedly decreased during chronic hypoxia, a 
rapid re-accumulation of HIF-1α protein was observed already one hour after 
exposing the cells to 0.2% oxygen (Fig. 4C). A similar result was obtained 
when cells adapted to chronic hypoxia were treated with the PHD inhibitor 
DMOG, suggesting that PHDs are responsible for HIF-1α regulation even in 
hypoxically adapted cells (Fig 4D).  
2.2.4.5 PHD2 and PHD3 silencing increases hypoxic HIF-1α 
accumulation.  
Like in HEK293 cells, simultaneous treatment of HeLa cells with 
hypoxia together with the PHD inhibitor DMOG led to additional accumulation 
of HIF-1α at oxygen concentrations as low as 0.2% (Fig. 5A). To provide 
further evidence that endogenous PHDs control HIF-1α protein levels even 
under hypoxic conditions, we applied siRNA to knock down PHD2 and PHD3 
in HeLa cells. Interestingly, silencing of either PHD2 or PHD3 equally 
increased HIF-1αlevels, irrespective of whether the cells were cultured at 20% 
or 1% oxygen (Fig. 5B). While apparently both isoforms are involved in 
regulating HIF-α stability over a broad range of oxygen concentrations, 
combined silencing of PHD2 together with PHD3 most efficiently upregulated 
HIF-1α at 20% as well as 1% O2 (Fig. 5B). 
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2.2.4.6 PHDs retain functional HIF-1α degradation activity even under 
severely hypoxic conditions in cell culture.  
The current knowledge about oxygen substrate requirements of the 
PHD-dependent hydroxylation reaction is exclusively based on data derived 
from biochemical in vitro studies using purified enzymes and short peptides 
containing one single HIF-1α hydroxylation site as substrates. To further 
examine the activity of PHD enzymes under lowered oxygen availability in a 
cellular context, a luciferase-based mammalian one-hybrid approach to 
quantify HIF-1α stability in a feedback-uncoupled cellular system was 
established. A series of mammalian expression vectors coding for the mouse 
HIF-1α ODD domain, including mutant forms of the hydroxylation sites 
(P402A and/or P563A) were N-terminally fused to the yeast GAL4 DNA-
binding domain (DBD) and C-terminally fused to the herpes simplex virus 
VP16 transactivation domain (TAD; Fig. 6A). The expressed fusion proteins 
cannot transactivate endogenous HIF-target genes, including PHD2 and 
PHD3, but activate a co-transfected GAL4-responsive reporter gene. The use 
of HIF-1α-deficient MEF-Hif1a-/- cells ensures very low basal levels of 
endogenous PHDs (Fig. 1A) and avoids confusion with hypoxic upregulation 
of endogenous PHD2 and PHD3 by endogenous HIF-1, allowing to 
experimentally define the PHD levels by transfection of expression vectors. 
Since the HIF-1α-ODD confers oxygen-dependent instability to the fusion 
protein, luciferase reporter gene activity directly reflects protein stability.  
 First, we tested the relative importance of the two PHD target proline 
residues within the mouse HIF-1α-ODD residues 359 to 685. While reporter 
gene activation of the wild-type and single proline mutant fusion proteins was 
similarly reduced by PHD2 overexpression, mutation of both prolines was 
necessary to render the HIF-1α-ODD insensitive to PHD2 overexpression 
(Fig. 6B). Whereas similar effects of PHD overexpression on ODD-stability 
have previously been reported only for normoxic conditions (Masson et al. 
2001), our data show functional relevance of both hydroxylation sites also for 
hypoxic (2% O2) regulation of HIF-1α protein levels (Fig. 6B).  
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 In a next step both, oxygen concentration and PHD protein abundance 
were titered simultaneously in co-transfection experiments. Interestingly, co-
expression of low amounts of PHD2, which were not yet detectable by 
immunoblotting, already reduced HIF-1α-ODD stability to a minimum which 
was not further lowered by increased amounts of PHD2 (Fig. 6C). Reducing 
the oxygen concentration to 4% or below revealed a successive decrease of 
hydroxylase activity at a given amount of PHD2 enzyme. However, increasing 
the abundance of PHD2 by stepwise duplication of the amount of transfected 
PHD2 expression vector, again demonstrated that induced PHD levels can 
compensate for reduced oxygen availability. Indeed, increased PHD2 
compensated for oxygen concentrations as low as 0.2% (Fig. 6C). 
 Similar results were obtained by PHD3 overexpression which also 
resulted in decreased HIF-1α-ODD stability under normoxic and moderately 
hypoxic conditions (Fig. 6D). However, forced expression of PHD3 failed to 
further decrease HIF-1α-ODD stability at 0.2% oxygen, suggesting a principal 
difference in oxygen-dependent hydroxylase activities between PHD2 and 
PHD3 under various degrees of hypoxia in vivo (Fig. 6D). 
2.2.4.7 Purified PHDs retain functional hydroxylation activity even 
under severe hypoxic conditions in a cell-free system in vitro 
The differences in hydroxylase activity of PHD2 and PHD3 under 
severe hypoxia described above prompted us to investigate the activity of 
PHDs using a cell-free in vitro approach. Therefore, GST-tagged PHD2 and 
PHD3 were purified from baculovirus-infected Sf9 insect cells (Fig. 7A). These 
enzymes were used to hydroxylate a mouse HIF-1α-ODD-derived peptide 
coupled to 96-well plates, and binding of a purified VBC complex to the 
hydroxylated peptide was measured by ELISA. Each PHD preparation was 
diluted to obtain equal VBC-binding after one hour of hydroxylation (arbitrarily 
defined as “1-fold input”). These enzyme concentrations were subsequently 
increased to mimic the hypoxic induction of PHDs in vivo. Under normoxic 
conditions, both PHDs showed a similar increase in activity with increasing 
protein amounts (Fig 7A). Peptide hydroxylation was within the linear range of 
 55
RESULTS 
the assay over the time frame of experiments, even at highest enzyme 
concentrations (data not shown).  
 When the assay was performed at an oxygen concentration of 2%, 
PHD2 hydroxylation activity was only about half of the normoxic activity after 
one hour of reaction (hydroxyproline contents of 10.1% ± 0.2% at 20% O2 and 
5.7% ± 0.5% at 2% O2; n=3, mean ± S.D.; 8-fold enzyme input). However, 
HIF-1α-ODD peptide hydroxylation by PHD3 was only slightly decreased 
under these conditions (10.3% ± 0.2% at 20% O2 and 8.2% ± 1.1% at 2% O2; 
n=3, mean ± S.D.; 8-fold enzyme input). Further reduction in oxygen 
availability decreased proline hydroxylation, but significant hydroxylation could 
still be observed at oxygen concentrations as low as 0.2%. Indeed, a 8-fold 
protein input of PHD2 or PHD3 resulted in similar peptide hydroxylation at 
0.2% O2 as a 4-fold input at 0.5% O2 or a 2-fold input at 1% O2, suggesting 
that increased PHDs can compensate for decreased oxygen also in vitro (Fig 
7A). Moreover, both enzymes showed a strikingly linear increase of activity for 
the range of 0.2% to 2% oxygen, thus fulfilling one of the most important 
criterions for a cellular oxygen sensor at physiologically relevant tissue O2 
concentrations (Fig. 7B). 
2.2.5 Discussion 
 The existence of a functional feedback loop limiting the hypoxic 
response has been suspected already when HIF was cloned, because nuclear 
HIF-1α declined despite ongoing hypoxia (Wang et al. 1995). Similar 
observations were then reported by a multitude of other groups. However, the 
underlying mechanism remained unknown. We previously reported that forced 
expression of HIF-1α followed a similar feedback kinetics, but in this case 
under normally oxygenated conditions (Hofer et al. 2001). This observation 
suggested that HIF itself, rather than the hypoxic stimulus, is required for the 
feedback regulation. One such mechanism might be HIF-dependent induction 
of pVHL by "late hypoxia" (Karhausen et al. 2005). However, other studies 
could not find any induction of pVHL under hypoxic conditions (Berra et al. 
2001; Demidenko et al. 2005), and we did not observe any oxygen- or HIF-
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1α-dependent difference in pVHL mRNA levels during the 256 hours time-
course described in this study (data not shown). 
 The identification of the PHD oxygen sensors shed new light on the 
process of HIF feedback control, as it became clear that PHD2 and PHD3 are 
hypoxia-inducible HIF target genes. (Epstein et al. 2001; D'Angelo et al. 2003; 
Appelhoff et al. 2004; Aprelikova et al. 2004; Marxsen et al. 2004; Metzen et 
al. 2005; Pescador et al. 2005). It has been postulated that this PHD 
upregulation confers accelerated degradation of HIFα upon re-oxygenation 
(Berra et al. 2001; Appelhoff et al. 2004; Marxsen et al. 2004). Indeed, re-
oxygenation from 1% to 20.9% (air) oxygen after 18 hours decreased the half-
life of HIF-1α when compared with similarly treated cells that were exposed to 
hypoxia for only one hour (Marxsen et al. 2004). 
 However, physiological tissue pO2 corresponds to approx. 2% to 5% 
oxygen concentrations in air rather than the widely used 20.9% "normoxic" 
oxygen concentration. Even though the pericellular pO2 is lower at the bottom 
of unstirred tissue culture dishes (Wolff et al. 1993), standard cell culture 
conditions are to be considered “hyperoxic”; which reflects an unphysiological 
condition PHDs normally are not exposed to. Rather, PHDs in vivo are 
constantly functioning under pO2 levels far below their in vitro Km values 
(Hirsila et al. 2003). These considerations suggested a PHD-HIF feedback 
loop which might be active even under chronically low tissue oxygenation. 
 In line with this hypothesis, we observed undulating HIF-1α-dependent 
mRNA levels of CAIX, GLUT1, PHD2 and PHD3 in MEF cells, and we 
detected tissue-specific variations in hypoxically induced PHD2 and PHD3 
mRNA levels in mice in vivo. So far PHD expression levels were only known 
from established tumor cell lines or normoxic tissues (Dupuy et al. 2000; Lieb 
et al. 2002; Oehme et al. 2002; Berra et al. 2003; Appelhoff et al. 2004; 
Metzen et al. 2005). We found an impressive upregulation of PHD3 mRNA 
levels in hypoxic lung tissue, confirming previous reports for lung cancer-
derived A549 cells (Appelhoff et al. 2004; Demidenko et al. 2005). Similarly, 
the observed induction factors in liver were roughly the same as determined in 
Hepa1 hepatoma cells used in this study.  
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 We then concentrated on three major organ systems which are 
particularly sensitive to hypoxia and hence involved in the pathophysiology of 
shock. Interestingly, while the examined HIF target genes were all induced in 
the brain, different kinetics for GLUT1, CAIX, PHD2 and PHD3 were observed 
in kidney and liver. Expression levels of CAIX were highly increased in kidney 
after 72 hours of hypoxia, whereas a reverse effect was observed in liver. 
Since the kidney, besides the lung, is the major organ involved in systemic pH 
regulation, these results suggest a physiological role for CAIX in pH 
maintenance during hypoxia, like it has been proposed for solid tumors 
(Svastova et al. 2004). Regarding PHD mRNA induction, temporal 
upregulation of at least one isoform was observed in each of the three tissues 
in hypoxic animals, confirming that PHD upregulation indeed occurs in a 
hypoxic organism, albeit the extent of induction is tissue-specific. Not 
surprinsingly, decreasing the oxygen transport capacity in mice by 0.1% CO 
inspriation was much more efficient in upregulation of HIF-target genes than 
inspiratory hypoxia itself, suggesting that adaptational mechanisms, such as 
increased heart rate, depth of breath, and reduced oxygen consumption 
compensated for decreased inspiratory O2-concentration when oxygen 
transport is intact. We have previously shown that temporal and spatial 
accumulation of HIF-1α in vivo greatly differs, even in neighboring cells, 
suggesting that factors other than oxygen availability affect the PHD-HIF 
system (Stroka et al. 2001). In fact, we recently found that the FK506-binding 
protein FKBP38 regulates specifically the abundance of PHD2 (S. Barth, R. 
Wirthner, R. H. Wenger and G. Camenisch, manuscript in preparation).  
 Whatever regulates cellular PHD levels, functional PHD induction 
requires that these enzymes must be active under a broad range of 
physiologically relevant conditions. In order to experimentally support this 
hypothesis, we used a HIF-1α-ODD reporter construct in a HIF-1α negative 
cell line to breach the suggested gene activation-protein degradation loop. 
The HIF-1α-ODD confers normoxic degradation to the resulting hybrid fusion 
protein (Pugh et al. 1997) and similar constructs have been used lately as 
bioluminescent reporter systems monitoring the state of tissue-oxygenation in 
 58 
Increased prolyl-4-hydroxylase domain (PHD) proteins compensate for decreased oxygen levels: 
evidence for an autoregulatory oxygen sensing system 
vivo (Safran et al. 2006). Our experiments revealed that PHD dependent 
fusion-protein destabilization was effective at oxygen concentrations as low as 
0.2% O2, and that increasing the amount of enzyme partially compensated for 
reduced oxygen availability. These data are consistent with a recent work 
employing hydroxylation-specific antibodies which showed persistent HIF-1α 
hydroxylation at equally low oxygen concentrations (Chan et al. 2005).  
 While we observed a comparable oxygen-dependence between PHD2 
and PHD3 purified from Sf9 insect cells in vitro, the ability of PHD3 to 
compensate for low oxygen concentrations in the cellular model was 
consistently lower than that of PHD2 (compare Figures 6C and D). In line with 
the former observation, in vitro transcribed and translated PHD2 and PHD3 
enzymes have been shown to be equally active in another study (Tuckerman 
et al. 2004). Thus, isoform-specific regulation of distinct PHDs in vivo are 
likely to depend on critical co-factors that might be depleted in purified 
enzyme preparations, or becoming limited when PHDs are overexpressed. 
Supporting this notion, PHD3 has recently been described to serve as a 
substrate of the eukaryotic chaperonin complex TRiC that might be required 
for appropriate folding and full enzymatic activity(Masson et al. 2004). 
 Another recent work demonstrated increased binding of PHD3 to HIF-
1α in the presence of OS-9 (Baek et al. 2005). As suggested by these 
authors, PHDs form functional multi-protein complexes which could affect 
binding affinity and target sequence selectivity in a cellular context. However, 
binding of OS-9 to human HIF-1α necessarily requires amino acids 692–785 
which were neither present in the peptide used for the hydroxylation assays 
nor in the one-hybrid construct. Thus, PHD3 activity rather than binding might 
be attenuated in our cellular model system. Of note, protein degradation of 
PHD3 (and PHD1) has been shown to be enhanced under hypoxia by a 
mechanism involving the ubiquitin ligase Siah2, adding yet another layer of 
regulation on the HIF-PHD system (Nakayama et al. 2004).  
 Also, binding of PHD2 to HIF-1α has been suggested to repress the N-
TAD activity (To and Huang 2005). Interestingly, we observed residual binding 
of recombinant PHD2 to immobilized HIF-1α ODD peptides in vitro, 
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suggesting a repressive function of PHD2 particularly on truncated HIF-1α 
(data not shown). While these effects were rather small compared with the 
HIF-1α-destabilizing function of enzymatic PHD activity, they still could have 
partially influenced the transcriptional activity of the fusion constructs used in 
our study.  
 In conclusion, the present work demonstrates that an essential pre-
requirement for a PHD abundance-dependent modulation of the oxygen-
sensing system is fulfilled: PHDs are operative under a wide variety of even 
severely hypoxic oxygen concentrations. These findings led to the intriguing 
suggestion of a flexible oxygen threshold of the PHD-HIF system which 
steadily adapts to altered tissue oxygenation. 
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Figure 1. HIF-1 target genes remain elevated during prolonged hypoxia. MEF-Hif1a+/+ and MEF- 
Hif1a-/- were cultured either at 20% or 2% oxygen for 4 to 256 hours (A) or 15 to 240 minutes (B). mRNA 
levels for PHD1, PHD2, PHD3, GLUT1 and CAIX were quantified by real-time RT-PCR and normalized 
to ribosomal protein S12 mRNA content. (C) PHD1, PHD2 and PHD3 mRNA levels in Hepa1 Arnt wild-
type (wt) and Hepa1c4 Arnt mutant (mt) cells cultured at 20%, 2% or 0.2% oxygen for 38 hours. Data 
are given as mean ± SEM of n = 3 independent experiments. 
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Figure 2. Effects of tissue hypoxia on the inducibility of PHD isoforms in vivo. Tissues were derived from 
mice kept either under normal air (FiCO 0%) or in a gas mixture containing 0.1% CO (FiCO 0.1%) for 4 
hours. PHD1, PHD2, PHD3, erythropoietin and GLUT1 mRNA levels were determined by real-time RT-
PCR and normalized to S12 mRNA. Organ-specific hypoxic induction factors are indicated below the 
bars. Note the different scales (n.d., not detectable). 
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Figure 3. Effects of inspiratory hypoxia on HIF target gene expression in vivo. Mice were kept at an 
inspiratory oxygen concentration (FiO2) of 20% O2 (“0” hours of hypoxia) or 7.5% O2 for up to 72 hours. 
erythropoietin mRNA levels in liver, brain and kidney were quantified by real-time RT-PCR (A) and 
corresponding serum levels of erythropoietin were measured by RIA (B). (C) GLUT1, CAIX, PHD2 and 
PHD3 mRNA levels were measured in all three tissues. All mRNA data were normalized to S12 mRNA 
levels and are expressed as hypoxic induction factors. Bars represent the mean ± SEM of n = 3 mice 
per group. 
 
 63
RESULTS 
 
 
 
 
 
 
 
Figure 4. Decreased HIF-1α protein levels parallel increased PHD2 and PHD3 under chronically 
hypoxic conditions. (A) HEK293 cells were cultured at 20% or 1% oxygen for up to 72 hours. HIF-1α, 
PHD2, PHD3 and β-actin (loading control) protein levels were estimated by immunoblotting of total cell 
lysates. A representative experiment is shown along with densitometric quantification of bands for n = 3 
(PHDs) or n = 4 (HIF-1α) independent experiments. For inter-assay normalization, timepoints 
expressing highest protein levels were arbitrarily defined as 1 (filled circles; mean ± SEM). (B) HIF-1α, 
PHD2 and PHD3 mRNA levels in HEK293 cells were quantified by real-time RT-PCR and normalized to 
ribosomal protein L28 mRNA. Bars represent mean ± SEM of triplicates. (C) HEK293 cells were 
exposed to 1% oxygen for 72 hours and subjected to 0.2% oxygen for additional 1 to 4 hours without 
reoxygenation. Lowering the oxygen concentration from 1 to 0.2% took approx. 30 minutes. 
Immunoblotting was performed as in (A). (D) HEK293 cells were grown as in (C) and treated with a PHD 
inhibitor ("+", 1 mM DMOG) or solvent alone ("-", 0.1% DMSO) for 1 to 4 hours at 1% O2. 
Immunoblotting was performed as described in (A). 
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Figure 5. Endogenous PHD2 and PHD3 enzymes control HIF-1α accumulation under normoxic as well 
as under hypoxic conditions. (A) HeLa cultures were subjected to 20%, 1% or 0.2% oxygen for 4 hours 
and simultaneously treated with a PHD inhibitor ("+", 1mM DMOG). PHD2, PHD3, HIF-1α and β-actin 
protein levels were determined by immunoblotting of total cell lysates. (B) HeLa cells were transiently 
transfected with siRNAs directed against either PHD2, PHD3, or a combination of both, and cultured at 
the indicated oxygen concentrations for 24 hours. Transfection of cells with a similarly constructed, but 
unspecific siRNA oligonucleotide served as negative control ("C"). Immunoblotting was performed as 
described above. 
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Figure 6. PHD2 and PHD3 retain hydroxylase activity at low oxygen concentrations. (A) Oxygen-
sensitive one-hybrid fusion constructs. Mutations of Pro402 and Pro563 are underlined. (B) MEF-Hif1a-/- 
cells were co-transfected with 2 µg one-hybrid construct, 1 µg of a GAL4-responsive reporter gene and 
1 µg of V5.PHD2 or empty expression vector. Luciferase activity was measured 24 hours after 
incubation at 20% or 2% oxygen and relative light counts were normalized to total protein content in the 
lysates. Likewise, the indicated amounts of V5.PHD2 (C) and V5.PHD3 (D) were co-transfected with 2 
µg of the wild-type one-hybrid construct and 1 µg of the reporter gene. Aliquots of transfected cells were 
then cultured simultaneously at various oxygen concentrations and luciferase activities determined after 
24 hours as described above. In addition, lysates were immunoblotted to verify expression of exogenous 
V5.PHD isoforms (bottom panels). Representative experiments performed in triplicates are shown as 
mean ± SEM.  
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Figure 7. Recombinant GST.PHD2 and GST.PHD3 proteins are active under hypoxic conditions in vitro. 
(A) GST.PHD2 and GST.PHD3 were purified from baculovirus-infected Sf9 insect cells and their purity 
checked by SDS-PAGE and coomassie blue staining (CBS) or by immunoblotting (IB) using polyclonal 
anti-PHD2 or anti-PHD3 antibodies. In vitro hydroxylation reactions were performed at various oxygen 
concentrations with increasing amounts of PHD2 and PHD3 enzymes and hydroxyproline content was 
estimated from a calibration curve. (B) Oxygen-dependency of hydroxylation is shown for 8-fold enzyme 
input. Enzyme activity is given as percentage of hydroxyproline after one hour of reaction. All values are 
in the linear range of the assay and are shown as mean values ± SEM of triplicates. 
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2.3.1 Abstract 
A mismatch between metabolic demand and nutrient delivery leads to 
microenvironmental changes in solid tumors. The resulting tumor hypoxia is 
associated with malignant progression and poor prognosis. Clinically, tumor 
hypoxia is also associated with resistance to chemotherapy and irradiation. 
However, the molecular mechanisms underlying therapy resistance in hypoxic 
tumors are not fully understood. The hypoxia-inducible factor (HIF) is a master 
transcriptional activator of oxygen-regulated gene expression. Using 
transformed mouse embryonic fibroblasts (MEFs) derived from mice deficient 
in HIF-1α, we previously found that the lack of HIF-1α is sufficient to confer 
increased chemotherapy and irradiation susceptibility. Here, we show by 
single-cell electrophoresis, histone 2AX phosphorylation and nuclear foci 
formation of γH2AX and 53BP1, that the number of DNA double strand-breaks 
(DSB) is increased in untreated and etoposide-treated HIF-deficient MEFs. In 
etoposide-treated cells, cell cycle control and p53-dependent gene expression 
were not affected by the absence of HIF-1α. Using a candidate gene 
approach to screen 17 genes involved in DNA repair, mRNA and protein of 
members of the DNA-dependent protein kinase (DNA-PK) complex were 
found to be decreased in HIF-deficient MEFs. Thus, these data establish a 
molecular link between HIF and DNA-DSB repair which is likely to contribute 
to HIF-dependent tumor therapy resistance. 
 68 
Hypoxia-inducible factor-dependent DNA double-strand break repair contributes to tumor cell 
chemoresistance 
2.3.2 Introduction 
 Due to inadequate vascularization, irregular blood flow, high oxygen 
consumption and sometimes anemia, solid tumors build up hypoxic areas, 
resulting in distinct tumor cell phenotypes. Tumor hypoxia is associated with 
malignant progression, increased metastasis, genetic instability, 
chemoresistance, radioresistance, and poor prognosis (Brown and Giaccia 
1998; Brown 2000; Pouyssegur et al. 2006). Therefore, understanding the 
molecular pathways induced by hypoxia in tumor cells became a major focus 
in the development of new strategies to improve cancer therapy efficiency. 
 Central to the physiological response to hypoxia is the oxygen-labile α 
subunit of the hypoxia-inducible factor-1 (HIF-1) (Wenger 2002). HIF-1 
activates a large number of oxygen-regulated genes required for the 
adaptation of normal cells to hypoxia (Wenger et al. 2005). In cancer, HIF-1 is 
responsible for vascular endothelial growth factor-dependent tumor 
angiogenesis, for carbonic anhydrase (CA) IX-dependent pH regulation, and 
for the increased glycolytic capacity of cancer cells, known as Warburg effect 
(Minchenko et al. 2002; Svastova et al. 2004). Thus, HIF-1 mediates many of 
the adverse effects of tumor hypoxia and is an established positive factor for 
tumor growth (Ryan et al. 1998; Ryan et al. 2000). Apart from tumor hypoxia 
stabilizing the HIF-1α protein, HIF-1 can be upregulated constitutively due to 
the loss of tumor suppressors such as pVHL, PTEN and p53, or oncogenes 
such as v-src (Brown and Giaccia 1998; Wenger 2002; Brown and Wilson 
2004; Pouyssegur et al. 2006). Indeed, HIF is overexpressed in the majority of 
human cancers with expression levels correlating with malignancy and 
negative survival prognosis (Zhong et al. 1999; Birner et al. 2000; Aebersold 
et al. 2001). 
 High HIF-1α expression levels in human cancers are also associated 
with incomplete responses to chemotherapy and radiotherapy (Aebersold et 
al. 2001; Koukourakis et al. 2002; Bachtiary et al. 2003; Generali et al. 2006). 
However, the precise molecular mechanisms underlying hypoxic cancer 
therapy resistance are not fully understood. One of the first reported molecular 
mechanisms explaining the involvement of HIF-1 in chemotherapy resistance 
was the observation that HIF-1 can augment multidrug resistance (MDR1) 
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gene expression (Comerford et al. 2002). However, MDR1 is not induced in all 
therapy resistant cancers and is not involved in hypoxic radioresistance. 
Dysregulated apoptosis in response to chemotherapy might be another 
explanation (Erler et al. 2004)(17), but the cell type-specific role for HIF-1 in 
apoptosis is not well established because cells do not undergo apoptosis 
under degrees of hypoxia sufficient for HIF-1 induction (Wenger et al. 1998). 
 Resistance to radiotherapy is generally attributed to lowered generation 
of oxygen-dependent radical formation, at least under severe hypoxic 
conditions, below the oxygen partial pressure required to induce HIF-1 
(Moeller and Dewhirst 2006). However, we previously reported that 
transformed mouse embryonic fibroblasts (MEFs) were more sensitive to 
chemotherapy as well as to radiotherapy in the absence of HIF-1α (Unruh et 
al. 2003). Experimental tumors using these cells were also more susceptible 
to chemotherapy when HIF-1α was absent. These data were confirmed by a 
large number of studies that showed reversal of chemoresistance as well as 
radioresistance by targeting HIF-1 (Zhang et al. 2004; Moeller et al. 2005; 
Williams et al. 2005; Brown et al. 2006; Li et al. 2006; Li et al. 2006; Song et 
al. 2006; Sasabe et al. 2007). On the other hand, experimentally increasing 
HIF-1α enhanced therapy resistance (Ji et al. 2006; Martinive et al. 2006). 
Because HIF-1-mediated therapy resistance was only observed when DNA 
double-strand break (DSB) but not single-strand break (SSB)-inducing 
treatments were applied, we suspected that HIF-1 might be involved in DNA-
DSB repair (Unruh et al. 2003). Therefore, we further characterized this 
putative novel role of HIF-1 in DNA damage and repair. 
2.3.3 Materials and Methods 
2.3.3.1 Cell culture.  
MEF-Hif1a+/+ and MEF-Hif1a-/- cell lines were derived from day 9.5 embryos, 
either wild-type (Hif1a+/+) or deficient (Hif1a-/-) for HIF-1α. MEF cells obtained 
from independent mouse strains were either transformed with H-ras and 
immortalized with SV40 large T antigen (Ryan et al. 1998), herein after 
referred to as rT (kindly provided by R. S. Johnson, LaJolla, CA), or 
immortalized with SV40 large T antigen alone (Feldser et al. 1999), referred to 
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as T (kindly provided by G. L. Semenza, Baltimore, MD). All cell lines were 
cultured in Dulbecco's modified Eagle's medium (high glucose) as described 
previously (Stiehl et al. 2006). For long-term hypoxia (up to 256 hours), MEFs 
were grown in a gas-controlled glove box to handle the cells under constant 
oxygen (InvivO2 400, Ruskinn Technologies, Leeds, UK). Cells were grown on 
145 mm culture dishes and splitted every 48 hours. Reagents used for 
splitting and permanent culturing were pre-equilibrated to the oxygen 
concentration in the glove box. Viability assays were performed with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) as described 
previously (Unruh et al. 2003). 
2.3.3.2 Clonogenic assays.  
Cells (1×106) were cultured on 150 mm tissue culture plates for 24 hours and 
subsequently treated with 1, 2.5 or 5 µM etoposide (Sigma, Buchs, 
Switzerland) for 60 minutes. Cells were then trypsinized and counted using a 
ViCell cell viability analyzer (Beckman-Coulter, Krefeld, Gemany). The cells 
(500 to 1,000) were seeded in triplicates on 100 mm culture plates and grown 
for an additional 6 days. Following fixation with 2% paraformaldeyde in PBS, 
the colonies were stained with crystal violet, counted and the numbers 
normalized to the untreated control groups.  
2.3.3.3 Indirect Immunofluorescence.  
MEFs (5×104 cells) were seeded on 24-well Lumox plates (Greiner, 
Frickenhausen, Germany) and treated with etoposide for 1 hour. Cells were 
rinsed with PBS and fixed with 2% paraformaldehyde in PBS for 5 minutes at 
room temperature, followed by permeabilization with 100% methanol at -30°C 
for 5 minutes. After blocking with 3% BSA for 1 hour, the primary antibodies 
rabbit anti-53BP1 (Novus Biologicals, Littleton, CO) and mouse anti-γH2AX 
(JBW103, Upstate, Charlottesville, VA) were allowed to bind for 2 hours and 
immunocomplexes were detected using secondary anti-rabbit Alexa488- and 
anti-mouse Alexa564-conjugates, respectively (Molecular Probes, Invitrogen, 
Basel, Switzerland). Nuclei were stained with DAPI. Membranes were cut, 
mounted in MOWIOL and dried over night in the dark. Epifluorescence was 
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analysed using an Axiovert fluorescence microscope (Zeiss, Feldbach, 
Switzerland) and images were captured with fixed exposure times. 
2.3.3.4 Single cell electrophoresis (comet assays).  
Single cell electrophoresis was performed essentially as described with minor 
modifications (33). Briefly, cells were grown on 100 mm plates and subjected 
to the indicated treatments. After rinsing with PBS, cells were detached using 
a 0.005% trypsin solution, collected by centrifugation at 4°C with 250×g and 
washed twice with ice-cold PBS. 2.5×104 cells were resuspended in 10 µl PBS 
and added to 190 µl of 0.5% low melting-point agarose (Sigma) equilibrated to 
37°C in a water bath. Remaining cells were immediately lysed with 1% SDS, 
50 mM Tris-HCl pH 6.8 and 10% glycerol for later immunoblot analyses. The 
agarose-cell suspension was subsequently distributed on dried, agarose-
precoated fully frosted slides, covered with a cover slip and allowed to solidify 
on a precooled aluminium plate. Slides were overlaid with a third layer of 
agarose and then subjected to precooled lysis solution (1% Triton-X100, 2.5 
M NaCl; 100 mM EDTA; 10 mM Tris-HCl pH 10.0) for 1 hour at 4°C in the 
dark. Afterwards, slides were equilibrated to alkaline electrophoresis buffer 
(300 mM NaOH; 1 mM EDTA) for 20 minutes to allow for unwinding of the 
DNA. The agarose-embedded cells were then subjected to horizontal 
electrophoresis for 30 minutes (~0.74V/cm; 300 mA) with corresponding 
slides running side by side to ensure equal electrophoresis conditions. Slides 
were neutralized for 20 minutes in 100 mM Tris-HCl pH 7.5 and allowed to dry 
over night in the dark. Before analysis, dried slides were reconstituted in water 
and stained with a SYBR green solution (Invitrogen) for 10 minutes. DNA 
migration was visualized by fluorescence microscopy and images captured 
using a fluorescence microscope. For quantitative comparism, the tail moment 
(%DNA in tail multiplied by tail length) was calculated from >150 cells per 
condition by two individuals using the CometScore software package (TriTek, 
Sumerduck, VA). 
2.3.3.5 Cell cycle analyses. 
 MEFs were treated with 1 µM etoposide for 1 hour before the medium was 
replaced and the cells were cultured for an additional period of up to 48 hours. 
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At the indicated time points, cell samples were washed and trypsinized. 
Detached cells were fixed with precooled 70% ethanol at -30°C and the DNA 
was stained with propidium iodide (PI). FACS analysis was perfomed using a 
FACScan (Beckman-Coulter) and a single cell population of 25.000 cells was 
monitored for DNA content. Percentages of cells in G1, S phase and G2/M 
were estimated using WinMDI 2.9 freeware. 
2.3.3.6 Protein extractions and immunoblot analyses. 
Cells were washed twice and scraped into ice-cold PBS. For detection of 
DNA-PKcs, pATM, pCHK1, pCHK2, nuclei were extracted with a high-salt 
extraction buffer containing 0.1% NP-40 essentially as described before 
(Stiehl et al. 2006). Protein concentrations were determined by the Bradford 
method. Alternatively, total cell lysates were prepared to analyse γH2AX 
levels. Therefore, cells were collected in ice-cold PBS, lysed with 1% SDS, 50 
mM Tris-HCl pH 6.8 and 10% glycerol, followed by sonification and boiling for 
5 minutes. Protein concentrations were determined using the detergent-
insensitive BCA-assay (Pierce, Perbio Science, Lausanne, Switzerland). 
Protein (50 to 80 µg) was separated by SDS-PAGE, electro-transferred onto 
PVDF membranes and probed with antibodies derived against DNA-PKcs 
(Ab-4 cocktail, Labvision, Fremont, CA), pATM (10H11.E12, Cell Signaling, 
Danvers, MA), pCHK1(133D3, Cell Signaling), pCHK2 (Cell Signaling), γH2AX 
(Upstate), HIF-1α (mAb69 and NB100-479, Novus), Ku70 (N3H10, Abcam, 
Cambridge, UK), Ku80 (QED Bioscience, San Diego, CA) and β-actin 
(Sigma). Bound antibodies were detected by respective secondary antibodies 
(Pierce) and visualized with ECL substrate (Pierce). 
2.3.3.7 mRNA quantification.  
Total RNA was extracted as described previously (Stiehl et al. 2006). 
Following reverse transcription (RT) of 5 µg total RNA, mRNA levels were 
quantified with 1% of the diluted cDNA reaction mix by quantitative (q) PCR 
using a SybrGreen qPCR reagent kit (Sigma) in combination with a MX3000P 
light cycler (Stratagene, La Jolla, CA). Initial template concentrations of each 
sample were calculated by comparison with serial dilutions of a calibrated 
standard. To control for equal input levels, ribosomal protein S12 mRNA was 
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determined and data expressed as ratios relative to S12 levels. Melting point 
analyses of amplified PCR products were performed after each run to verify 
specific amplification. 
2.3.3.8 Transient transfections and reporter gene assays. 
 MEF cells were transfected using polyethyleneimine as described previously 
(Stiehl et al. 2006). In brief, 2 µg reporter plasmid were co-transfected with 
100 ng of pRL-CMV (Promega). After 24 hours the cells were equally 
distributed onto 12-well plates and exposed to 20% or 0.2% oxygen for 
another 20 hours. After cell lysis with passive lysis buffer (Promega), dual 
luciferase activity was determined according to the manufacturer's instructions 
(Promega). To generate the pGL3-mPRKDC luciferase reporter gene 
construct, the 5'-region of mouse PRKDC was amplified from genomic DNA 
derived from MEF cells, using specific NheI-flanked forward (5'-
CATCGCTAGCGCGCGACAAAAGAAATCTG-3') and XhoI-flanked reverse 
(5'-TGCACTCGAGATCACGCCGGCACCGCTTC-3') PCR primers. The 
products were ligated into NheI and XhoI sites of pGL3basic (Promega, 
Madison, WI). Sequencing confirmed that they were identical to the respective 
database entry (GenBank accession NT_039624), regardless of whether the 
genomic DNA was isolated from MEF-Hif1a+/+rT or MEF-Hif1a-/-rT. The 
pH3SVL hypoxia-inducible reporter gene has been described previously (34).  
2.3.4 Results 
2.3.4.1 Etoposide induces cell cycle arrest in MEFs irrespective of the 
presence of HIF-1α.  
We had shown previously that chemosensitivity and radiosensitivity are 
increased in HIF-1α-deficient MEFs (Unruh et al. 2003). To investigate the 
underlying mechanism(s), colony formation, cell cycle distribution and p53 
function were analyzed. As shown in Fig. 1A, treatment with increasing doses 
of etoposide reduced colony formation in HIF-1α-deficient MEFs, confirming 
our previous IC50 determinations using MTT assays (Unruh et al. 2003).  
 Because corrupted cell cycle control could explain the enhanced 
susceptibility to etoposide in HIF-1α-deficient MEFs, we next assessed their 
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ability to initiate cell cycle arrest in response to DNA damage. Therefore, the 
cells were treated with 1 µM etoposide for 1 hour and subsequently cultured 
for up to 12 hours. As shown in Fig. 1B, 6 hours after exposure to etoposide 
the percentage of cells with a duplicated genome increased from 31.7% to 
44.5% in MEF-Hif1a+/+rT and from 31.7% to 41.7% in MEF-Hif1a-/-rT, 
suggesting accumulation at the G2/M-checkpoint. Of interest, 12 hours after 
etoposide administration, the fraction of cells in G2/M was almost restored to 
the initial values in both cell lines. However, a substantial increase of cells in 
G1 phase at this time point (55.9% compared to 42.8% in untreated MEF-
Hif1a+/+rT and 53.1% to 44.1% in MEF-Hif1a-/-rT, respectively) was denoted, 
providing evidence for re-entry from the G2/M checkpoint into the cell cycle 
(Fig. 1B). No further fluctuations were observed at later time points and 
neither the generation time nor the cell cycle distribution differed between the 
two untreated MEF cell lines (data not shown). 
 Since the MEF cell lines used in this work were originally immortalized 
by stable expression of SV40 large T antigen and oncogenically transformed 
by infection with a recombinant retrovirus expressing activated H-ras 61L 
(Ryan et al. 2000), differential expression of these two genes might have 
caused differential chemosensitivity. However, as shown in Fig. 1C, no 
difference in large T antigen levels could be observed between the two cell 
lines. No human H-ras mRNA was detectable by RT-qPCR, suggesting 
genomic silencing of the stably integrated cDNA. 
 Finally, we considered differential functional inactivation of p53 by the 
large T antigen which might confound the response to DNA damage. 
However, after 8 hours of etoposide treatment a robust induction of the p53 
target gene p21CIP1 was detected in both MEF lines, irrespective of the 
presence of HIF-1α or the cell culture oxygenation (Fig. 1D). The p53 target 
genes Bax and Noxa were similarly regulated (data not shown). The mRNA 
levels of the two cell cycle regulatory proteins p16INK4a and p27KIP1 showed no 
marked differences in the two cell lines, while induction of the known pro-
apoptotic HIF target gene BNIP3 confirmed hypoxia and HIF-1-dependent 
target gene activation (Fig. 1D). Thus, these data show that there are no 
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major differences in p53 inactivation in the two cell lines due to cell 
immortalization. 
2.3.4.2 Increased accumulation of DNA-DSBs in HIF-1α-deficient MEF 
cells following etoposide treatment. 
 While etoposide might affect DNA integrity by several mechanisms, inhibition 
of topoisomerase II, leading to stalled replication forks, is thought to result in 
DNA-DSB in transcriptionally active cells (Burden and Osheroff 1998). 
Therefore, we applied alkaline single cell electrophoresis to quantify the DNA 
damage in MEF cells in response to treatment with etoposide. As reflected by 
the extended migration of fragmented DNA in comet tails, both cell lines 
showed an increase in DNA damage which dose-dependently correlated with 
the etoposide concentrations (Fig. 2A). At least 150 comet tails per 
experiment were quantified and DNA migration was expressed as tail moment 
(Fig. 2B). Of note, DNA migration was higher in MEF-Hif1a-/-rT than in MEF-
Hif1a+/+rT in etoposide-treated as well as in untreated cells, suggesting HIF-
1α-dependent changes in DNA integrity.  
 To characterize the nature of this increased susceptibility to DNA 
damage, aliquots of cells from the same experiments were analyzed by 
immunoblotting for phosphorylated histone 2AX (γH2AX), an established and 
sensitive marker of DNA-DSB. In line with the comet data, MEF-Hif1a-/-rT also 
showed increased γH2AX (Fig. 2C). We next determined nuclear foci 
formation of p53-binding protein 1 (53BP1) and γH2AX at sites of DNA-DSB. 
Indeed, in response to doses of etoposide as low as 0.25 µM, increased 
overlapping immunofluorescence of 53BP1 and γH2AX was seen in MEF-
Hif1a-/-rT compared with MEF-Hif1a+/+rT (Fig. 2D). These data suggest 
increased numbers of basal and inducible DNA-DSBs in HIF-1α-deficient 
MEFs. 
2.3.4.3 Analysis of DNA-DSB repair pathways in MEF-Hif1a+/+rT and 
MEF-Hif1a-/-rT.  
Two conserved major DNA-DSB repair pathways have been implicated in the 
response to DNA-DSB damage: homologous recombination (HR) and non-
homologous end joining (NHEJ). When DNA-DSBs accumulate, ATM/ATR 
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and DNA-PKcs kinases are activated by phosphorylation. Each of these 
kinases preferentially phosphorylates specific targets, leading to cell cycle 
arrest by phosphorylation of checkpoint kinases (CHK1 and CHK2) and/or 
sustained recruitment of DNA repair proteins to the DNA-DSB foci via 
phosphorylation of H2AX. Upon treatment with etoposide, ATM Ser1981 
autophosphorylation was strongly enhanced in both cell lines with a slightly 
higher degree in HIF-1α-deficient MEFs (Fig. 3A). However, while basal 
CHK1 Ser345 phosphorylation was slightly increased in MEF-Hif1a-/-rT, 
Thr387 autophosphorylation of CHK2, a downstream event of ATM activation, 
showed similar signals in the two cell lines (Fig. 3A). 
 To identify the factor(s) involved in dysregulated DNA-DSB repair in 
HIF-1α-deficient MEF cells, candidate genes were screened by RT-qPCR of 
RNA derived from MEFs kept under normoxic (20% O2) or hypoxic (0.2% O2) 
conditions. Transcript levels of PHD3 and CAIX were determined to control for 
hypoxia- and HIF-dependent gene expression (Stiehl et al. 2006), whereas 
growth arrest and DNA damage (GADD)153 mRNA was used as a HIF-
independent hypoxia-inducible gene (Carrière et al. 2004). As shown in Fig. 
3B, mRNA levels of 17 genes involved in DNA repair were measured. While 
none of these genes were regulated in a hypoxia-inducible manner, an up to 
3-fold reduction in basal mRNA levels of members of the DNA-PK complex 
was detected in MEF-Hif1a-/-rT cells (not visible in the scale chosen for Fig. 
3B).  
2.3.4.4 Dysregulation of DNA-PK complex members in HIF-1α-
deficient MEF cells.  
Because the previously reported HIF-dependent chemoresistance was 
oxygenation-independent (Unruh et al. 2003), we further evaluated the HIF-
1α-dependent differences in basal DNA-PK expression. As shown in Fig. 4A, 
DNA-PKcs and Ku80 mRNA levels were significantly reduced in MEF-Hif1a-/-
rT when compared with MEF-Hif1a+/+rT cells, independent of the oxygen 
concentration. In contrast, Ku70, ATM and ATR mRNA levels were not 
affected by the absence of HIF-1α. HIF-dependent and/or oxygen-dependent 
gene regulation was controlled in the same samples by monitoring BNIP3 and 
GADD153 mRNA levels, respectively. As shown in Fig. 4B, also the protein 
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levels of all three DNA-PK subunits, including Ku70, were reduced in MEF-
Hif1a-/-rT cells. 
 The Mcm4 gene (minichromosome maintenance-deficient 4 homolog, 
also known as cell division control protein 21, Cdc21) is structurally organized 
in a head-to-head arrangement with the DNA-PKcs gene, only separated by a 
conserved CpG-rich promoter region of approx. 700 bp and 500 bp in humans 
and mice, respectively (Connelly et al. 1998; Saito et al. 1998). Interestingly, 
MCM4 mRNA is regulated in the same HIF-1α-dependent but oxygen-
independent manner as DNA-PKcs (Fig. 4A), suggesting transcriptional co-
regulation. To determine promoter activity, the shared 5' region of the mouse 
PRKDC and MCM4 genes (a 695 bp DNA fragment spanning 16 bp 5' of the 
MCM4 and 2 bp 3' of the PRKDC translational start sites) was amplified by 
PCR using genomic DNA derived from MEF-Hif1a+/+rT and MEF-Hif1a-/-rT 
cells. Of note, no sequence variations between the two cell lines were 
observed in this region. Transient transfections of a luciferase reporter gene 
driven by this promoter region revealed a substantial decrease in reporter 
gene activity in MEF-Hif1a-/-rT when compared with MEF-Hif1a+/+rT cells (Fig. 
4C). Exposure of the transfected cells to 0.2% oxygen for 20 hours reduced 
reporter gene activity by about 50%, irrespective of the presence of HIF-1α. 
Parallel transfections of the two cell lines with the HRE-driven pH3SVL 
confirmed HIF-dependent hypoxic gene induction (Fig. 4C). Forced 
expression of exogenous HIF-1α in MEF-Hif1a-/-rT failed to increase the 
activity of the co-transfected 695 bp mPRKDC promoter region, although 
transfected HIF-1α protein was clearly detectable by immunoblotting of 
parallel cultures (data not shown). While reduced promoter activity is sufficient 
to explain the decreased DNA-PKcs basal mRNA levels in HIF-1α-deficient 
MEFs, these data suggest that increased HIF-1α levels do not further induce 
mouse PRKDC gene expression, as expected from the lack of hypoxic 
induction of DNA-PKcs mRNA in wild-type MEF cells.  
2.3.4.5 Cell model-specific effects of HIF-dependent chemoresistance. 
To test our findings in an independent HIF-1α-deficient model, we generated 
HIF-1α mRNA knock-down cell lines by stable shRNA transfection in MEF-
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Hif1a+/+rT cells. However, partial HIF-1α mRNA knock-down only marginally 
affected the expression of DNA-PK complex members (data not shown). 
Therefore, we repeated our experiments in a HIF-1α-deficient MEF cell line 
derived from an independent knock-out mouse strain (Stiehl et al. 2006). 
These cell lines were named MEF-Hif1a+/+T and MEF-Hif1a-/-T since they 
were not transformed by H-ras. However, whereas MEF-Hif1a-/-rT showed the 
expected increased susceptibility to etoposide, MEF-Hif1a-/-T cells were 
equally sensitive to etoposide as the corresponding wild-type control (Fig. 5A).  
 In line with this finding, no difference in protein levels of DNA-PKcs 
could be detected between MEF-Hif1a+/+T and MEF-Hif1a-/-T, while DNA-
PKcs was clearly lower in MEF-Hif1a-/-rT than in MEF-Hif1a+/+rT (Fig. 5B, left 
panel). To control for the genotype of the MEF-Hif1a-/-T cells, HIF-1α 
immunoblotting of nuclear extracts was included. Interestingly, following 
prolonged exposure there was an immunoreactive truncated but still hypoxia-
inducible form of HIF-1α protein detectable in MEF-Hif1a-/-T but not in MEF-
Hif1a-/-rT (Fig. 5B, right panel). This truncated HIF-1α protein cannot be 
directly transcriptionally active since it is derived from a targeted deletion of 
exon 2, containing the bHLH DNA-binding region of HIF-1α. Indeed, protein 
levels of the HIF target gene PHD2 were no longer hypoxically induced in both 
HIF-1α-deficient cell lines. Finally, the levels of SV40 large T antigen were 
similar in all 4 cell lines, ruling out major differences due to changes in large T 
levels. Another major difference between the two cell lines might be the H-ras 
levels. However, using RT-qPCR we could not detect any H-ras mRNA, 
neither in the MEF-Hif1a+/+T/MEF-Hif1a-/-T nor in the MEF-Hif1a+/+rT/MEF-
Hif1a-/-rT cell lines, while diluted H-ras plasmid cDNA was still detectable 
(data not shown). 
 To further confirm lack of HIF-dependent transcriptional activity, MEF-
Hif1a+/+T and MEF-Hif1a-/-T cells were transiently transfected with the HRE-
driven pH3SVL reporter plasmid. As expected, there was no residual hypoxic 
induction of HIF-dependent reporter gene expression in MEF-Hif1a-/-T (Fig. 
4C). Similar results were obtained for the endogenous transcripts of BNIP3 
which were only induced in HIF-1α-containing MEF-Hif1a+/+T (Fig. 4D). 
Induction of GADD153 in both cell lines confirmed their hypoxic status. 
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2.3.5 Discussion 
 Due to microenvironmental changes as well as oncogenic 
transformation, HIF-1α levels are constitutively increased in solid tumors. In 
this work we established a new molecular link between HIF-1α and tumor 
therapy resistance by demonstrating that both basal and etoposide-induced 
DNA damage is increased in HIF-1α-deficient cells. The DNA-PK complex 
members DNA-PKcs and Ku80 were found to be downregulated in HIF-1α-
deficient cells on the mRNA levels. On the protein level, not only DNA-PKcs 
and Ku80 but also the third DNA-PK member Ku70 was decreased in HIF-
deficient cells. The reduced Ku70 protein levels, despite similar mRNA levels, 
are likely explained by the lack of mutual protein stabilization of the three 
DNA-PK complex members: radiosensitive CHO cells expressing reduced 
levels of Ku80 also showed lowered levels of Ku70 and forced expression of 
Ku86 in such cells concomitantly restored Ku70 protein levels (Errami et al. 
1996; Singleton et al. 1997). Importantly, defective DNA-PK is known to lead 
to increased efficiency in tumor therapy, including to etoposide treatment 
(Lees-Miller et al. 1995; Zhao et al. 2006). 
 Supporting our results using HIF-1β-deficient hepatoma cells, Um and 
colleagues reported induction of DNA-PKcs, Ku70 and Ku80 by hypoxia and 
iron chelation in a HIF-1β-dependent manner (Um et al. 2004). While Ku has 
been reported to be induced by hypoxia in other cell types as well (Ginis and 
Faller 2000; Lynch et al. 2001), we could not observe any hypoxia-inducible 
Ku or DNA-PKcs expression in MEF cells. How could a HIF-dependent but 
non-hypoxia-inducible gene expression be explained? Genetically HIF-1α-
deficient cells are well known to have even lower HIF target gene levels than 
wild-type cells when both cell lines are cultured under the standard "oxic" 20% 
oxygen conditions (Iyer et al. 1998). This finding is remarkable since HIF-1α 
protein is usually below the detection limit of standard methods in 
subconfluent cells cultured at 20% oxygen, which in principle should suffice to 
completely degrade HIF-1α. A new hint to the mechanism of "oxic" HIF-1α 
function was provided by the interesting finding that a HIF-1α knock-out-
derived MEF cell line that still contained a truncated version of HIF-1α neither 
showed increased chemosensitivity nor increased DNA-PKcs protein levels. 
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Thus, only the complete absence of HIF-1α in MEF cells conferred "oxic" 
chemosensitivity and residual HIF-1α might be sufficient to reverse this effect. 
In line with this conclusion, partial downregulation of HIF-1α by shRNA 
interference only weakly affected chemoresistance in MEF-Hif1a+/+rT cells, 
while hypoxic induction of HIF-1α target genes was strongly impaired (data 
not shown). DNA-binding activity appears not to be required, ruling out a 
direct transcriptional function. Indeed, despite the presence of putative HRE 
sites, the DNA-PKcs promoter was not found to be induced by hypoxia. 
Rather, the DNA-PKcs promoter as well as endogenous DNA-PKcs mRNA 
expression were downregulated by the (complete) absence of HIF-1α. 
 The concept of "oxic" HIF-1α was further developed by Giaccia and co-
workers who showed that loss of HIF-1α under aerobic conditions accelerated 
cellular senescence in a macrophage migration inhibitory factor (MIF)-
dependent manner (Welford et al. 2006). The VE-cadherin gene has been 
reported to be induced by HIF-2 but not by hypoxia (Le Bras et al. 2007). 
Finally, Zeng and colleagues recently reported that HIF-1α decreased the 
sensitivity of lung cancer cells to paclitaxel under normoxic conditions, further 
supporting our data (Zeng et al. 2007). Thus, these examples demonstrate 
that the low concentrations of HIF-1α under normoxic conditions are sufficient 
for certain cellular processes. Translated to tumor biology, this could imply 
that slight changes in HIF-1α mRNA expression levels by oncogenic 
transformation early in tumor formation might already lead to changes in HIF 
target gene expression, even before the growing tumor creates severely 
hypoxic regions with massively induced HIF-1α protein. 
 In apparent contrast to our findings, Huang and co-workers reported 
that HIF is responsible for genomic instability by downregulating several 
factors involved in DNA repair (Huang et al. 2007). However, only treatments 
that cause DNA-DSBs were effectively impaired by HIF in our model system 
(20). While DNA-DSB repair by NHEJ confers resistance to DNA-DSB-
causing agents, NHEJ is an error-prone process. Thus, HIF-dependent DNA-
DSB repair might even boost genomic instability and malignant progression. 
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Figure 1. Etoposide-induced cell cycle arrest in wild-type and HIF-1α-deficient MEFs. A, MEF-Hif1a+/+rT 
and MEF-Hif1a-/-rT were treated with 1, 2.5 and 5 µM etoposide for 1 hour, trypsinized and plated in 
triplicates for each concentration. Colonies were counted after 6 days and normalized to the untreated 
control plates. Shown are mean values + SEM of a representative experiment performed in triplicates. 
Asterisks indicate statistically significant differences (** p < 0.01) as calculated by student's t-test. B, Cell 
cycle distribution of MEF-Hif1a+/+rT and MEF-Hif1a-/-rT was determined by FACS analysis following 
treatment with 1 µM etoposide as indicated. C, MEF lysates were immunoblotted for SV40 large T 
antigen and β-actin. Spontaneously immortalized MEFs (spont.) served as negative controls. D, MEFs 
were treated with 1 µM etoposide for 8 hours at either 20% or 0.2% oxygen and p21, p16, p27 and 
BNIP3 mRNA levels were quantified by RT-qPCR. Values were normalized to the mRNA levels of the 
housekeeping ribosomal protein s12. Mean values + SEM of 3 independent experiments are shown.  
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Figure 2. DNA fragmentation in wild-type and HIF-1α-deficient MEFs after a genotoxic insult. A, DNA 
fragmentation in MEF-Hif1a+/+rT and MEF-Hif1a-/-rT cells was quantified by single-cell electrophoresis 
following exposure to increasing amounts of etoposide for 1 hour. DNA was stained with SYBR green 
and all images were acquired with fixed exposure times. B, DNA fragmentation was quantified by 
determining the tail moment of at least 150 comets per condition using CometScore software. C, 
Aliquots of cell cultures from A were subjected to immunoblotting for γH2AX. Band intensity was 
quantified by densitometry and normalized to β-actin levels. Ponceau staining served to demonstrate 
equal extraction of histones. D, MEF cells were grown on lumox membranes and treated with up to 1 µM 
etoposide for 1 hour. Immunofluorescence was performed using antibodies directed against 53BP1 and 
γH2AX and nuclei were counterstained with DAPI. All data are given as mean values + SEM and 
asterisks indicate statistically significant differences (** p<0.01, *** p<0.001) as calculated by Tukey's 
multiple comparison test (B, C). 
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Figure 3. Analysis of DNA repair pathways in wild-type and HIF-1α-deficient MEFs. A, MEF-Hif1a+/+rT 
and MEF-Hif1a-/-rT cells were treated with 1 µM etoposide for 0 to 16 hours under normoxic conditions. 
Phosphorylation of ATM, CHK1, CHK2 and H2AX was analyzed by immunoblotting using 
phosphoprotein-specific antibodies. β-actin served as loading control.  
B, MEF-Hif1a+/+rT and MEF-Hif1a-/-rT cells were permanently cultured at 20% or 0.2% O2 for 0, 4, 16, 64 
or 256 hours in a hypoxic work station. Transcript levels of 17 candidate genes involved in DNA repair 
were quantified by RT-qPCR. Hypoxic induction factors are shown following normalization to the mRNA 
levels of ribosomal protein S12. 
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Figure 4. Reduced expression of DNA-PK subunits in HIF-1α-deficient MEFs. A, mRNA levels of the 
three DNA-PK subunits DNA-PKcs, Ku70 and Ku80, as well as MCM4, ATM and ATR, were quantified 
in MEF-Hif1a+/+rT and MEF-Hif1a-/-rT cells after exposure for 16 hours to 0.2% oxygen. BNIP3 and 
GADD153 mRNA levels were determined as controls. All values were normalized to ribosomal protein 
s12 mRNA levels. Mean induction factors +SEM of 3 independent experiments performed in triplicates 
are shown. B, Immunoblot analyses of DNA-PKcs, Ku70 and Ku80 in nuclear extracts of MEF cells 
treated as above. HIF-1α protein levels were determined to control for hypoxic induction and genotype. 
-actin levels were determined as loading control. Reduced levels for Ku80 were confirmed in total cell 
lysates (bottom panel) and HIF-dependent hypoxic induction of PHD2 is shown. C, Relative luciferase 
activities were determined in MEF cells transiently co-transfected with 2 µg pGL3-mPRKDC or pH3SVL 
and 0.1 µg pRL-CMV as transfection control. Transfected cultures were incubated for 20 hours at either 
20% or 0.2% oxygen and dual luciferase activity was measured. Data are shown as mean values of 
hexaplicates +SEM. 
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Figure 5. Increased chemosensitivity to etoposide is not observed in HIF-1α knock-out MEFs containing 
residual truncated HIF-1α. A, Relative MTT conversion in response to etoposide treatment for 24 hours 
was determined in two independent MEF cell lines distinguished by the presence (rT) or absence (T) of 
H-ras transfection. Cultures were treated in triplicates and values normalized to untreated control cells. 
Data are given as mean values of triplicates + SEM. B, Nuclear protein was subjected to immunoblot 
analysis of DNA-PKcs (left) or HIF-1α, PHD2 and SV40 large T antigen protein levels. C, MEF-Hif1a+/+T 
and MEF-Hif1a-/-T were transiently co-transfected with 2 µg pH3SVL and 0.1 µg pRL-CMV as 
transfection control. Dual luciferase activity was measured and values expressed as mean of 
hexaplicates + SEM. D, BNIP3 and GADD153 mRNA levels were quantified by RT-qPCR in MEF-
Hif1a+/+T and MEF-Hif1a-/-T after exposure for 16 hours to 0.2% oxygen. All values were normalized to 
ribosomal protein s12 mRNA levels and are shown as mean + SEM of experiments performed in 
triplicates. 
 
 87
RESULTS 
2.4 Induction of the HIF system by low levels of HSP90 
inhibitors1 
Nadia O. Ibrahim, Torsten Hahn, Corinna Franke, Daniel P. Stiehl, Renato Wirthner, Roland 
H. Wenger, and Dörthe M. Katschinski2 
 
Cell Physiology Group, Medical Faculty, Martin-Luther-University Halle, D-06112 Halle, Germany [N.O.I., T.H., C.F., 
D.M.K.]; Institute of Physiology, University of Zürich, CH-8057 Zürich, Switzerland [D.P.S., R.W., R.H.W.] 
 
1Supported by grants from the DFG (Ka1269/5-1 to D.M.K.), Kultusministerium des Landes Sachsen-Anhalt 
(PA3515A/0603M to D.M.K.), BMBF (NBL3 to D.M.K.), DAAD (to N.O.I) Krebsliga des Kantons Zürich (to R.H.W.) 
and 6th Framework Programme of the European Commission/SBF (EUROXY LSHC-CT-2003-502932/SBF Nr. 
03.0647-2 to R.H.W.). 
 
2To whom requests for reprints should be adressed, at Cell Physiology, Martin-Luther University Halle, Magdeburger 
Str. 2, D-06097 Halle, Germany. Tel: +49 (0)345 557 1374; Fax: +49 (0)345 557 1378; E-Mail: 
doerthe.katschinski@medizin.uni-halle.de 
 
Published in Cancer Research 2005, 65(23): 11094-100 
2.4.1 Abstract 
The heterodimeric hypoxia-inducible factor (HIF)-1 is involved in key steps of 
tumor progression and therapy resistance and thus represents an attractive 
anti-tumor target. Since HSP90 plays an important role in HIF-1α protein 
stabilization and because HSP90 inhibitors are currently being tested in 
clinical phase I trials for anti-cancer treatment, we investigated their role as 
anti-HIF-1α agents. Surprisingly, low dose (5–30 nM) treatment of HeLa cells 
with three different HSP90 inhibitors (17-AAG, 17-DMAG and GA) increased 
HIF-1-dependent reporter gene activity, whereas higher doses (1-3 µM) 
resulted in a reduction of hypoxia-induced HIF-1 activity. In line with these 
data, low-dose treatment with HSP90 inhibitors increased and high-dose 
treatment reduced hypoxic HIF-1α protein levels, respectively. HIF-1α protein 
stabilized by HSP90 inhibitors localized to the nucleus. As a result of HSP90-
modulated HIF-1 activity, the levels of the tumor relevant HIF-1 downstream 
targets CAIX, PHD3 and VEGF were increased or decreased after low-dose 
or high-dose treatment, respectively. Bimodal effects of 17-AAG on vessel 
formation were also seen in the chick chorioallantoic membrane angiogenesis 
assay. In summary, these results suggest that dosage will be a critical factor 
in the treatment of tumor patients with HSP90 inhibitors. 
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2.4.2 Introduction 
The hypoxia-inducible factor-1 (HIF-1) activates a number of oxygen-
regulated genes critically involved in adaptation to hypoxia (Semenza 2000; 
Wenger 2002; Kaelin 2005). Under normoxic conditions, the von Hippel-
Lindau tumor suppressor protein (pVHL) targets the HIF-1α subunit for rapid 
ubiquitination and proteasomal degradation (Maxwell et al. 1999). Binding of 
the pVHL tumor suppressor protein requires modification of HIF-1α by a 
family of low-affinity oxygen-dependent prolyl-4-hydroxylase domain proteins 
(PHD) (Epstein et al. 2001; Ivan et al. 2001; Jaakkola et al. 2001). Three HIF-
1α modulating PHDs, i.e. PHD1, 2, and 3, have been described so far.  
HIF-1 is constitutively upregulated in many cancer types and plays a major 
role in tumor progression (Semenza 2002; Brown and Wilson 2004; Vaupel 
2004); HIF-1 elevates vascular endothelial growth factor (VEGF)-dependent 
tumor angiogenesis, it regulates tumor acidosis by increasing carbonic 
anhydrase IX (Wykoff et al. 2000), and it mediates the increased glycolytic 
capacity of tumor cells, known as Warburg effect (Seagroves et al. 2001). 
Moreover, we and others have recently shown that HIF-1 confers resistance 
against chemo- and radiotherapy (Unruh et al. 2003; Williams et al. 2005). 
Since HIF-1 regulates key steps of tumor progression and therapy resistance 
it represents an attractive anti-tumor target. Anti-HIF-1 effects have been 
described for a variety of agents, including several drugs already in clinical 
use such as taxol, topotecan or the HSP0-inhibiting ansamycin derivatives (for 
review see (Giaccia et al. 2003; Yeo et al. 2004)). The mechanism by which 
taxol and topotecan destabilize HIF-1α is currently unknown. With regard to 
ansamycin derivatives, we and others have previously shown that HSP90 is 
important for hypoxic stabilization of HIF-1α (Isaacs et al. 2002; Katschinski et 
al. 2002; Zhou et al. 2004). In HSP90β-deficient cells, hypoxic stabilization of 
HIF-1α was significantly delayed compared to wild type cells (Katschinski et 
al. 2004). A similar effect could be shown by inhibiting HSP90 with the 
ansamycin derivative geldanamycin (GA), suggesting that HSP90 is required 
for the rapid hypoxic stabilization of HIF-1α which otherwise might be 
degraded by unspecific pathways (Katschinski et al. 2004). To inhibit the HIF 
system, doses in the micromolar range have usually been used (Katschinski 
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et al. 2002; Mabjeesh et al. 2002; Isaacs et al. 2004). Besides HIF-1α a 
variety of other classical HSP90 client proteins have been demonstrated to be 
targeted by ansamycin derivatives, including v-src, FAK, ErbB2 and Akt 
kinase (Goetz et al. 2003). Since the clinical application of GA is restricted 
due to severe side effects, modified ansamycin derivatives like 17-AAG or the 
water soluble 17-DMAG have been developed (Sausville 2004). The safety of 
17-AAG application in humans was demonstrated in three recently published 
clinical phase I trials (Banerji et al. 2005; Goetz et al. 2005; Ramanathan et al. 
2005).  
Because it is difficult to control the local dose of an intravenously or orally 
applied drug within the tumor tissue, we have determined the effect of GA, 17-
AAG and 17-DMAG on the HIF-system over a wide dose range. Surprisingly, 
an increase in HIF-1α protein levels as well as HIF-target gene expression 
was found for all three compounds following application in the low nanomolar 
range, whereas higher doses efficiently downregulated the HIF-system. These 
results should be considered when HSP90 inhibitors are to be tested for anti-
tumor therapy.  
2.4.3 Materials and Methods 
2.4.3.1 Chemicals 
Geldanamycin (GA), 17-demethoxy-17((2-(dimethylamino)ethyl)amino) 
geldanamycin hydro-chloride (17-DMAG) and 17-allylamino-17-
demethoxygeldanamycin were a kind gift of Kosan Biosciences Inc. (Hayward, 
CA). All three drugs were dissolved in DMSO to generate 2 mM stock 
solutions. All further dilutions were prepared in cell culture medium. All other 
chemicals were obtained from Sigma (Taufkirchen, Germany) or Roth 
(Karlsruhe, Germany).  
2.4.3.2 Cell lines and cell culture 
All cell lines were cultured in Dulbecco's modified Eagle's medium (high 
glucose) as described previously. Oxygen partial pressures in the hypoxic 
incubator (Binder, Tuttlingen, Germany) were either 140 mm Hg (20% O2 
vol/vol, normoxia) or 7 mm Hg (1% O2 vol/vol, hypoxia).  
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2.4.3.3 Transient transfections 
HeLa and Hep3B cells were transiently transfected with the HIF-dependent 
firefly luciferase reporter gene construct pH3SVL, containing a total of 6 HIF-1 
DNA-binding sites derived from the transferrin gene by the calcium phosphate 
co-precipitation method as described previously (Rolfs et al. 1997). HeLa or 
Hep3B cells were seeded in 24 well plates at a concentration of 5 x 104 
cells/well. One day after seeding, cells were co-transfected with 0.25 µg 
pH3SVL together with 0.04 µg renilla luciferase control plasmid pRL-SV40 
(Promega, Mannheim, Germany). Cells were treated with HSP90 inhibitors 
dissolved in DMSO or DMSO alone and subsequently exposed to normoxic or 
hypoxic conditions for 24 hours. Luciferase activities were determined using 
the dual-luciferase assay kit (Promega, Mannheim, Germany). Results were 
normalized to the solvent-treated normoxic control values which were 
arbitrarily defined as 1. 
2.4.3.4 Protein extraction and immunoblot analyses 
Combined cytoplasmic and nuclear extracts of cultured cells were prepared 
using 0.4 M NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA and 0.1% NP-40. 
Protein concentrations were determined by the Bradford method using BSA 
as a standard. For immunoblot analysis, 50 µg cellular protein was 
electrophoresed through 7.5% SDS-polyacrylamide gels and 
electrotransferred onto nitrocellulose membranes (Amersham, Freiburg, 
Germany) by semi-dry blotting (BioRad, München, Germany). Membranes 
were stained with Ponceau S (Sigma) to confirm equal protein loading and 
transfer. HIF-1α, HSP70, HSP90, Akt, HSF-1 and β-actin were detected using 
the following antibodies: mouse monoclonal anti-HIF-1α IgG1 (Transduction 
Laboratories, Heidelberg, Germany), mouse monoclonal anti-HSP70 IgG1 
(StressGen, Victoria, Canada), rat monoclonal anti-HSP90 IgG2a rabbit 
(StressGen, Victoria, Cancada), rabbit polyclonal anti-Akt (Cell Signaling 
Tehnology, Beverly, USA), polyclonal anti-HSF-1 (Santa Cruz Biotechnology) 
and mouse monoclonal anti-β-actin IgG1 (Sigma) followed by the appropriate 
secondary horseradish peroxidase-conjugated polyclonal antibodies raised in 
goats (Santa Cruz Biotechnology, Santa Cruz, CA). Chemiluminescence 
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detection of horseradish peroxidase was performed by incubation of the 
membranes with 100 mM Tris-HCl (pH 8.5), 2.65 mM H2O2, 0.45 mM luminol 
and 0.625 mM coumaric acid (all purchased from Sigma) for 1 minute followed 
by exposure to X-ray films (Amersham).  
2.4.3.5 HIF-1α immunofluorescence 
Cells were fixed with methanol for 5 minutes. The non-specific binding sites 
were blocked with 3% BSA in PBS for 30 minutes. The cells were incubated 
for 1 hour with a mouse monoclonal anti-HIF-1α IgG1 antibody (Transduction 
Laboratories) diluted 1:10 in 3% BSA in PBS followed by a TRITC-coupled 
secondary anti-mouse (Dako) antibody diluted 1:200 with 3% BSA in PBS. 
Subsequently, all cells were stained with Hoechst 33258 dye for 5 minutes. 
After extensive washings with PBS, the slides were mounted and analyzed by 
fluorescence microscopy (Axioplan 2000, Carl Zeiss Vision, Mannheim, 
Germany). 
2.4.3.6 RNA extraction and real-time RT-PCR 
Hep3B cultures were grown on 6 well plates for 24 hours and total RNA was 
extracted. First strand cDNA synthesis was performed with 1 µg of RNA using 
the first strand synthesis kit from Fermentas (Fermentas, St. Leon-Rot, 
Germany). Subsequently, mRNA expression levels for CAIX, PHD1, PHD2, 
and PHD3 were quantified with 1 µl of cDNA reaction by real-time RT-PCR 
using a SybrGreen Q-PCR reagent kit (Sigma) in combination with the 
MX3000P light cycler (Stratagene). Initial template concentrations of each 
sample were calculated by comparison with serial dilutions of a calibrated 
standard. To verify RNA integrity and equal input levels, ribosomal protein L28 
mRNA was determined and data expressed as ratios relative to L28 levels. 
Primers were as follows: hCAIX forward, 5’-gggtgtcatctggactgtgtt-3’; hCAIX 
reverse, 5’-cttctgtgctgccttctcatc-3’; PHD2 forward, 5’-gaaagccatggttgcttgtt-3’; 
PHD2 reverse, 5’-ttgccttctggaaaaattcg-3’; PHD3 forward, 5’-
atcgacaggctggtcctcta-3’; PHD3 reverse, 5’-cttggcatcccaattcttgt-3’; hL28 
forward, 5’-gcatctgcaatggatggt-3’; hL28 reverse, 5’-tgttcttgcggatcatgtgt-3’. 
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2.4.3.7 Chick embryo chorioallantoic membrane (CAM) assay 
CAM assays were performed as described before (Linden et al. 2003). In 
brief, fertilized eggs (purchased from Lohmann Tierzucht, Cuxhaven, 
Germany) were incubated at 37°C in a humidified atmosphere. The eggs were 
kept on their sides and turned upside down twice a day. After 3 days, a small 
hole was drilled through the shell into the air sac (visualized using a strong 
light source), 2 ml of egg white were aspirated and a window of approx. 0.5 
cm2 was sawed into the side of the egg. The window was sealed with tape, 
and the eggs were reincubated until day 10, when 17-AAG was applied to the 
CAM using the Elvax method. Therefore, ethylene/vinyl acetate copolymer 
beads (elvax 40L-03, DuPont,Wilmington, DE; kindly provided by C. H. 
Erbslöh KG, Krefeld, Germany) were extensively washed in ethanol and dried 
under vacuum. The Elvax beads were then dissolved in methylene chloride at 
10% (w/v), and 17-AAG was added to the desired concentration. One drop 
(40 µl) of this solution was pipetted onto a siliconized glass slide, and the 
solvent was allowed to evaporate completely. Using foreceps, the Elvax disk 
was carefully lifted from the glass slide and placed onto the CAM. At day 13, 
the window was enlarged and the CAM was documented using a digital 
camera (Olympus, Hamburg, Germany) coupled to an ocular of a 
stereomicroscope.  
2.4.4 Results and Discussion 
2.4.4.1 Modulation of HIF-1activity is highly dependent on HSP90 
inhibitor concentration 
HeLa cells were treated with 17-AAG, 17-DMAG or GA at concentrations 
ranging from 5 nM to 3 µM under normoxic or hypoxic conditions for 4 hours. 
We first demonstrated the efficiency of the HSP90 inhibitors in HeLa cells by 
determining the concentration of the heat shock transcription factor-1 (HSF-1). 
HSF-1 mediates the increased expression of HSPs following induction of a 
heat shock response with HSP90 inhibitors as reported previously (Sittler et 
al. 2001; McLean et al. 2004). In non-stressed HeLa cells grown at 37°C, 
HSF-1 was detected as an approx. 85 kDa protein by immunoblotting (Fig. 1). 
After treating HeLa cells for 4 hours at 42°C, however, the HSF-1 appeared 
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as an approx. 95 kDa protein. This shift in molecular mass most likely 
corresponds to the phosphorylation of HSF-1 and hence indicates the extent 
of its activation. A similar shift in molecular mass was observed after treating 
HeLa cells with increasing concentrations of 17-AAG (Fig. 1). Similar effects 
were seen after treatment with 17-DMAG and GA (data not shown), 
demonstrating that the HSP90 inhibitors were fully functional and confer a 
heat-shock-like response.  
To explore whether the HSP90 inhibitors affect HIF-1 activity, transient 
transfections were performed with a HIF-1-dependent reporter gene. After 
simultaneous treatment with hypoxia and increasing concentrations (5 nM – 3 
µM) of 17-AAG, 17-DMAG or GA, luciferase activity was measured as a 
marker for HIF-1 transcriptional activity (Fig. 2A to C). Hypoxia alone resulted 
in a roughly 50-fold induction of HIF-1 activity compared to normoxia. 
Surprisingly, treatment of HeLa cells with 5 nM or 30 nM of 17-AAG or GA 
resulted in a significant increase of hypoxia-mediated HIF activity. A similar 
effect was observed after treating the cells with 5 nM 17-DMAG. However, 
treatment with higher concentrations, i.e. 1-3 µM 17-AAG, 17-DMAG or GA, 
significantly decreased reporter gene activity. To rule out a cell line specific 
effect, Hep3B cells were treated with 17-AAG, 17-DMAG or GA (Fig. 2D). Like 
in HeLa cells, low-dose treatment with 5 nM of all three drugs resulted in an 
increased activity of HIF-1α, whereas the activity was decreased after 
treatment with 3 µM 
2.4.4.2 Bimodal effect of HSP90 inhibitors on HIF-1α protein levels 
Exposure of HeLa cells to 1% oxygen for 2-24 hours resulted in hypoxic 
stabilization of HIF-1α (Fig. 3). Hypoxic stabilization was strongest after 4 
hours incubation at 1% O2, whereas at later time points, i.e. 12 hours and 24 
hours, the hypoxic stabilization was less pronounced. Treatment with 5 nM or 
3 µM 17-AAG effected a heat shock-like response with increased expression 
of HSP70 and to a minor extent HSP90. This effect was more pronounced 
after treatment with 3 µM compared to 5 nM. In addition, the expression of 
HSPs increased with duration of 17-AAG treatment. In line with the decreased 
HIF-1 transcriptional activtiy and as described previously by us and others, 
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treatment with high doses of 17-AAG (3 µM) decreased hypoxic HIF-1α 
protein accumulation (Isaacs et al. 2002; Katschinski et al. 2002; Mabjeesh et 
al. 2002; Isaacs et al. 2004). However, consistent with the increased HIF-1 
transcriptional activity, treatment with low doses of 17-AAG (5 nM) further 
increased the hypoxic stabilization of HIF-1α most prominently at early time 
points and to a lesser extent after 24 hours incubation. This may be explained 
by the fact that 17-AAG is accumulating intracellularly with time (Chiosis et al. 
2003). The affinity of the isolated HSP90 protein for ansamycins has been 
determined to be in the low micromolar range (Panaretou et al. 1998; Roe et 
al. 1999). However, since ansamycins accumulate intracellularly, even 
nanomolar concentrations may be effective to reach this level inside the cells. 
In contrast to the treatment with 5 nM 17-AAG, the effect with 3 µM 17-AAG 
on HIF-1α accumulation as well as the full heat shock-like response were 
seen at later time points. Decreased levels after treatment with 3 µM but no 
increase with 5 nM 17-AAG were seen for the HSP90 client protein Akt, 
demonstrating that the dose-dependent modulation of HIF-1α is not a general 
phenomenon of all HSP90 client proteins. The PI3 kinase/Akt pathway is 
involved in HIF-1α stabilization (Zundel et al. 2000). Since Akt was 
downregulated after 3 µM 17-AAG treatment, this effect may be involved in 
the downregulation of HIF-1α after high dose 17-AAG treatment and may 
explain partly the time- and dose-dependent effects on the HIF-system. Other 
signal transduction pathways involved in the stabilization or activation of HIF-
1α especially in cancer have also been described to be affected by HSP90 
inhibitor treatment. In this respect it is interesting to note that erbB2 as well as 
the Raf/Ras/MAP kinase pathways, which are involved in HIF-1α stabilization 
and activation, have likewise been described to be affected by HSP90 
inhibition(Goetz et al. 2003; Zhang and Burrows 2004; Peng et al. 2005)  
2.4.4.3 HIF-1α protein induced by HSP90 inhibitors localizes to the 
nucleus 
We next determined whether HSP90 inhibitors affect the nuclear translocation 
of hypoxia-induced HIF-1α protein. Therefore, HeLa cells were treated with 
1% O2 with or without addition of 5 nM or 3 µM 17-AAG for 4 hours. As shown 
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by indirect immunofluorescence analysis, HIF-1α protein accumulated 
exclusively within the nucleus under hypoxic conditions. Addition of 5 nM 17-
AAG did not affect nuclear translocation of HIF-1α whereas 3 µM 17-AAG 
reduced HIF-1α protein levels (Fig. 4). Similar results were obtained by 
treating HeLa cells with GA or 17-DMAG (data not shown). 
2.4.4.4 HSP90 inhibitors modulate HIF-dependent target gene 
expression involved in hypoxia adaptation 
Modulation of HIF-1α protein expression and HIF-1 transcriptional activity by 
HSP90 inhibitors suggest that these drugs may affect pathways involved in 
tumor progression. Therefore, we investigated the effects of 17-AAG on the 
expression of the HIF-1 target gene CAIX (Grabmaier et al. 2004). CAIX has a 
major role in regulating proton flux and blockade of CAIX results in increased 
cell death under severe hypoxia, indicating an important mechanism of 
hypoxic adaptation (Potter and Harris 2004). Exposure of Hep3B cells for 24 
hours at 1% O2 indeed resulted in a strong increase in CAIX mRNA levels 
compared to cells grown at 20% O2 (Fig. 5). Low-dose (5 nM) 17-AAG 
enhanced CAIX mRNA expression at 20% O2 and even more pronounced at 
1% O2 (p<0.05), whereas treatment with 3 µM 17-AAG resulted in a significant 
decrease of CAIX mRNA levels (p<0.001). PHD2 and PHD3, which regulate 
HIFα stability in an oxygen-dependent manner, are HIF target genes 
themselves (Metzen et al. 2005; Pescador et al. 2005). A similar regulation as 
for CAIX by 5 nM 17-AAG was seen for PHD3 mRNA but not PHD2 mRNA 
(Fig. 5). PHD1 mRNA was barely detectable in these cells (data not shown). 
Previously, it has been reported that PHD3 is strongly induced by hypoxia, 
which is mediated by HIF-1 (Pescador et al. 2005). The hypoxic induction of 
PHD3 limits HIF-1α accumulation during long time hypoxia and enables rapid 
destabilization following reoxygenation (Appelhoff et al. 2004; Marxsen et al. 
2004). The increased expression of PHD3 by hypoxia and 5 nM 17-AAG may 
explain the downregulation of hypoxic stabilization of HIF-1α after 24 hours as 
well as the diminished effect of 5 nM 17-AAG after 24 hours treatment. 
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2.4.4.5 Effects of HSP90 inhibitors on angiogenesis 
Besides metabolic tumor adaptation towards hypoxia, tumor angiogenesis is a 
major event during tumor progresssion. A major regulator of tumor 
angiogenesis is the HIF-1 downstream target VEGF. Therefore, we 
investigated whether HSP90 inhibitors also induce VEGF synthesis. 
Consistent with the reporter and target gene studies, treatment of HeLa or 
Hep3B cells with 5 nM 17-AAG increased hypoxia-induced VEGF secretion, 
whereas treatment with 3 µM significantly reduced VEGF production (Fig. 6A 
and B).  
In two previous studies the effects of GA, 17-AAG or 17-DMAG on 
angiogenesis were investigated in Matrigel angiogenesis assays (Kaur et al. 
2004; Sun and Liao 2004). In both studies HSP90 inhibitors decreased the 
motility response of endothelial cells to VEGF or fibroblast growth factor-2 in a 
dose-dependent manner. However, in a complex tumor model the effects of 
HSP90 inhibitors not only on endothelial cells but also on tumor cells have to 
be taken into account. Our data suggest that HSP90 inhibitors may increase 
or decrease the HIF-system, including the expression of VEGF in tumor cells, 
depending on the local concentrations. VEGF acts on endothelial cells as both 
chemotactic and mitogenic factor, via cell-specific receptors. VEGF within a 
solid tumor is produced in part by endothelial cells, in part by tumor cells, in 
part by stroma cells and in part by invading macrophages, mainly as a result 
of changes in oxygenation (Tang et al. 2004). In order to mimic the complexity 
of the in vivo situation, we thus used the CAM assay to investigate the effect 
of HSP90 inhibitors on angiogenesis. Treating CAMs with 5 nM and 3 µM 17-
AAG resulted in significant changes compared to the solvent-treated control 
CAMs. In line with HIF-1 transcriptional activity and VEGF production, 36% (5 
out of 14 total) of 5 nM 17-AAG-treated eggs showed clear signs of pro-
angiogensis and 50% (5 out of 10 total) of 3 µM 17-AAG-treated eggs showed 
signs of deteriorated and decreased vessel formation as illustrated in Fig. 6B. 
None of the eggs treated with 5 nM or 3 µM 17-AAG showed signs of anti-
angiogenesis or pro-angiogenesis, respectively.  
Taken collectively, our data demonstrate bimodal effects of HSP90 inhibitors 
on the HIF-system which are highly dose-dependent. HIF-1α stabilizing 
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effects have also been described for other anti-cancer/chemopreventive 
agents like epicatechin gallate and cisplatin (Yang et al. 2004; Zhou et al. 
2004). These data support the need for the development of more specific 
inhibitors of the HIF-system since the in vivo effects of pleiotropic HSP90 
inhibitors are difficult to predict over a wide dose-range.  
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Figure 1. 17-AAG activates a heat shock response in HeLa cells. HeLacells were treated under 
normoxic (20% O2) or hypoxic (1% O2) conditions with increasing concentrations of 17-AAG as 
indicated. After 4 hours, the cells were lysed and HSF-1 activation by phosphorylation was detected by 
immunoblotting as described in Material and Methods. Protein extracts derived from HeLa cells 
incubated at 37°C or 42°C for 4 hours were used as negative and positive controls, respectively, for 
HSF-1 activation. As a control for equal loading and blotting, β-actin was subsequently determined on 
the same blot. 
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Figure 2. HSP90 inhibitors affect HIF-1 activity. (A-C) HeLa cells were transiently transfected with a 
HIF-1-dependent reporter gene plasmid as described in Materials and Methods. Subsequently, the cells 
were treated with the indicated concentrations of 17-AAG (A), 17-DMAG (B) or GA (C) and exposed to 
20% O2 or 1% O2. After 24 hours, the cells were lysed and luciferase activity was measured. Induction 
factors were normalized to non-treated cells cultured under normoxic conditions. Mean values ± SEM of 
n = 3 independent experiments are shown. (D) Reporter gene assays were performed in Hep3B cells as 
described above. The concentrations of 17-AAG, 17-DMAG or GA are indicated. Mean values ± SEM of 
n = 6 independent experiments are shown.  
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Figure 3. Effects of HSP90 inhibitors on HIF-1α protein levels. HeLa cells were treated for 2-24 hours 
with 17-AAG at the indicated concentrations under hypoxic (1% O2) conditions. Subsequently, 
combined cytoplasmic and nuclear protein was extracted and HIF-1α, Akt, HSP70, HSP90, and β-Actin 
were detected by immunoblotting.  
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Figure 4. Subcellular localization of HIF-1α after treatment with 17-AAG. HeLa cells were exposed to 
normoxic (20% O2) or hypoxic (1% O2) conditions without or with the addition of 5 nM or 3 µM 17-AAG 
for 4 hours. The cells were prepared for indirect immunofluorescence analysis as described in Materials 
and Methods. Left panel, Hoechst 33258 staining of the nuclei; right panel, anti-HIF-1α staining using a 
TRITC-coupled secondary antibody.  
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Figure 5. Effects of 17-AAG on HIF-1 target gene expression. Hep3B cells were exposed to normoxic 
(20% O2) or hypoxic (1% O2) conditions without or with the addition of 5 nM or 3 µM 17-AAG for 24 
hours. The cells were lysed, total RNA was extracted, reverse transcribed and the CAIX, PHD2, PHD3 
and L28 mRNA levels were quantitated by real-time PCR. Mean values ± SEM of n = 3 are shown. 
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Figure 6. Effects of 17-AAG on VEGF protein secretion and angiogenesis in the CAM. (A) HeLa cells or 
(B) Hep3B cells were exposed to normoxic (20% O2) or hypoxic (1% O2) conditions for 24 hours without 
or with the addition of 5 nM or 3 µM 17-AAG. Subsequently, the supernatants were collected and VEGF 
protein concentration was estimated by ELISA. Mean values ± SEM of n = 6 experiments (HeLa cells) or 
n = 3 experiments (Hep3B cells) are shown (C) Inert polymer discs containing solvent only (control), 5 
nM or 3 µM 17-AAG were placed onto the CAM at day 10 of embryonic development as described in 
Materials and Methods. Pictures were taken three days later.  
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2.5 Unpublished data 
2.5.1 Introduction 
DNA-PKcs mRNA level in wild-type MEF-Hif1a+/+ are significantly higher than 
in mutant MEF-Hif1a-/- , possibly resulting in a different etoposide sensitivity of 
the cell lines. We tried to further elucidate the HIF-dependent nature of the 
observed difference. However, stable as well as transient reconstitution of the 
mutant MEF-Hif1a-/- cell line resulted in no detectable HIF target gene 
induction upon hypoxic exposure. Therefore other strategies should reveal the 
mechanism behind the observed etoposide resistance of mutant MEF-Hif1a-/-.  
In a first approach we established stable shRNA clones of the wild-type 
MEF-Hif1a+/+. Two clones (Bd10, Be7) with stably down-regulated HIF (Fig. 
1A and 1C) were obtained by clonal selection for cells having only marginal 
HIF-dependent PHD3 (one of the strongest induced genes by HIF) induction 
(Fig. 1B). In order to have a control, one additional clone (Bc12) with intact 
PHD3 induction in hypoxia was chosen (Fig. 1B).  
However, none of the three shRNA transfected wild-type MEF-Hif1a+/+ 
clones differed in their sensitivity towards etoposide when compared to each 
other and to the wild-type cell line MEF-Hif1a+/+ (Fig. 1D). Even though HIF-
dependent target gene induction, as expected, is blunted in the clones Bd10 
and Be7 they did not show any sign of enhanced etoposide sensitivity.  
In addition, also known HIF inhibitors (Fig.2) could not sensitize wild-
type MEF-Hif1a+/+ to etoposide (Fig. 3). Thus, the observed etoposide 
sensitivity might require only minimal basic levels of HIFα to become apparent 
and may be independent of HIFs transcriptional activity as indicated by the 
missing effect on etopside sensitivity upon hypoxic HIF induction or the 
inhibition of HIF by chemical compounds.  
Indeed, reporter gene assays with the mouse or human DNA-PKcs 
promoters could not provide any hint to a transcriptional activity directed by 
HIF. On the contrary, the over-expression of HIFα in HeLa cells did not 
activate the DNA-PKcs promoter construct (Fig. 4), neither did HIFα, 
transiently introduced into mutant MEF-Hif1a-/- cells, result in an enhanced 
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expression of luciferase from the DNA-PKcs reporter construct when 
compared to a transfected β-galactosidase expression vector as a negative 
control (Fig. 5). However, transcriptional activity of the DNA-PKcs promoter is 
different when comparing the MEF cell lines wild-type MEF-Hif1a+/+ and 
mutant MEF-Hif1a-/-, providing evidence for another factor, affected by the 
absence of HIFα, that influences transcription control of DNAPKcs.  
2.5.2 Materials and Methods 
2.5.2.1 Chemicals 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and 4'-
desmethylepipodophyllotoxin 9-(4,6-O-ethylidene-b-D-glucopyranoside) 
(etoposide) were purchased from Sigma. 
 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG), 17-
(Allylamino)-17-demethoxygeldanamycin (17-AAG) were a kind gift of Kosan 
Biosciences Inc. (Hayward, CA). (5'-hydroxymethyl-2'-furyl)-1-benzylindazole 
(YC1) was purchased from Biomol international, L.P. (Plymouth Meeting, PA) 
All three drugs were dissolved in DMSO to generate 10 mM stock solutions. 
All further dilutions were prepared in cell culture medium. 
2.5.2.2 Cell culture 
MEFs were derived from mouse day 9.5 embryos, either wild-type (MEF-
Hif1a+/+) or deficient (MEF-Hif1a-/-) for HIF-1α, immortalized with SV40 large T 
antigen and transformed with H-ras (Ryan et al. 2000; Seagroves et al. 2001). 
All cell lines were cultured in Dulbecco's modified Eagle's medium (high 
glucose) as described previously (Stiehl et al. 2006). For hypoxic experiments, 
MEFs were grown in a gas-controlled glove box to handle the cells under 
constant oxygen (InvivO2 400, Ruskinn Technologies, Leeds, UK). 
2.5.2.3 Protein extractions and immunoblot analyses 
Cells were washed twice and scraped into ice-cold PBS. Soluble nuclear 
protein was extracted with a high-salt extraction buffer containing 0.1% NP-40 
essentially as described before (Stiehl et al. JBC 2006). Protein 
concentrations were determined by the Bradford method and 80 µg protein 
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was subjected to immunoblot analysis. Primary antibodies for HIF-1α was 
from Novus Biologicals (Littleton, CO). Bound antibodies were detected by 
respective secondary antibodies (Pierce) and visualized with ECL substrate 
(Pierce). 
2.5.2.4 mRNA quantification 
Total RNA was extracted as described previously (Stiehl et al. 2006). 
Following reverse transcription (RT) of 5 µg total RNA, mRNA levels were 
quantified with 1% of diluted cDNA reaction by real-time RT-PCR. A 
SybrGreen qPCR reagent kit (Sigma) was used in combination with a 
MX3000P light cycler (Stratagene). Initial template concentrations of each 
sample were calculated by comparison with serial dilutions of a calibrated 
standard. To control for equal input levels, ribosomal protein S12 mRNA was 
determined and data expressed as ratios relative to S12 levels. Melting point 
analyses of amplified PCR products were performed after each run to verify 
specific amplification.  
2.5.2.5 MTT cell viability assay 
Cells were plated onto 96-well plates and allowed to attach o.n. previous to 
exposure to various concentration of etoposide and/or HIF-1α inhibitors (17-
AAG, DMAG, YC-1). Following exposure for 24h or 48h 10 µl MTT (5 mg/ml) 
was added for up to 12 h and incubated under 37°C, 5% CO2 atmosphere.  
Solubilization of the formed formazan crystals with 100 µl 10% sodium 
dodecyl sulphate (SDS), 0.001 M HCl for 24 h resulted in yellow to purple 
colored wells. Subsequent determination of absorbance at 550 nm relative to 
a wavelength of 630 nm was performed with a microplate reader. 
2.5.2.6 Generation of HIF-1α shRNA MEF cell lines 
MEFs wild-type (MEF-Hif1a+/+) or mutant (MEF-Hif1a-/-) were transfected 
using PEI with a pSilencer 2.6 vector (Ambion, Huntington, United Kingdom) 
containing a modified HIF-1α sequence. The original sequence has been 
shown to effectively down regulate HIF-1α (Erler et al. 2004) and was 
modified to 5`GTCTCGAGATGCAGCCAGA-3` corresponding to the 
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respective murine mRNA sequence. Cells were selected for stable 
transfection using hygromycin-containing (300 µg/µl) medium. Stably 
expressing clones were obtained by diluting the transfected pool and plating 
onto 96-well plates. Immunoblot for HIF-1α, mRNA level of HIF-1α and 
induction values of HIF-1α target genes was used to validate stable 
expresson of HIF-1α shRNA.  
2.5.2.7 Plasmids  
DNA isolated from MEFs wild-type (MEF-Hif1a+/+) or mutant (MEF-Hif1a-/-) 
was used to amplify the promoter region of DNA-PKcs by PCR. Luciferase 
reporter constructs were obtained by cloning a fragment corresponding to the 
DNA-PKcs promoter into the pGl3-basic vector. In detail, the region from –719 
to +1 flanked NheI and XhoI was inserted into pGL3-basic leading to 
pGL3_mPRKDC. The vectors pGL3_hPRKDC was a kind gift from (CW. 
Anderson). Construction of the pH3SVL, containing a total of 6 HIF-1 DNA-
binding sites derived from the transferrin gene by calcium phosphate co-
precipitation method as described previously (Rolfs et al. 1997). Co-
transfected renilla luciferase control plasmid pRL-SV40 (Promega, Mannheim, 
Germany) served to normalize transfected DNA content. 
2.5.2.8 Transfection and luciferase assay  
 Transient transfection was performed on 100 mm dishes using PEI. To 
equalize the transfected DNA amount pcDNA3 or pcDNA3_CMV was used. In 
order to normalize for transfection efficiency a renilla reporter gene was co-
transfected. Transfected cells were grown over night and split onto 6-well 
plates priory to normoxic or hypoxic (16 h, 0.2% O2) incubation. Cell lysates 
were prepared with passive lysis buffer (Promega) and aliquots were assayed 
for luciferase expression with a microplate luminometer (Berthold, 
Regensdorf, Switzerland).   
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Figure 1. HIF-1α-shRNA stably down-regulated clones of the MEF wild-type (Hif1a+/+) cell line.  
(A) Normalized HIF-1α mRNA levels as determined by quantitative real-time PCR. MEF wild-type 
(Hif1a+/+) and selected HIF-1α-shRNA stable down-regulated clones (Bc12 with intact HIF-1α levels; 
Bd10, Be7 with suppressed HIF-1α levels). (B) Normalized mRNA levels of a HIF-1α target gene 
(PHD3) as determined by RT-qPCR. Bc12 with intact hypoxic response, Bd10 and Be7 without hypoxic 
HIF-1α target gene activation. (C) Immuno-detection of HIF-1α-in wild-type (Hif1a+/+) and mutant (Hif1a-/-
) cells and HIF-1α-shRNA stable down-regulated clones (termed Bf8, Bd10, Ec1, Bc12, Be7). (D) 
Etoposide sensitivity of the HIF-1α-shRNA stably down-regulated clones (Bc12, Bd10, Be7), MEF wild-
type (Hif1a+/+) and MEF mutant (Hif1a-/-). Only the mutant (Hif1a-/-) cells differed in their sensitivity 
towards etoposide. 
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Figure 2. Titration curve of HIF inhibitors in MEF wild-type (Hif1a+/+) and MEF mutant (Hif1a-/-). Cells 
were exposed to the drugs for 24h and MTT assay was used to quantify the amount of viable cells (that 
is toxicity of the compounds). Under normoxic (20% O2) as well as under hypoxic (0.2% O2) conditions 
the inhibitors were equally toxic for both cell lines MEF wild-type (Hif1a+/+) and MEF mutant (Hif1a-/-). 
However, under hypoxia higher doses of the ansamycin derivatives (17-AAG, DMAG) had to be applied 
when compared to normoxia, even though the concentrations were identically higher in the two ell lines 
MEF wild-type (Hif1a+/+) and MEF mutant (Hif1a-/-). 
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Figure 3. (A) Titration of etoposide to wild-type 
(Hif1a+/+) and MEF mutant (Hif1a-/-). in the 
presence or absence of 17-AAG. ATP 
concentration were measured by determining 
luciferase activity, thus reflecting cell viability. 24 
h exposure to etoposide at different 
concentrations. The cells wild-type MEF (Hif1a+/+) 
and mutant MEF (Hif1a-/-) differs in their 
sensitivity towards etoposide. Addition of 17-AAG 
(5 µM) had no effect. Data points were measured 
as triplicates. 
 
(B) Titration of etoposide to wild-type (Hif1a+/+) 
and MEF mutant (Hif1a-/-) in the presence or 
absence of YC-1. MTT conversion capacity was 
used to determine the amount of viable cells after 
24 h exposure to etoposide at different 
concentrations. The cells wild-type MEF (Hif1a+/+) 
and mutant MEF (Hif1a-/-) differs in their 
sensitivity towards etoposide. Addition of YC1 
(50 µM) had no effect. Data points were 
measured as duplicates.  
 
(C) Titration of etoposide to wild-type (Hif1a+/+) 
and MEF mutant (Hif1a-/-) in the presence or 
absence of DMAG. MTT conversion capacity was 
used to determine the amount of viable cells after 
24h exposure to etoposide at different 
concentrations. The cells wild-type MEF (Hif1a+/+) 
and mutant MEF (Hif1a-/-) differs in their 
sensitivity towards etoposide. Addition of DMAG 
(5 µM) had no effect. Data points were measured 
as duplicates. 
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Figure 4. Titration of HIF-1α  in HeLa cells in combination with luciferase reporters. Co-transfection of a 
mouse or human DNA-PKcs promoter construct with a plasmid expressing HIF-1α did not induce 
luciferase expression. pH3SVL as positive control (with 3 hypoxia response elements (HRE)) could be 
activated to express luciferase by addition of HIF-1α under normoxia and hypoxia. The empty vector did 
express only basaic levels of luciferase.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112 
Unpublished data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Titration of HIF-1α  mutant MEF-Hif1a-/- cells. Transfection of increasing amounts of a HIF-1α 
expressing plasmid resulted in minimal enhanced expression from the DNA-PKcs co-transfected 
reporter construct (4 µg) under normoxia (white bars) as well as under hypoxia (black bars). However, 
same trend was observed with a lacZ plasmid expressing β-galactosidase. Thus, no HIF-1α specific 
effect on the DNA-PKcs promoter could be observed. 
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3 Discussion 
3.1 Oxygen sensing 
3.1.1 
3.1.2 
Acute and chronic oxygen-dependent regulation of HIF 
In order to respond to changes in the oxygen partial pressure a, cell has to 
register the available oxygen concentrations which is then translated by the 
transcription factor HIF in the respective transcriptional profile as part of the 
cell`s response. The “sensory system” consists of PHDs which depend on 
molecular oxygen for their function. Therefore oxygen concentration is closely 
linked to PHD activity. On the other hand, the PHDs are responsible for the 
degradation of HIFα by adding oxygen to a proline residue in the ODD 
domain. Thus, PHD activity is also linked to the concentration of HIF, which in 
turn results in the transcriptional profile of the cellular response to changes in 
oxygenation. This mechanism hence provides a cell with an ideally suited 
switch to trigger the activation of genes necessary to endure periods of acute 
hypoxia. However, it might also be possible that basic levels of HIFα are 
permanently adjusted to the prevalent concentration of oxygen by the same 
system under chronic hypoxic conditions.  
Prolyl-4-hydroxylases set the basic levels of HIFα under 
chronic hypoxia  
The concentration of HIFα is not permanently up-regulated during hypoxic 
exposure. After a short period of time with elevated HIFα-levels, reflecting an 
acute response to the hypoxic stimulus, HIFα-levels decrease and settle at a 
different set point; possibly corresponding to the current oxygen concentration 
of the chronically hypoxic conditions. In addition, HIF target genes, after being 
induced, decrease to permanently higher levels than before exposition to 
hypoxia reflecting a similar response as HIFα protein. Even though the 
oxygen sensory system, i.e. the PHDs, was characterized for its behavior 
under standard conditions of acute hypoxia, providing evidence for a linear 
HIFα regulation over the whole range of physiologically relevant oxygen 
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concentrations, the role of HIFα regulation under chronic hypoxia by the 
PHDs is not well understood. During tumor formation, cancerous areas are 
exposed to acute as well as to chronic hypoxia. The connection between PHD 
activity and the (re)setting of basic levels of HIFα under chronic hypoxic 
conditions might impact on tumor progression and tumor therapy outcome. 
During in vitro VHL-binding assays we could show that PHD activity remains 
detectable even under severe hypoxic conditions, when oxygen as substrate 
is limited, thus representing the rate determining component in the processes 
leading to the degradation of HIFα. Also degradation of a HIFα-ODD domain 
containing reporter gene constructs occurred efficiently under severe hypoxia. 
Thus, PHDs retain significant hydroxylase activity even under severe hypoxic 
conditions. Furthermore, PHD2 and PHD3 mRNAs are HIF-dependently 
induced. This results in increased concentrations of PHD2 and PHD3 
proteins, strictly depending on the concentration of HIFα and HIF activity 
respectively. Since increased concnetrations of an enzyme is equivalent to 
increased activity under otherwise unchanged conditions, PHD2 and PHD3 in 
concert with HIFα thus might establish a feedback loop that levels off the 
concentration of HIFα during chronic hypoxia. Of note, induced PHD2 and 
PHD3 protein levels in effect correlate nicely with decreased HIFα, indicating 
interweaved relations of sensory and processor system.  
3.1.3 Prolyl-4-hydroxylase assays 
In light of the strong link between HIF activity and PHD activity it appears 
probable that the correlation between elevated HIF and tumor therapy 
resistance might indeed be caused by the PHD system, potentially involving 
other factors regulated by the PHDs. There are in fact several proteins 
interacting for each PHD variant and at least two transcription factors (ATF4) 
was suggested to be hydroxylated by PHD3 in addition to HIF-1α (Koditz et al. 
2007). Therefore we established PHD assays to measure hydroxylation of 
potentially new PHD targets. One methode we used to detect hydroxylation 
was in-gel digestion followed by mass spectrometry (ms). However, in vitro 
hydroxylation did not yet result in a percentage of hydroxylated protein high 
enough to be detected by ms.  
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An other method to determine hydroxylation is to monitor oxygen addition by 
targeting the hydroxylated moiety with a specific interactor. The VHL-binding 
assay is based on the specific recognition of the hydroxylated HIFα -ODD 
domain by pVHL. We used this method to quantify hydroxylation of HIFα -
ODD domain under various experimental conditions. However, due to its 
specificity this assay is purely restricted to the ODD domain of HIFα, thus not 
adaptable to unknown proteins. 
A completely different approach makes use of the co-substrate conversion by 
the PHDs to measure PHD activity. We exploited the conversion of 
radioactively labeled oxoglutarate to radioactively labeled succinate to 
determine PHD activity. Unfortunately, when using crude protein extracts as 
source of PHD activity the reaction of oxoglutarate to succinate is also 
performed by other enzymes, resulting in a very high background and 
impeding a clear quantification of the activity of the PHDs. Thus purification of 
the target protein as well as the PHD is required for this assay. In addition, the 
reaction is stoichiometrical; meaning that per hydroxylation event only one 
oxoglutarate will be converted to succinate. When using large proteins it is 
difficult to obtain enough concentrated protein solutions to provide sufficient 
hydroxylation sites and thus enough conversion reactions of oxoglutarate to 
succinate in order to pass a minimal threshold of succinate formed. 
Neverthless, the application of this assay to discover hydroxylation of novel 
PHD substrates should be possible, eventually leading to the identification of 
novel, only “indirectly” HIF-dependent factors involved in tumor therapy 
resistance.  
3.2 HIF and cancer therapy resistance 
3.2.1 HIF and cancer progression: a positive factor in tumor growth  
High HIF levels correlate with tumor progression and tumor therapy 
resistance.(Unruh et al. 2003; Moeller and Dewhirst 2006) The contribution of 
HIF to cancer progression seems to depend on the tumor micro-environment 
and to a major part on its involvement in vasculogenesis.(Pouyssegur et al. 
2006) The tumor environment selects for tumor cell phenotypes and cells with 
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(pathologically) up-regulated HIF levels profit from the set of HIF-target 
genes.(Semenza 2003; Wenger et al. 2005) The HIF-dependent release of 
cytokines and growth factors build the base for further proliferation of the 
cancerous lesions. Thus, HIF will sustain cellular life and trigger the formation 
of new blood vessels. Vascularization is crucial for the tumor mass to grow 
over a limited size, underlining the importance of HIF in the course of cancer 
development. (Hanahan and Weinberg 2000; Weinberg 2007) 
3.2.2 
3.2.3 
HIF and cancer therapy: a negative factor in tumor therapy  
Tumor progression and tumor therapy are connected since faster growing and 
more voluminous tumors are more difficult to treat. The tumor growth-
promoting effect of HIF (due to its central role in angiogenesis) would already 
be sufficient to target the transcription factor as a negative factor in tumor 
therapy. However, several studies attributed additional functions to HIF in 
tumor therapy; independent of angiogenesis. Cell culture studies with cell 
lines deficient for HIF or impaired in HIF function (dominant negative mutants, 
molecular inhibitors, or RNAi studies) confirm on a molecular action exerted 
by HIF, which shelter cells from chemo- or radio-therapeutic treatments. 
(Unruh et al. 2003; Erler et al. 2004; Zhang et al. 2004; Williams et al. 2005; 
Brown et al. 2006; Hussein et al. 2006; Song et al. 2006) However, the 
interpretation of the observed therapy resistance differs and no definitive 
answer to HIF`s role in therapy resistance could be given up to date. 
Studying HIF in vitro; the cell culture model 
We addressed the question of HIF`s contribution to therapy resistance by the 
use of mouse embryonic fibroblast cell lines, either wild-type MEF-Hif1a+/+ or 
mutant MEF-Hif1a-/-. In half of all human cancer cell genomes p53 is mutated 
and p53 signaling networks are probably altered in every malignant 
transformation. (Weinberg 2007) In order to mimic cancer cell conditions p53 
was inactivated by SV40 largeT-antigen introduction, leading to 
immortalization. Moreover, transformation with HRAS to enhance proliferation 
rate and cancer cell behavior was performed. (Ryan et al. 2000)The use of 
embryonic fibroblasts was believed to result in enhanced homogeneity of the 
transcriptional profile (as compared to embryonic stem cells). During all 
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experiments high glucose concentration was used to keep intracellular ATP 
constant and thus be independent of metabolic effects unrelated to HIF. 
3.2.4 
3.2.5 
Different behavior of the cell lines after drug administration 
By comparing the two cell lines for their sensitivity to known genotoxic agents 
such as etoposide a clear difference in cell viability was observed. Likewise 
tumor-regression in xenografted animal models was higher in case of the 
mutant MEF-Hif1a-/- cells after etoposide administration. Puzzeling, however, 
the cell lines showed the same difference on etoposide treatment under 
normoxic conditions as well as under hypoxic conditions. Normoxia is used to 
describe the availability of oxygen in air at sea level atmospheric pressure, 
thus refers to the oxygen partial pressure (pO2) of room air. During cell culture 
studies “normoxic” experiments are operated with 18% oxygen in the gas 
phase (due to the use of a gas mixture containing nitrogen, carbon dioxide 
(5%) and oxygen - the room air pO2 (160 mmHg) corresponds to 18% oxygen 
in this gas mixture). Hypoxic experiments on the other hand specify conditions 
with lower percentages of oxygen in the gas mixture, thus with a lowered pO2. 
By decreasing the pO2 in cell culture experiments HIF gradually becomes 
stabilized until at mild hypoxia (at around 5% oxygen (pO2 of around 40 
mmHg)) HIF is detectable by immunoblotting with maximal levels at around 
0.2% oxygen (pO2 of 1.6 mmHg). Therefore, HIF accumulation (that is hypoxic 
incubation vs. normoxic cultivation of the cell line) had no effect on the 
displayed etoposide sensitivity, which obviously not responds to acute (viz. 
inducible) HIF activity. Furthermore, under normoxic conditions HIF target 
gene expression is marginal due to the degradation of HIF and the inhibitory 
modification by FIH. But how could the observed resistance be assigned to 
HIF?  
HIFα stabilization in the cell culture model system 
When comparing HIFα levels of normal healthy tissue with neoplastic tissue, 
elevated HIFα levels are detected in the malignant lesion in the majority of the 
cases. HIFα is not only controlled by the PHDs. In addition, activated MAPK 
pathways contribute to the action of HIFα and the PI3K pathway also plays a 
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role in the regulation of the activity of the transcription factor. (Jiang et al. 
2001) Both pathways converge in the up-regulation of general protein 
synthesis by stimulation of protein translation. In the case of HIFα the fine-
tuned turn-over of synthesis and degradation becomes easily disturbed. While 
HIFα-degradation continues at same pace the rate of protein synthesis is 
elevated and thereby HIFα accumulates. However, at present still inhibited by 
FIH hydroxylation. Both pathways are commonly up-regulated in cancer and 
are activated in the cell culture model system used in this study. Thus, it 
seems very likely that HIF-dependent effects can be found under normoxic 
conditions owing to the elevated HIFα levels in cancer tissue and probably 
also in the cell culture model system. Under normoxic cell culture conditions 
HIFα may indeed have a transcriptional function as indicated by the 
observation that, even cultured under normoxia, HIFα-deficient cells have a 
reduced gene expression of HIF-1 target genes. 
3.2.6 HIF function unrelated to the available oxygen amount - “oxic” 
activity of the N-terminal trans-activation domain  
The nature of the transcription factor HIF appears to be quite distinct from the 
nature of other transcription factors. Not only the mode of regulation, with 
HIFα subunits being permanently degraded, but also the fact that HIFα 
contains two trans-activation domains separates it from the bulk of other 
transcription factors. HIF target gene expression is tightly controlled and 
induction of classical HIF target genes is primarily dictated by the action of the 
PHDs. Thus, HIF activity in general inversely matches PHD activity. (Schofield 
and Ratcliffe 2005) The inhibitory hydroxylation by FIH signifies another 
threshold for proper HIF activity but does not per se dictate the fate of the 
transcription factor. Interestingly, the destabilizing hydroxylation by the PHDs 
and the inhibitory hydroxylation by FIH are separated by the respective 
enzyme activities, possibly resulting in a gap with stable but partially inhibited 
HIFα (owing to FIH`s hydroxylation of the C-terminal trans-activation domain). 
Therefore, a small set of HIF target genes might not be regulated by inhibition 
of the C-terminal trans-activation domain - stable HIFα might be sufficient. 
Attempts to group HIF-target genes depending on the N-terminal trans-
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activation domain or the C-terminal trans-activation domain have been 
reported. (Dayan et al. 2006) According, the FIH-restricted C-terminal trans-
activation domain could promote HIF-target gene induction upon strong 
hypoxic insults, only.  
In contrary, the N-terminal trans-activation domain might serve to promote 
transcription of a subset of genes by only moderately responding to changes 
in pO2 (i.e. igfbp). (Dayan et al. 2006) Thus, it rather maintains the basal 
transcription of target genes. In this case stabilized HIFα would be important 
under normoxic conditions as well.  
3.2.7 Screening for cadidate genes possible provoking the observed 
etoposide sensitivity 
The knock-out of HIFα was expected to abrogate the response to hypoxia of 
numerous target genes. Therefore, the resulting etoposide sensitivity of the 
mutant MEF-Hif1a-/- cell line could have its origin in at least one of several 
possible pathways affected. In order to narrow down the list of possible 
candidates other assumptions had to be taken into account.  
Candidate genes that might be responsible for the observed etoposide 
sensitivity were assumed to be involved in double-strand break repair or to 
participate in the repair of double-strand breaks. Two arguments led to this 
assumption.  
First, the mutant MEF-Hif1a-/- cell line responded only to double-strand-
breaking drugs but not to other toxins differentially then the wild-type cell line 
MEF-Hif1a+/+. 
Second, a plasmid rejoining assay had been published, showing that the 
MEF-Hif1a+/+ wild-type cell line was able to re-ligate transfected, linearized 
plasmids to a much higher extent than the mutant MEF-Hif1a-/- cell line.(Unruh 
et al. 2003)  
Dealing with a transcription factor, the etoposide tolerance of the MEF-Hif1a+/+ 
wild-type cell line was expected to derive from a differential transcriptional 
gene regulation. HIF-dependent gene regulation under hypoxia leads to a 
pronounced mRNA induction for wild-type MEF-Hif1a+/+ but not mutant MEF-
Hif1a-/- for classical HIF-target genes. When comparing mRNA levels of wild-
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type MEF-Hif1a+/+ with mutant MEF-Hif1a-/- the difference in mRNA 
concentration for a classical HIF-target gene becomes much more 
pronounced upon hypoxic exposure but is minimal for normoxic “basla level” 
conditions. Opposite to classical HIF-target genes, the candidate gene(s) 
would only moderately respond to hypoxic induction. However, display a 
“basal level” difference in the mRNA concentration, even under normoxic 
conditions, when comparing wild-type MEF-Hif1a+/+ with mutant MEF-Hif1a-/-.  
3.3 Non-homolgous end-joining and HIF 
3.3.1 
3.3.2 
 DNA-PKcs a key player in non-homologous end-joining 
A candidate screen for double-strand break repair factors revealed a “basal 
level” difference in mRNA concentrations for DNA-PKcs, which did not 
respond to changes in the available oxygen concentration. Moreover, the 
difference in DNA-PKcs mRNA led us to measure the protein levels which 
were even more lowered in the mutant MEF-Hif1a-/- cell line. Due to its 
important function in end-joining, DNA-PKcs likely contributes to the 
remarkable etoposide sensitivity in mutant MEF-Hif1a-/- cells. In addition, low 
DNA-PKcs expression levels correlate with etoposide and IR sensitivity, 
(Jeggo et al. 1989; Caldecott et al. 1990; Blunt et al. 1995; Lees-Miller et al. 
1995; Finnie et al. 1996; Taccioli et al. 1998; Johnson and Jones 1999; Smith 
and Jackson 1999; Boulton et al. 2000; Anderson et al. 2001; Belenkov et al. 
2002; Eriksson et al. 2002; Lees-Miller and Meek 2003) (Gao et al. 1998; 
Willmore et al. 2004; Hardcastle et al. 2005; Zhao et al. 2006) whereas high 
levels of DNA-PKcs confer resistance to double strand inducing 
agents..(Tanaka et al. 1993; Shen et al. 1998; Hansen et al. 2003) 
Wild-type MEF-Hif1a+/+ differ from mutant MEF-Hif1a-/- in the 
number of double-strand breaks after genotoxic insult  
Additional mechanisms might contribute to drug resistance in wild-type MEF-
Hif1a+/+. Accumulation of etoposide due to different cell cycle regulation or 
different detoxification of the interior milieu of the cell would also result in 
increased clonogenic survival of the MEF-Hif1a+/+. However, detoxification of 
such different genotoxic stimuli as etoposide and the radicals formed by 
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ionizing radiation (IR) is unlikely to happen by similar means without resulting 
in similar patterns for other toxins (DFX, CPX, topoisomerase I inhibitor 
SN38). (Unruh et al. 2003) Anyhow, cell cycle regulation of the two cell lines 
(wild-type MEF-Hif1a+/+ and mutant MEF-Hif1a-/-) appears to be identical since 
cell doubling time and cell cycle distribution (as determined by fluorescence 
activated cell scanner (FACS) analysis) are comparable. Also etoposide 
induced cell cycle-arrest appears similar for both cell lines, wild-type MEF-
Hif1a+/+ and mutant MEF-Hif1a-/-, as reflected by a simultaneous redistribution 
of the cell cycle profile after exposure to the toxin, further underscoring the 
uniformity in cell cycle regulation of the two cell lines. 
However, differences become apparent in the amount of H2AX 
phosphorylation after genotoxic insult as detected by immuno-staining for 
γH2AX. ATM and ATR the only two kinases, apart from DNA-PKcs, known to 
phosphorylate H2AX in the course of DNA double-strand breaks, were 
checked for differential activity in the wild-type MEF-Hif1a+/+ and mutant MEF-
Hif1a-/- cell lines. It is likely that elevated ATM or ATR activity could result in 
etoposide sensitivity due to the role of ATM and ATR in mediating DNA repair 
and cell cycle control. Yet, after etoposide exposure, known ATM or ATR 
targets (Chk2 or Chk1, respectively) are phosphorylated equally well in wild-
type MEF-Hif1a+/+ as for mutant MEF-Hif1a-/-. Therefore, the quantitative 
higher extent of H2AX phosphorylation after topoisomerase II inhibition is not 
based on differences in the activity of the kinases ATM or ATR. However, the 
higher sensitivity towards double-strand break-inducing agents of the mutant 
MEF-Hif1a-/- cells correlates with a larger degree of etoposide-induced H2AX 
phosphorylation of the mutant MEF-Hif1a-/- cell line when compared to the 
wild-type MEF-Hif1a+/+ cell line. In addition, after etoposide administration the 
higher number of strand breaks as determined by comet assays also 
correlates with higher etoposide sensitivity and increased γH2AX for the 
mutant MEF-Hif1a-/- vs. wild-type MEF-Hif1a+/+ cells. Thus, the amount of 
double-strand breaks after genotoxic insult differs from mutant MEF-Hif1a-/- to 
wild-type MEF-Hif1a+/+ and is paralleled by etoposide sensitivity and low DNA-
PKcs concentration.  
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3.3.3 Not only DNA-PKcs but also Ku80 transcription is lower in the 
mutant MEF-Hif1a-/- cells  
Though possible that mutations in the DNA-PKcs coding or promoter 
sequence are responsible for the observed etoposide sensitivity of mutant 
MEF-Hif1a-/- cells, this appears unlikely since other genes showed a similar 
expression pattern as DNA-PKcs. Also the Ku80 protein levels were clearly 
lower in the mutant MEF-Hif1a-/- cells. Interestingly, the protein but not the 
mRNA levels of Ku70 were also decreased. However, the protein levels of the 
Ku-heterodimers were reported to be interdependent due to structural 
stabilization. (Downs and Jackson 2004) Therefore, HIF-deficiency affects the 
expression levels of several genes. Not only the induction of HIF-target genes 
is missing, but in the mutant MEF-Hif1a-/- cell line also the “basal levels” of a 
range of downstream genes are affected. This might be further supported by 
DNA microarray data. Data published include a set of genes with “basal level” 
differences even under normoxic conditions for HIF-1α-containing vs. HIF-1α-
deficient mouse fibroblasts, possibly indicating a role for basic levels of HIF. 
(Greijer et al. 2005)   
Under pathological conditions (i.e. cancer) basic levels of HIFα might be 
higher and the complex network of HIF- and hypoxia-dependent gene 
regulation disturbed. There is a set of HIF- and hypoxia-responsive factors 
which are repressors of the e-cadherin promoter.(Krishnamachary et al. 2006) 
Experiments with dominant-negative HIF-1α identified the transcriptional 
repressors (TCF3, Slug and Snail) and their target e-cadherin as downstream 
regulated genes of HIF-1α. Pathologically up-regulated HIF-1α contributes 
under normoxia to elevated mRNA expression levels of the repressors (TCF3, 
Slug and Snail) and therefore e-cadherin mRNA suppression. Paradoxically, 
under hypoxic conditions mRNA levels of the repressors (TCF3, Slug and 
Snail) are HIF-independently decreased and e-cadherin expression induced. 
Even though the transcription of the repressors (TCF3, Slug and Snail) does 
apparently not respond to hypoxia-induced HIF-1α levels, basic level of HIF-
1α contributes to the “basal level” regulation of the repressors (TCF3, Slug 
and Snail) and therefore to the regulation of e-cadherin - especially in 
normoxia. Thus, HIF-1α might impact on the “basal level” of several genes 
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(i.e. by means of secondary factors) resulting in a complex HIF-dependent 
network, as exemplified for e-cadherin.  
3.3.4 
3.3.5 
HIF deficiency and etoposide sensitivity  
In order to confirm the HIF-dependent nature of our observation, HIF-1α was 
stably down-regulated by shRNA transfection. However, probably due to 
incomplete down-regulation of HIF-1α, shRNA-clones were not more sensitive 
to etoposide than the parental cell line. This, however, implies that already 
very low basic levels of HIF-1α suffice to confer etoposide resistance. 
Likewise, luciferase reporter activity (irrespective of mouse or human DNA-
PKcs promoter) did not respond to increasing amounts of co-transfected HIF-
1α in HeLa cells. Also the reintroduction of HIF-1α in MEF-Hif1a-/- cells did not 
affect luciferase activity of co-transfected reporter construct with the DNA-
PKcs promoter. Even though two putative HIF-binding sites were found in the 
DNA-PKcs promoter, transcriptional activity of the DNA-PKcs promoter does 
apparently neither respond to transiently variable basic levels of HIF-1α nor 
transient presence of HIF-1α in MEF-Hif1a-/- cells. However, the relative 
luciferase activity of a transfected reporter construct with the DNA-PKcs 
promoter was substantially higher in the wild-type MEF-Hif1a+/+ - consistent 
with a higher endogenous DNA-PKcs mRNA expression, elevated DNA-PKcs 
protein levels, decreased γH2AX-foci number after exposure to etoposide and 
enhanced resistance to double-strand break-inducing agents of the wild-type 
MEF-Hif1a+/+ cells when compared to the MEF-Hif1a-/- cells. Though a direct 
transcriptional effect on the DNA-PKcs promoter is possible rather an indirect 
HIF-1 dependent effect might result in lower DNA-PKcs expression in the 
MEF-Hif1a-/- cells. Moreover, transient re-introduction of HIF-1α had no effect 
on DNA-PKcs expression indicative for a slow adaptation process that leads 
to change of DNA-PKcs promoter regulations.  
Differences in the basic levels of HIF selects for different cell 
constitutions    
The stable down-regulation of HIF-1α in the wild-type MEF-Hif1a+/+ cell line 
did neither confer etoposide sensitivity nor affect DNA-PKcs expression. Not 
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even did the transient re-introduction of HIF-1α in mutant MEF-Hif1a-/- cells 
activate a co-transfected luciferase reporter with the DNA-PKcs promoter. 
Thus, the decrease in DNA-PKcs and the higher sensitivity to double-strand 
break inducers may only become evident when basic levels of HIF-1α are 
profoundly down-regulated for an extended period of time. These are exactly 
the conditions present in our MEF-Hif1a-/- model system where the levels of 
HIF-1α are maximally decreased (with no HIF-1α at all) for eternity.  
Therefore, erasing HIF-1α from the cellular pool of regulatory factors may 
select for other cellular constitutions and thereby impact on the nicely 
balanced networks of factors involved in maintaining cell homeostasis. This 
result in a reorganization of regulatory networks to compensate for the lack of 
basic levels of HIF-1α. But why are most of the regulatory circuits in the MEF-
Hif1a-/-  not completely deregulated when compared to the wild-type MEF-
Hif1a+/+ ? Indeed, the uniformity of the two cell lines is striking, especially 
regarding the fact that HIF-1α is important for numerous cellular functions and 
is involved in the fine-tuning of several major pathways.(Wenger et al. 2005; 
Gordan et al. 2007; Kaidi et al. 2007)  
However, the number of newly emanating cellular structures is limited. In 
order to cover for missing HIF-1α some cells will restructure their regulatory 
networks into inappropriate compositions for cellular homeostasis and thus 
collapse. Moreover, adaptations are probably only possible in a narrow range 
without disturbance of too many cellular processes (that is risk to loose control 
over cellular homeostasis).(Lovelock 1979) Maintenance of cell integrity, 
therefore, leads to mutant MEF-Hif1a-/- cells with reorganized but nearly 
identical regulatory networks to wild-type MEF-Hif1a+/+ cells under standard 
cell culture conditions. Differences between the cell lines, wild-type MEF-
Hif1a+/+ and mutant MEF-Hif1a-/-, will be manifested only under conditions of 
stress i.e. hypoxia. 
There are, however, changes owing to the reorganization of regulatory 
networks (or redistribution of regulatory factors to cover up for HIF-1α) which 
set conditions different to the original cell status. In particular factors which do 
per se not influence cell homeostasis may be affected to changes. In their 
case the selective pressures to accurately compensate for devoid basic levels 
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of HIF-1α does not play a role. Since there is no influence on important 
cellular processes their deregulation does not jeopardize cell integrity under 
standard conditions, thus selection is not possible and even heavy 
deregulation will not end in a cellular break-down. These factors thus respond 
by adopting the new cellular settings, provoked by the absence of HIF-1α, 
without restraint. Therefore they may appear deregulated in mutant MEF-
Hif1a-/- in relation to the wild-type MEF-Hif1a+/+ cells, even under standard cell 
culture conditions, however without consequence for cellular continuity.  
Although deregulated cells have to rely on such factors under special 
conditions i.e. stress after genotoxic insult. After stimulation with an 
appropriate stress the deregulated factors become now active, resulting in a 
different response of wild-type MEF-Hif1a+/+ and mutant MEF-Hif1a-/- cell line. 
Thus, in addition to a different response to a hypoxic insult, other stress 
stimuli are likely to result in a different phenotype for wild-type MEF-Hif1a+/+ 
cells compared to mutant MEF-Hif1a-/- cells. This may be the case for DNA-
PKcs and the resulting etoposide sensitivity of mutant MEF-Hif1a-/-. 
Summarized, the lack of basic levels of HIF-1α leads to aberrant cellular 
compositions which are the base for a differing reaction on stress stimuli. On 
the other hand also cells with elevated basic levels of HIF-1α may result in 
aberrant cellular compositions and yet other phenotypes. Thus, anomalous 
basic levels of HIF-1α, as arising in cancerous tissue, spawns cells with 
different reaction on stress stimuli. Targeting such cells as in the case of 
cancer therapy then will select for more resistant clones and thereby poorer 
clinical outcome of tumor therapy. 
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